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1. INTRODUCTION
Major depressive disorder is a debilitating mental illness that represents 
the main cause of disability throughout the world (Collins et al., 2011). In 
general, it is characterized by low mood, anhedonia, and loss of interest in daily 
activities. It is associated with severe consequences including suicide and risk of 
cardiovascular events (Zarate et al., 2013). Clinical depression leads to severe 
health and socioeconomic consequences (Kessler et al., 2003) and although its 
estimated lifetime prevalence in the United States is ~ 17 % (Kessler et al., 
2005), its worldwide prevalence ranges depending on the country (Andrade et
al., 2003; Kessler and Ustun, 2004; Kessler et al., 2010). According to the 
Diagnostic and Statistical Manual of Mental Disorders, fifth Edition (DSM-5), 
major depression is presented when a patient exhibits during a consecutive 2-
week time frame, 5 or more symptoms including depressive mood, decreased 
interest (apathy) or pleasure in activity, significant weight loss, insomnia or 
excessive sleep, psychomotor retardation or agitation, loss of energy, feelings of 
inappropriate guilt and recurrent thoughts of death. 
Many efforts have been made in order to understand the 
pathophysiology of this mental illness over the last forty years, and as a result 
multiple depression hypotheses have been postulated, all of which could be 
interrelated. The monoamine hypothesis of depression is, till date, the most 
established one and that in which the currently antidepressant treatments are 
based on. It proposes that the underlying biological or neuroanatomical basis of 
depression is a deficiency of central monoamine neurotransmitters
noradrenaline (NA), serotonin (5-HT), and/or dopamine (Schildkraut, 1965; 
Delgado, 2006). The main sources of NA and 5-HT monoamines are the 
noradrenergic locus coeruleus (LC) and the serotonergic dorsal raphe nucleus
(DR), respectively. Therefore, these brain regions have been extensively 
considered and studied in the research of the etiology of this psychiatric disease 
(Lowry et al., 2008; Itoi and Sugimoto, 2010). 
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More than 20 different antidepressant medications, all of which target 
monoaminergic systems, are currently available (Abdallah et al., 2015). 
However, they are still considered a matter of debate, given the limited efficacy 
of these medications. A substantial proportion of patients fail to achieve a 
sustained remission (Rush et al., 2006) and others suffer side effects, 
complicating the compliance of the treatment (Racagni and Popoli, 2010). 
Moreover, the full clinical benefit of these traditional antidepressants is only 
achievable following weeks to months of treatment (Katz, 2004), although brain 
monoaminergic levels are rapidly restored. It has been proposed that the time 
needed for 5-HT1A receptor desensitization may be responsible for the delay in 
the response to selective serotonin reuptake inhibitors (SSRIs) (Artigas et al.,
1996; Blier et al., 1998), proposing 5-HT1A receptors and/or their downstream 
effectors as candidates for the study of antidepressant treatment responses. In 
addition, other hypotheses involving adult neurogenesis and neurotrophic 
factors have emerged in order to give alternative explanations. It is proposed 
that chronic stress, which frequently precipitates depression, reduces adult 
neurogenesis in the hippocampus (Dranovsky and Hen, 2006; Pittenger and 
Duman, 2008). Moreover, antidepressant treatments increase hippocampal adult 
neurogenesis, and the time needed to obtain this effect is coincident with the 
appearance of a clinical benefit (Malberg et al., 2000), suggesting that there is a 
requirement of adult neurogenesis to obtain a behavioral response to 
antidepressants. Subsequent studies suggest that the antidepressant-induced 
increase in neurogenesis is mediated by 5-HT1A receptors (Santarelli et al., 
2003). Altogether, 5-HT1A receptor-mediated signaling plays a relevant role in 
the etiology of depression and response to antidepressants. However, there is 
still a need of a better understanding of the specific mechanisms responsible for 
the delay in the response to antidepressants, in order to progress in the 
development of new faster-acting efficacious antidepressant drugs.
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Nevertheless, research in the field of depression continues, and 
currently, targeting brain regions and neurotransmission systems other than the 
monoaminergic ones seems a promising field to elucidate possible unknown 
mechanisms and processes involved in the etiology of depression. In this sense,
dysfunctional glutamatergic and gamma-aminobutyric acid (GABA) systems 
are also considered to play a relevant role in the pathophysiology of depression 
and anxiety (Luscher et al., 2011; Sanacora et al., 2012). Indeed, glutamatergic 
transmission currently represents a novel target for drug development and 
pharmacotherapy of affective disorders (Soiza-Reilly and Commons, 2011; 
Musazzi et al., 2013). 
1.1. Serotonergic system: the dorsal raphe nucleus
1.1.1. Anatomy
The serotonergic system is formed by 5-HT cell clusters typically 
divided into nine groups (B1-9) (Dahlstroem and Fuxe, 1964), known as the 
raphe nuclei. There are two anatomical regions, 1) the rostral group, including 
the nucleus linearis, the dorsal raphe nucleus, the medial raphe nucleus and the 
raphe pontis, all of them located in the mesencephalon and rostral pons; and 2) 
the caudal group, which comprises the nucleus raphe magnus and the raphe 
pallidus and obscure. It extends from the caudal pons to the caudal portion of 
the medulla (Baumgarten and Grozdanovic., 1997). The DR is the largest of the 
brainstem serotonergic nuclei containing about 50% of 5-HT neurons in the rat 
central nervous system (CNS) (Wiklund and Bjorklund, 1980; Descarries et al., 
1982). In mice, it contains approximately 9000 5-HT neurons, in rats 10000-
12000, representing approximately two thirds of all neurons in the nucleus 
(Molliver, 1987; Jacobs and Azmitia; 1992), and in humans it contains 
approximately about 235000 5-HT neurons (Baker et al., 1990). Rostrally, the 
DR is bound by the Edingher Westphal nucleus (III) and, caudally, it extends 
ventral to the confluence of the fourth ventricle and the cerebral aqueduct 
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(Steinbusch, 1981; Descarries et al., 1982; Imai et al., 1986; Tork, 1990; Jacobs 
and Azmitia, 1992). In most species, the DR is composed of several subregions 
distinguished by their different cell density, morphology, and projections: 1) a 
medial portion, subdivided in turn into dorsomedial and ventromedial 
components, just below the cerebral aqueduct and surrounding the medial 
longitudinal fasciculi, respectively; 2) lateral portions or wings which are in the 
dorsoventral portion, and 3) a caudal component (Azmitia and Gannon, 1986; 
Johnson and Ma, 1993) (Fig. 1.1). While the DR is not exclusively composed of 
5-HT neurons, it is frequently defined anatomically by four major clusters of 5-
HT cells within its borders (Diaz-Cintra et al., 1981; Steinbusch, 1981; Agnati 
et al., 1982; Abrams et al., 2004). Accordingly, there are dorsomedial, 
ventromedial, and two bilateral groupings of 5-HT cells in the lateral wings of 
the nucleus. Hence, there is an anatomical proximity between different 5-HT 
cell clusters that provides the ground for a network of interconnections of high 
degree cross-talk among 5-HT neurons at the somatodendritic level (Pineyro 
and Blier, 1999).
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Figure 1.1. Representative picture of the dorsal raphe localization in a coronal 
section. On the left, the localization of the dorsal raphe (DR), ventral to the cerebral 
aqueduct. On the right, a magnified representation of the DR showing its different 
subregions. DRd: dorsal parts of the dorsal raphe, DRv: ventral part of the dorsal 
raphe, DRvl: lateral portions or wings of the dorsal raphe, DRif: caudal part of the 
dorsal raphe, dorsal raphe interfascicular. Taken and modified from Stopper and 
Floresco (2014).
1.1.2. Physiology
The DR is a nucleus of heterogeneous nature, composed by neuronal 
groups that differ in cellular morphology, electrophysiological properties and 
the expression of neurotransmitters and neuromodulators (Jacobs and Azmitia, 
1992).
1.1.2.1. Serotonergic neurons
A) Localization, morphology, and electrophysiological and 
pharmacological properties
The 5-HT neurons are highly concentrated in the DR, at rostral levels 
essentially confined to the midline, at more caudal levels spreading out with two 
lateral wings, and a dorsal and more ventral midline nucleus, and most caudally 
“returning” to the midline (Fu et al., 2010) (Fig. 1.2). Most of the 5-HT neurons 
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are immunopositive for the 5-HT-synthesizing enzyme tryptophan hydroxylase 
(TrPH) (Weissmann et al., 1990). Morphologically, 5-HT neurons have 
fusiform, triangular or multipolar cell bodies with a diameter ranging from 15 to 
35 µm. The dendrites display a poorly branched radiating pattern of arborization 
(Li et al., 2001).
Figure 1.2. Tryptophan hydroxylase (TrPH, the enzyme responsible for serotonin 
production) immunostained coronal sections across the rostral (left) to caudal 
(right) extent of the rat dorsal raphe. Pictures showing the localization of TrPH 
immunostained neurons, corresponding to 5-HT neurons, across the sections of the 
dorsal raphe (DR). At rostral levels, 5-HT neurons are confined in the midline, 
spreading to the lateral parts of the DR at more caudal levels, and returning to the 
midline at the most caudal sections (from the left to the right).Taken and modified from 
Vasudeva et al. (2011). 
The electrophysiological and pharmacological properties of DR 5-HT 
neurons have been widely characterized. In vivo intracellular recordings 
followed by neurochemical identification, found that 5-HT neurons have a slow 
(0.5 - 3 Hz) and rhythmic firing pattern, a large afterhyperpolarization potential 
(AHP), gradual interspike depolarization, and a long duration action potential (1 
- 2 ms) (Aghajanian et al., 1978). Later, intracellular recordings in brain slices 
found that 5-HT neurons are either silence or spontaneously active with a slow, 
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regular firing rate (0.5 - 2.5 Hz), a high input resistance (150- 	
 nd
have a long duration action potential (AP, approximately 1.8 ms) followed by a 
large and slow AHP (amplitude = 10 - 20 mV, duration = 200 - 800 ms) 
(Vandermaelen and Aghajanian, 1983; Burlhis and Aghajanian, 1987). Spike
trains elicited by weak long depolarizing current pulses in these neurons show 
no adaptations of spike frequency (Li et al., 2001). In addition, 
pharmacologically, 5-HT neurons are hyperpolarized and their firing inhibited 
by stimulation of inhibitory 5-HT1A receptors. It has been broadly described two 
different populations of 5-HT neurons (Hajos et al., 1995a; Hajos and Sharp, 
1996; Hajos et al., 2007). There are single-spike neurons, which exhibit the 
previous electrophysiological characteristics, and also another population of 5-
HT neurons of burst-firing neurons, that also show the previously mentioned 
properties but their firing pattern is comprised of doublets, triplets, or even 
quadruplets of broad spikes. Spikes within these brief bursts have a short 
interspike time interval (>10 ms) and diminishing spike amplitude (Hajos et al., 
1995a; Hajos et al., 1995b).
B) Auto-regulation of 5-HT firing activity and release
To date, seven serotonergic receptors (5-HT1 - 5-HT7) with a 15 total 
variants have been identified and cloned (Barnes and Sharp, 1999; Hoyer et al., 
2002; Kroeze et al., 2002). The 5-HT G protein coupled receptors, which are all 
the 5-HT receptors with the exception of the 5-HT3 receptor that is a ligand-
gated ion channel, can be divided into three major subgroups depending on 
which G protein signaling they activate. 5-HT1 receptors couple mainly to the 
Gi/o pathway; 5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptors couple to the Gs
pathway; and 5-HT2 receptors activate the Gq/11 pathway (Maejima et al., 2013). 
Some of them are expressed as autoreceptors, which in the case of the 5-HT 
system are defined as receptors that are expressed within 5-HT neurons and 
provide feedback in modulating the activity of those neurons. These receptors 
are also expressed on non 5-HT neurons and in this case they are defined as 
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heteroreceptors. All members of 5-HT1 family are expressed in 5-HT neurons 
and consist of 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F. They share high 
affinity for 5-HT, and provide negative feedback in 5-HT neuronal firing and 5-
HT release (Andrade, 1998), maintaining a certain homeostatic tone in 
serotonergic function (McDevitt and Neumaier, 2011) (Fig. 1.3).
Auto-regulation of 5-HT neuronal firing is predominantly regulated by 
5-HT1A receptors located in the DR (Sprouse and Aghajanian, 1987). Also 5-HT 
release is under the control of 5-HT1A receptors (Stamford et al., 2000). Their 
activation leads to inhibition of action potentials via opening G protein coupled 
inwardly rectifying potassium (GIRK) channels in a Gi/o-dependent manner 
(Aghajanian and Lakoski, 1984; Innis and Aghajanian, 1987; Bayliss et al., 
1997). The opening of GIRK channels upon 5-HT1A receptor stimulation results 
in an enhanced K+ conductance that leads to a hyperpolarization of the 
membrane potential and inhibition of 5-HT action potential (VanderMaelen et 
al., 1986; Sprouse and Aghajanian, 1987; Sinton and Fallon, 1988). In addition, 
polysynaptic feedback loops through the medial prefrontal cortex (mPFC) also 
exert a control of the 5-HT firing in the DR, since 5-HT1A receptors in ventral 
regions of the mPFC exert inhibitory and excitatory control over DR 5-HT 
neuronal activity (Hajos et al., 1999; Martin-Ruiz et al., 2001) by modulating 
glutamatergic excitatory input to DR GABAergic and 5-HT neurons (Bambico 
et al., 2007).
5-HT1A receptors are the predominant autoreceptors in the DR. They are 
found on soma and dendrites of 5-HT neurons and non 5-HT cells (Sotelo et al., 
1990; Miquel et al., 1992). In fact, there is also a modest expression of 5-HT1A
receptors in a number of GABAergic neurons throughout the rostrocaudal axis 
of the DR (Beck et al., 2004; Day et al., 2004). The DR, medial raphe and 
hippocampus are the most enriched areas with 5-HT1A receptors (Pompeiano et 
al., 1992; Kia et al., 1996a) but they are also present in cortical areas and the 
hypothalamus, ventral tegmental area (VTA), substantia nigra compacta, and 
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LC (Austin et al., 1994; Azmitia et al., 1996; Kia et al., 1996a; Kia et al., 
1996b).
5-HT1B autoreceptors are the predominant 5-HT receptors at the 
presynaptic terminal. Electrophysiological experiments have shown that the 5-
HT1B autoreceptor inhibits 5-HT release from the axonal varicosities (Sprouse 
and Aghajanian, 1987; Boeijinga and Boddeke, 1993; Morikawa et al., 2000). It 
has also been shown that it reduces extracellular 5-HT concentrations in 
terminal regions, synthesis of 5-HT (Hjorth et al., 1995), and up-regulates the 
reuptake via the 5-HT transporter (SERT) (Xie et al., 2008; Hagan et al., 2012). 
Moreover, 5-HT1B receptors have been shown to underlie presynaptic 
autoinhibition of 5-HT release in which 5-HT1A receptor-mediated slow 
inhibitory postsynaptic currents are reduced by previous 5-HT release activating 
presynaptic 5-HT1B receptors (Morikawa et al., 2000). It is distributed in axon 
varicosities and terminals but not in the soma or dendrites of 5-HT neurons 
(Boschert et al., 1994; Sari et al., 1999). It is also present in glutamatergic 
terminals as a heteroreceptor (Li and Bayliss, 1998). 
5-HT1D autoreceptor contributes to autoinhibition of 5-HT function at 
terminals and possibly dendrites (Pineyro et al., 1995; Pineyro and Blier, 1996;
Trillat et al., 1997), and also controls the 5-HT release (Stamford et al., 2000). 
Its distribution is very similar to that of 5-HT1B receptor (Bruinvels et al., 1994). 
Little is known about 5-HT1E and 5-HT1F receptors. However, it has been 
described the presence of 5-HT1E receptors in cortical areas, caudate putamen,
amygdale, and hypothalamus (Bruinvels et al., 1994). 5-HT1F receptor has been 
identified in the DR (Bruinvels et al., 1994).
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Figure 1.3. Possible location and functions of 5-HT1 receptors in the dorsal raphe.
Localization of 5-HT1A receptors (represented by red circles) in the 5-HT cell soma and 
proximal dendrites controlling 5-HT cell firing, and throughout the dendritic field, 
modulating the 5-HT release. 5-HT1B receptors (dark blue circles), which control the 5-
HT release, are located on serotonergic afferents, glutamatergic terminals, and terminal 
portions of efferent axons. 5-HT1D receptors (yellow circles) are found on the dendrites
and preterminal axons, modulating 5-HT release. 2-amino-3-(3-hydroxy-5-methyl-
isoxazol-4-yl) propanoic acid (AMPA)/Kainate receptors location is represented by 
light blue circles. Taken and modified from Stamford et al. (2000).
5-HT2 receptor mRNA and proteins have been identified in embryonic 
5-HT neurons of the DR (Clemett et al., 2000; Wylie et al., 2010), and are also 
expressed on GABAergic interneurons (Liu et al., 2000; Leysen, 2004).There is 
no direct modulatory effect of 5-HT2 receptors on 5-HT neurons, but they may 
increase 5-HT1A receptor-mediated responses in these neurons (Kidd et al., 
1991).
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5-HT3 receptors enhance 5-HT release in various brain areas including 
the DR (Bagdy et al., 1998), but there is no direct evidence of the presence of 5-
HT3 receptors in 5-HT neurons (van Hooft and Vijverberg, 2000).
5-HT4 receptors may be presynaptically localized since 5-HT release is 
modulated by 5-HT4 agonists (Vilaro et al., 2005).
The functional role of 5-HT5, 5-HT6, and 5-HT7 receptors in the 
modulation of 5-HT neurons is uncertain, although 5-HT6 and 5-HT7 receptor 
protein and mRNA have been detected in the DR (Ruat et al., 1993; To et al., 
1995; Gustafson et al., 1996; Woolley et al., 2004).
C) Serotonin reuptake: serotonin transporter
Following release, the reuptake of 5-HT by 5-HT neurons is the 
principal mechanism of terminating the action of the transmitter on postsynaptic 
sites, and this process is carried out by the high-affinity SERT, located on the 
presynaptic plasma membrane (Kuhar et al., 1972; O'Reilly and Reith, 1988). It 
functions in series with another type of carrier, the vesicular transporter, which 
sequesters intracellular 5-HT within secretory vesicles (Pineyro and Blier, 
1999). Two different types of SERT have been described, one is located in the 
CNS, and the other is peripheral. In the CNS, SERT mRNA is abundantly 
expressed in the DR and in 5-HT projection areas such as frontal cortex,
hippocampus and neostriatum (Lesch et al., 1993). Disruption of the gene 
coding for the SERT does not alter the basal firing rate of DR 5-HT neurons 
(Mannoury la Cour et al., 2001). 
SERT is the pharmacological target for various therapeutic and abused 
substances. SSRIs block 5-HT transporter increasing extracellular 5-HT, which 
has been considered to be the basis for their therapeutic role in depression and 
other psychiatric disorders (Pineyro and Blier, 1999). There is much evidence 
demonstrating that the acute administration of SSRIs increases 5-HT levels 
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preferentially in the raphe nuclei (Bel and Artigas, 1992; Gartside et al., 1995; 
Malagie et al., 1995; Hervas and Artigas, 1998). However, after sustained 
treatment with SSRIs 5-HT release is also increased in the forebrain (Bel and 
Artigas, 1992; Invernizzi et al., 1995; Le Poul et al., 1995; Hervas et al., 2001). 
Tricyclic antidepressants block SERT and NA transporter.
In addition to its role in the reuptake of extracellular 5-HT, SERT can 
promote the release of 5-HT through reversal of uptake mechanism, being the 
process involved in the mechanism of some drugs of abuse, such as cocaine, p-
chloroamphetamine and 3,4-methyl-enedioxymethamphetamine (MDMA) 
(Rudnick and Wall, 1992a; Rudnick and Wall, 1992b; Adell et al., 1993).
D) Hetero-regulation and afferent pathways of dorsal raphe
The hetero-regulation of the 5-HT neurons involves various 
neurotransmitter systems since 5-HT modulates complex behaviors. Therefore, 
the 5-HT system receives feedback and feedfordward information from other 
brain areas and networks involved in regulating the different behaviors (Adell et 
al., 2002; Sharp et al., 2007) (Fig. 1.4). 5-HT neurons within the DR receive in 
particular GABAergic but also glutamatergic input. GABAergic input onto 5-
HT neurons reduces the neuronal firing, and glutamatergic input increases the 
firing activity (Pan and Williams, 1989; Levine and Jacobs, 1992; Becquet et 
al., 1993a; Becquet et al., 1993b). These effects are attributed to the expression 
of ionotropic GABA and glutamate receptors in 5-HT neurons (Tao and 
Auerbach, 2000; Gartside et al., 2007). 
There is a prominent GABAergic input not only from intrinsic 
GABAergic interneurons, but also from the periaqueductal gray, the lateral and 
posterior hypothalamic areas, lateral preoptic area, the substancia nigra
reticulata, and VTA (Boschert et al., 1994; Gervasoni et al., 2000). The two 
main GABA receptors involved in the regulation of serotonergic transmission 
are the GABAA and GABAB, and both types have been described in the DR 
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(Bowery et al., 1987; Chu et al., 1990; Bischoff et al., 1999). GABAA receptors 
belong to 5-HT cell bodies (Mennini et al., 1986), whereas GABAB receptors 
are present in 5-HT cell bodies (Innis and Aghajanian, 1987) and also in 
GABAergic terminals as autoreceptors (Waldmeier et al., 1988; Bowery, 1993). 
GABA inhibits DR 5-HT cell firing (Baraban and Aghajanian, 1980; Abellan et 
al., 2000a) and 5-HT release in forebrain projection areas (Gallager and 
Aghajanian, 1976; Gervasoni et al., 2000). However, it has been reported that it 
does not alter 5-HT release in the DR (Abellan et al., 2000b). The GABAA
receptor antagonist, bicuculline increases 5-HT release in the DR, suggesting 
that GABAergic transmission exerts a tonic inhibition on 5-HT release (Tao et 
al., 1996). However, the fact that GABA inhibits DR cell firing but not release, 
suggests that at least one part of the 5-HT release does not depend on 5-HT cell 
firing. Regarding the GABAB receptor activity, different results have been 
obtained when the GABAB receptor agonist baclofen was perfused in DR 
neurons. In some studies baclofen increased the 5-HT release (Abellan et al., 
2000a; Abellan et al., 2000b) but in others it decreased 5-HT release (Tao et al., 
1996). These different results might be due to the different GABAergic tone 
across the sleep/wake cycle. Hence, in light conditions, in a presence of an 
active GABAergic input onto DR, baclofen removes the tonic GABAA input 
through its preferential activation of presynaptic GABAB receptors reducing 5-
HT firing activity, via activation of GIRK channels (Innis and Aghajanian, 
1987; Cornelisse et al., 2007). Thus, this leads to an increase in 5-HT release 
through a GABAA disinhibiton (Adell et al., 2002). In contrast, during darkness, 
the presynaptic effect of baclofen is quantitatively less important and its direct 
inhibitory effect on 5-HT neurons overcomes the presynaptic (indirect) effect, 
resulting in a reduction of 5-HT release (Tao et al., 1996). In addition, since 
GABAB receptor antagonists are without effect either in light or dark conditions 
(Tao et al., 1996; Abellan et al., 2000a) it is assumed that GABAB receptors do 
not tonically control the release of 5-HT in the DR. 
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The sources for glutamatergic input into the DR are the lateral 
habenula, periaqueductal gray, lateral hypothalamus, mPFC, the 
interpeduncular nucleus, and medullary regions, including the parabrachial 
nucleus, (Aghajanian and Wang, 1977; Maciewicz et al., 1981; Kalen et al., 
1985; Kalen et al., 1986; Marcinkiewicz et al., 1989; Behzadi et al., 1990).
These diverse areas are associated with many functions. For example, 
hypothalamic sites are linked to endocrine and metabolic functions, the 
habenula to reward state, medullary areas to autonomic function, visceral and 
somatic sensation, and the mPFC with conscious perception and decision 
making, all of which influence mood and motivated behavior associated with 5-
HT function. The glutamatergic receptors involved in the regulation of 5-HT 
neurons are N-methyl-D-aspartate (NMDA), 2-amino-3-(3-hydroxy-5-methyl-
isoxazol-4-yl) propanoic acid (AMPA) and kainate receptor, all of which are 
expressed in 5-HT neurons (Wylie et al., 2010). The application of glutamate in 
the DR stimulates DR 5-HT cell firing, and kainate, which binds both to AMPA 
and kainate receptors, increases 5-HT release (Tao et al., 1997; Tao and 
Auerbach, 2000). Similarly, NMDA receptor agonists elicit an increase of 5-HT 
release (Tao and Auerbach, 2000). However, there is a low tonic influence of 
glutamatergic inputs into 5-HT neurons since perfusion of AMPA and kainate 
receptor antagonists entails a moderate reduction of 5-HT release but prevents
the effect of AMPA/kainate receptor agonist on the increase in 5-HT release 
(Tao et al., 1997; Tao and Auerbach, 2000). The control by glutamate of 5-HT 
cell firing and release also involves AMPA receptors in mPFC. They mediate 
the activation of ascending serotonergic pathways via descending glutamatergic 
inputs onto the DR (Celada and Artigas, 1993). Little is known about the role of 
the different metabotropic glutamate receptors in the control of 5-HT activity 
and release within the DR so far (Maejima et al., 2013). It has been reported that 
administration of group II metabotropic glutamate receptors antagonist 
increases 5-HT neuronal activity. This seems to be an indirect effect that 
involves presynaptic excitatory neurons (Kawashima et al., 2005). Nicotinic 
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acetylcholine receptors (nAChRs) can increase 5-HT neuronal firing 
(Mihailescu et al., 2002) via presynaptic modulation of glutamate release 
(Garduno et al., 2012), or via opening of nAChR expressed in 5-HT neurons 
(Galindo-Charles et al., 2008; Chang et al., 2011).
There are prominent dopamine projections from the VTA, the 
substantia nigra, and the A11 cell group of the hypothalamus (Sakai et al., 
1977; Beckstead et al., 1979; Kalen et al., 1988; Peyron et al., 1996). Dopamine 
increases 5-HT neuronal firing and also 5-HT release (Ferre and Artigas, 1993; 
Ferre et al., 1994; Matsumoto et al., 1996; Mendlin et al., 1998; Haj-Dahmane, 
2001; Martin-Ruiz et al., 2001). To date, low levels of dopamine D2 and D3 
receptors have been detected in the DR (Bouthenet et al., 1987; Yokoyama et 
al., 1994; Suzuki et al., 1998). The modulatory effects of dopamine on 5-HT 
neurons are mediated by direct activation of D2 receptors expressed in 5-HT 
neurons (Haj-Dahmane, 2001), or by activation of D1 and D2 receptors located 
outside the DR, possibly in the substantia nigra since the local perfusion of 
apomorphine in this region enhances the release of 5-HT in the DR (Martin-
Ruiz et al., 2001).
The DR receives noradrenergic innervation from the LC and the input 
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# 2 adrenergic receptor mRNA and protein have been detected in the DR 
(Unnerstall et al., 1985; Scheinin et al., 1994; Rosin et al., 1996; Day et al., 
1997; Strazielle et al., 1999	 % 1 adrenoceptor is located on 5-HT cell 
&"##'#(#)1 adrenoceptor varies across the sleep-wake 
*' # '+#"#
 ,-.$	 *"#  1B adrenoceptor subtype 
predominates in the DR it seems to be the responsible for the tonic stimulatory 
action of noradrenaline on 5-HT neurons (Pieribone et al., 1994; Day et al., 
,--.	 % 2 adrenergic receptors are highly expressed in the DR and their 
activation by agon" ) 2 adrenergic receptors located on the soma or 
presynaptic terminal of 5-HT neuron reduces 5-HT neuronal firing (Hopwood 
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2 adrenergic receptor antagonists increase DR 
5-HT neuronal firing (Freedman and Aghajanian, 1984; Garratt et al., 1991). In 
addition, NA inhibits the release of 5-HT in the DR and it has been 
#  " )) " " & 2 adrenergic receptors 
(Frankhuijzen et al., 1988; Bortolozzi and Artigas, 2003).
The cannabinoid CB1 receptor is expressed in serotonergic fibers 
(Haring et al., 2007; Ferreira et al., 2012). CB1 receptor activation in DR 
decreases 5-HT release in projection areas and may regulate the function and 
expression of 5-HT1A receptors (Nakazi et al., 2000; Egashira et al., 2002; Aso 
et al., 2009; Moranta et al., 2009; Zavitsanou et al., 2010). Within the DR, 
endocannabinoids mainly act on glutamatergic terminals and probably also on 
GABAergic terminals (Haj-Dahmane and Shen, 2009; Mendiguren and Pineda, 
2009; Tao and Ma, 2012). Their action on these terminals leads to a reduction in 
glutamate and GABA release onto 5-HT neurons and therefore changes in the 
activity of the 5-HT neurons (Maejima et al., 2013).
5-HT neurons in the DR also receive dynorphinergic, enkephalinergic,
# 0-endorphinergic innervation (Adell et al., 2002). Activation of µ opiod 
receptors in GABAergic neurons within the DR inhibits GABAergic neurons 
and results in an increase in 5-HT release in projection areas (Tao and 
Auerbach, 1994; Jolas and Aghajanian, 1997	 ""# ) 1 #2 ""
receptors increases and decreases 5-HT release in the DR, respectively (Tao and 
Auerbach, 2002).
Substance P influence 5-HT transmission through neurokinin 1 (NK1) 
receptors, which are extensively expressed in the DR (Maeno et al., 1993; 
Sergeyev et al., 1999; Froger et al., 2001). NK1 receptors are found in the 
cytoplasm of 5-HT neurons and in dendritic membranes of GABAergic neurons 
and modulate 5-HT neuronal firing under certain physiological conditions 
(Lacoste et al., 2009). Activation of NK1 receptors in the DR increases the 5-
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HT release within the DR and decreases 5-HT release in frontal cortex (Guiard 
et al., 2007).
Galanin is a peptide expressed in the DR and appears to potentiate the 
inhibitory effect of 5-HT on 5-HT1A receptors, possibly via a galanin-5-HT1A
receptor interaction (Hokfelt et al., 1998; Xu et al., 1998; Razani et al., 2000).
Cholecystokinin and hypocreatin-orexin display direct excitatory 
actions on DR 5-HT neurons (Boden et al., 1991; Brown et al., 2001), whereas 
corticotropin-releasing factor (CRF) appears to be predominantly inhibitory 
(Kirby et al., 2000).
Figure 1.4. Schematic representation of the main structures involved in the 
regulation of 5-HT neurons. LC: locus coeruleus; mPFC: medial prefrontal cortex;
LHb: lateral habenula; SN: substantia nigra; PAG: periaqueductal gray matter; HTL: 
hypothalamus; VTA: ventral tegmental area. Taken from Adell et al. (2002).
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1.1.2.2. Non serotonergic neurons
Non 5-HT neurons are also present in the DR and occur in equal or 
greater number to 5-HT neurons (Descarries et al., 1982; Kohler and 
Steinbusch, 1982; Van Bockstaele et al., 1993; Kiss et al., 2002; Li et al., 2011). 
However, for any given neurotransmitter, the number of non 5-HT neurons is 
one third to one tenth less than the number of 5-HT neurons. These neurons are 
5-HT immunonegative and produce dopamine, enkephalin, neurotensin, 
substance P, somatostatin, cholecystokinin, GABA or glutamate (Pineyro and 
Blier, 1999). In general, they present a similar morphology and size to 5-HT 
neurons, but in contrast rarely have dendritic spines (Li et al., 2001). GABA cell 
bodies, also known as GABAergic interneurons, constitute a large population of 
non 5HT neurons forming a GABAergic intrinsic network in the DR (Massari et 
al., 1976). They can be seen in the lateral wings of DR or in areas devoid of 5-
HT neurons (Calizo et al., 2011). These cells are markedly smaller and fire 
spikes characterized by short width and high frequency (Allers and Sharp, 
2003). CRF cell bodies are also present in the DR, predominantly distributed in 
the dorsomedial part (Allers and Sharp, 2003; Commons et al., 2003; Day et al., 
2004). In addition, there are also dopamine neurons, immunopositive for 
tyrosine hydroxylase, which overlap in the rostral portion with 5-HT neurons 
(Fu et al., 2010); glutamatergic neurons expressing the vesicular glutamate 
transporter 3 (VGLUT3), which co-localize with 5-HT in the midline region 
(Commons, 2009); and nitrergic neurons (NOS-containing) which co-localize 
with 5-HT neurons in the dorsomedial and ventromedial part, but rarely co-
localize in the lateral wings (Vasudeva et al., 2011).
Electrophysiologically, using the traditionally-defined parameters alone 
(large membrane resistance, large AHP, long AP duration and a 
hyperpolarization in response to 5-HT1A receptor activation) is difficult to 
differentiate non 5-HT neurons from 5-HT neurons. However, in all subfields, 
there are some perceptible differences, though the magnitude of the differences 
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varies (Calizo et al., 2011). Compared to 5-HT neurons, non 5-HT neurons have 
a more depolarized membrane potential, a smaller amplitude and duration of 
AP, a faster and more irregular train of spikes in response to small depolarizing 
current steps, and spike trains elicited in these non 5-HT cells frequently show 
adaptations of spike frequency (Li et al., 2001; Calizo et al., 2011).
Pharmacologically, the 5-HT1A receptor-mediated response is smaller in 
non 5-HT neurons, although the sensitivity to the 5-HT1A agonist, 5-CT, is 
different among subfields regardless of cell type (Calizo et al., 2011). However, 
both 5-HT and non 5-HT neurons are heterogeneous with respect to their 
response to 5-HT, given that in both groups the majority of the neurons show an 
outward current in response to 5-HT but some show an inward current, which 
are similar in magnitude (Marinelli et al., 2004).
1.1.3. Dorsal raphe projections
5-HT neurons of the DR display a topographic organization with 
respect to efferent projections. Neurons located more rostrally project to more 
rostral areas of the brain than neurons located more caudally in the DR 
(Michelsen et al., 2007). There are three ascending pathways, the dorsal, medial 
and ventral ascending pathways, being the dorsal and ventral ascending 
pathways the two most important efferent projections of the DR. Dorsal 
ascending pathway innervates the striatum, globus pallidus and nucleus 
accumbens. Medial ascending pathway projects to substantia nigra compacta
and to a lesser extent the striatum. Ventral ascending pathway targets 
hypothalamic nuclei, habenula, septum, amygdala, cortex, the olfactory bulb,
hippocampus, interpeduncular nucleus, and geniculate body (Michelsen et al., 
2007).
In addition, four descending projections leave the DR, the bulbospinal 
pathway, cerebellar pathway, propriobulbar pathway, and a pathway that 
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innervates the LC, dorsal tegmental nucleus and pontine raphe nucleus
(Michelsen et al., 2007) (Fig. 1.5). 
Figure 1.5. Dorsal raphe nucleus and its major ascending and descending 
projections. Schematic sagittal section of a rat brain, showing the locations of the most 
important groups of 5-HT neurons and the distribution of their axons and terminal 
buttons.
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1.1.4. Serotonergic system, dorsal raphe, and depression
It is well-known that 5-HT is involved in many physiological aspects 
and behavioral processes including mood, core temperature, appetite, sleep, 
activity, suicide, sexual behavior, and cognition. Several clinical conditions, 
such as affective disorders, anxiety, obsessive-compulsive disorders, eating 
disorder, aggression, suicide, impulsive disorders, alcohol abuse, and 
premenstrual syndrome are linked to alterations in serotonergic function (Jans et 
al., 2007). In depression, which is one of the most intensively studied affective 
disorders in relation to a diminished serotonergic function, all the previously 
mentioned physiological and behavioral processes are affected. 
Based on the physiological and behavioral evidence that relates
serotonergic system and depression the DR has long received much attention in 
the study of depression, as it is the nucleus where the majority of the 5-HT cells
are located on. In this sense, controversial results have been obtained from 
diverse postmortem studies examining the number of 5-HT cells, SERT binding 
sites, and functionality of 5-HT1A receptors in the DR of depressed patients. 
While some investigations have observed a reduction in the number of neurons 
in the DR of depressed patients (Baumann et al., 2002), others have failed to 
find evidence of a variation in the neuronal number (Hendricksen et al., 2004). 
Regarding SERT, one study has reported a reduction in the number of SERT 
binding sites but another reported no changes (Bligh-Glover et al., 2000; 
Arango et al., 2001). In the same line, some positron emission tomography 
studies have observed a reduced 5-HT1A receptor signaling in DR of depressed 
suicide victims (Drevets et al., 1999; Arango et al., 2001; Drevets et al., 2007) 
also observed in animals after chronic stress (Fernandes et al., 1997), while an 
increased 5-HT1A receptor density has been reported in others (Stockmeier et 
al., 1998).
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Genetic and imaging studies in humans have suggested that different 
levels or regulation of the 5-HT1A receptor are associated with anxiety, 
depression and the response to antidepressants (Strobel et al., 2003; Lesch and 
Gutknecht, 2004; Le Francois et al., 2008). An association between a C(-109)G 
polymorphism in the promoter region of the Htr1a gene and depression and 
response to antidepressant treatment has been reported (Lemonde et al., 2004; 
Le Francois et al., 2008). However, whether this polymorphism controls only 
autoreceptor or both auto and heteroreceptor levels remains unclear, since some 
studies suggest that heteroreceptor levels are not affected and others suggest 
that both 5-HT1A auto- and heteroreceptors are affected (Lemonde et al., 2004; 
Parsey et al., 2006). 
The in vivo implication of 5-HT system and DR 5-HT1A autoreceptors 
in the response to antidepressants has been widely studied during the last years. 
During the 80’, preclinical and clinical evidence was accumulated indicating the 
involvement of the 5-HT system in the therapeutic action of some 
antidepressant drugs (Blier and de Montigny, 1994). It was demonstrated, for 
example, that compounds that increase serotonergic function, such as 
tryptophan and lithium, potentiated the effect of antidepressant drugs (de 
Montigny et al., 1983). Conversely, impairment of 5-HT synthesis led to a 
reappearance of depressive symptoms in patients in remission obtained with 
various antidepressant drugs (Shopsin et al., 1975; Delgado et al., 1990). In fact, 
it was by that time when electrophysiological findings were obtained 
demonstrating that short-term administration of SSRIs and monoamine oxidase 
inhibitors reduces the firing activity of 5-HT and increases the 5-HT levels in 
the DR in the rodent brain, but also that the firing activity was recovered as the 
treatment was pursed. This was shown to be due to a desensitization of DR 5-
HT1A autoreceptors, which control their firing activity (Quinaux et al., 1982; 
Blier and de Montigny, 1994) and the levels of extracellular 5-HT through 
GIRK channel activation (VanderMaelen et al., 1986; Sprouse and Aghajanian, 
Introduction
23 
 
1987; Sinton and Fallon, 1988). In fact, it has been reported that GIRK channels 
are implicated in the action of some SSRIs. Specifically, one study describes 
that the local administration of the SSRI citalopram into the DR produced a 
decrease in the extracellular 5-HT levels in DR projection areas, such as
striatum, and this effect was prevented by a pretreatment with pertussis toxin 
(Romero et al., 1994), which uncouples 5-HT1A receptors from GIRK channels, 
and prevents the inhibitory action of 5-HT on DR neurons (Innis and 
Aghajanian, 1987).
It is proposed that at the beginning of the antidepressant treatment, or 
with short-term treatments, 5-HT levels in the synaptic cleft in DR neurons 
increase, 5-HT couples to 5-HT1A receptors and thus DR firing activity is 
reduced. This, in turn, prevents an increase of 5-HT extracellular levels in 
forebrain projection areas (Artigas, 1993). However, as the treatment continues, 
or with a long-term treatment, DR 5-HT1A autoreceptors desensitize and firing 
rate completely recovers, leading to a robust increase in basal 5-HT 
extracellular levels in the DR and projection areas (Rutter et al., 1994; 
Invernizzi et al., 1995; Kreiss and Lucki, 1995) and obtaining the antidepressant 
effect (Fig. 1.6).
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Figure 1.6. The proposed mechanism of action of SSRIs involving the 5-HT1A
autoreceptor desensitization. (A) Representation in the depressed state, where there 
are low levels of 5-HT in the synaptic cleft, low 5-HT postsynaptic release and an up-
regulation of 5-HT1A autoreceptors. (B) Antidepressant action state, beginning of an 
antidepressant treatment. SERT blockade produces an increase in 5-HT levels and 
therefore a reduction in the firing rate. (C) As the treatment continues, the increase in 5-
HT levels causes the desensitization of 5-HT1A autoreceptors. (D) 5-HT1A sustained 
desensitization leads to a completely recovery of the firing rate and therefore 5-HT 
postsynaptic levels are increased obtaining the therapeutic benefit of the antidepressant 
treatment. Taken and modified from 'Essential Psychopharmacology' by McCarver 
(2011).
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Thus, nowadays, it is generally accepted that DR 5-HT1A autoreceptor 
desensitization is needed to obtain the antidepressant response, and that this 
desensitization is the responsible for the delay in the response to antidepressant 
drugs (Artigas et al., 1996; Blier et al., 1998; Berney et al., 2008). This idea of 
the involvement of the DR 5-HT1A receptor desensitization in the antidepressant 
response was supported by the fact that when 5-HT1A autoreceptors are blocked, 
the time needed to obtain the clinical improvement is shorter. In two clinical 
studies, the administration of the 5-HT1A receptor antagonist pindolol, which 
blocks 5-HT1A receptors (Romero et al., 1996), in combination with paroxetine 
accelerated the antidepressant effects in patients with major depression (Artigas 
et al., 1994; Blier and Bergeron, 1995). 
However, despite significant interest and evidence regarding the 
involvement of the 5-HT1A autoreceptors in the treatment and etiology of 
depression in humans, a direct test of their involvement has not been possible
due to the lack of available techniques (Richardson-Jones et al., 2010). The 5-
HT1A receptor involvement in the modulation of depression related behaviors 
has been reported from studies in mice (Heisler et al., 1998; Klemenhagen et al., 
2006), but these studies have not distinguished between auto- and 
heteroreceptors. In this sense, using the classic transgenic techniques, it was 
created the constitutive 5-HT1A receptor knockout mice. This animal model 
typically showed an “antidepressed” phenotype but also a robust anxiety-like 
behavior (Heisler et al., 1998; Parks et al., 1998; Ramboz et al., 1998), making 
this combined phenotype difficult to interpret given the co-morbidity of anxiety 
and depression in humans, and therefore it has been somehow ignored. 
However, the development of modern techniques made possible to 
conditionally decrease the 5-HT1A receptor expression specifically in the DR. It 
has been reported that the selective DR 5-HT1A receptor knockdown increases 
the antidepressant response and 5-HT release in stressful conditions, as well as 
promotes an “antidepressive-like” behavior (Ferres-Coy et al., 2013) without 
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altering the anxiety-like behavior. In the same line, another study where mice 
with high and low levels of 5-HT1A autoreceptors were generated reports that 
mice with high levels of 5-HT1A autoreceptors in the DR show a blunted 
response to acute stress and no behavioral response to antidepressants.
Moreover, it also reports that reducing the 5-HT1A autoreceptor levels prior to 
antidepressant treatment is sufficient to convert non-responders into responders 
(Richardson-Jones et al., 2010). Altogether, it seems that development of new 
techniques, which are making possible to distinguish between auto- and 
heteroreceptors, is confirming the particular involvement of DR autoreceptors in 
the etiology and treatment of depression. 
However, it cannot be ruled out the involvement of other components in 
this phenomenon of desensitization. In this sense, the low functionality of 5-
HT1A receptors could be due to reduced levels and/or function of the receptor, 
but also to alterations of downstream components, such as the GIRK channels. 
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1.2. GIRK channels
1.2.1. Overview
G protein coupled inwardly rectifying K+ (GIRK, also known as Kir3.x) 
channels are members of the inwardly rectifying K+ (Kir) channels family. Kir 
channels were first described in the skeletal muscle and the term “inwardly 
rectifying” comes from fact that Kir channels allow K+ to move more easily into 
the cell, having a greater conductance, rather than out to the cell (Hibino et al., 
2010). This is possible because the outward flow of K+ ions is inhibited by the 
intracellular polyamines and Mg2+, which block the pore in a voltage-dependent 
manner (Whorton and MacKinnon, 2011).
The primary sequences of the first Kir channels were elucidated in 
1993, and Kir1.1 and the classical Kir2.1 (Kubo et al., 1993) were also isolated 
(Ho et al., 1993). To date, 15 Kir subunit genes have been identified and 
classified into seven subfamilies categorized into four functional groups:
1. K+ transport channels: Kir1.x, Kir4.x, Kir5.x, and Kir7.x 
2. Classical Kir channels: Kir2.x
3. G protein coupled Kir channels: Kir3.x or GIRK 
4. ATP-sensitive K+ channels: Kir6.x
Kir channels play pivotal roles in controlling insulin release, vascular 
tone, heart rate, neuronal signaling, and membrane excitability (Hille, 1992). 
All of them share the same basic topology and are activated by 
phosphatidylinositol 4,5-bisphosphate (PIP2). However, GIRK channels are the 
unique in this family that also require G protein, in combination with PIP2, for 
activation (Wickman et al., 1994; Huang et al., 1998). Intracellular Na+ ions can 
also modulate certain GIRK channels (Lesage et al., 1995; Sui et al., 1996). 
GIRK are the downstream effectors of some G protein coupled receptors 
(GPCRs), such as the 5-HT1A receptors, and they can be activated by direct 
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binding of the 0 subunit of G protein to the channels, an interaction with 
important physiological consequences (Wickman and Clapham, 1995; Yamada 
et al., 1998). 
GIRK channels hyperpolarize neurons in response to activation of Gi/o
protein coupled receptors and decrease the excitability of neurons, slow 
synaptic potentials, and volume transmission (Krapivinsky et al., 1995; 
Wickman and Clapham, 1995; Luscher et al., 1997; Signorini et al., 1997; 
Wickman et al., 1998). Therefore, abnormal GIRK function can lead to 
excessive or deficient neuronal excitability, which is related to several 
pathologies such as epilepsy or Down’s syndrome. Thus, GIRK channels are 
proposed as new pharmacological targets for the treatment of a plethora of 
illnesses.
1.2.2. Structure, composition, and localization of GIRK channels in the 
brain 
The GIRK channel primary structure, which is common for all types of 
Kir channels, is that observed in a GIRK subunit. It is composed by a common 
motif of two putative transmembrane domains (TM1 and TM2), linked by an 
extracellular pore-forming region (H5), and cytoplasmic amino (NH2-) and 
carboxy (COOH-) terminal domains. The H5 region serves as the “ion-
selectivity filter” (Heginbotham et al., 1994) (Fig. 1.7A).
This primary structure is insufficient to form a complete ion channel, 
and therefore functional GIRK channels are made up of four such subunits in a 
tetrameric complex. These four subunits combine to form a canonical K+ pore 
forming trasmembrane domain (TMD), and a large cytoplasmatic domain 
(CTD) (Whorton and MacKinnon, 2011) (Fig. 1.7B). 
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Figure 1.7. Structure of GIRK channels. (A) Primary structure of a GIRK channel 
subunit, which contains two transmembrane domain (TM1 and TM2) regions, a pore-
forming region (H5) loop, and cytosolic NH2 and COOH termini. (B) Cartoon diagram 
of a complete GIRK channel. Each subunit of the tetramer is in a different color. The 
approximate boundary of the phospholipid bilayer is indicated by the thick black lines 
separating the transmembrane domain (TMD) from the cytoplasmatic domain (CTD). 
The extracellular surface is on top. Taken and modified from (A) Hibino et al. (2010) 
and (B) Whorton and MacKinnon (2011).
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In mammals, four subunits (GIRK1-4) have been cloned, which 
assemble into homo and heterotetrameric channels (Wickman et al., 2002). 
GIRK1, GIRK2, and GIRK3 are broadly expressed in many areas of the CNS, 
whereas GIRK4 expression is restricted to a small number of neuron 
populations including some specific areas of the neocortex, ventromedial 
hypothalamic nucleus, laterodorsal and lateral posterior thalamic nuclei,
insular cortex, and Golgi cells from the cerebellum (Karschin et al., 1996; 
Wickman et al., 2000; Aguado et al., 2008). This narrow distribution effectively 
reduces its contribution to neuronal GIRK channel formation. 
GIRK2 and GIRK4 subunits can form homomeric channels (Inanobe et 
al., 1999; Kobayashi et al., 1999). Although homomeric GIRK2 and GIRK4 
channels have been found in native tissues, exogenously expressed homomers 
of these channels give very brief and poorly resolved open-time kinetics that are 
different from native channels (Chan et al., 1997; Corey and Clapham, 1998). 
Both GIRK2 and GIRK4 can recruit GIRK1, greatly increasing its surface 
expression and resulting in highly active channels that are indistinguishable 
from native channels (Krapivinsky et al., 1995; Chan et al., 1997; Woodward et 
al., 1997; Kennedy et al., 1999). 
GIRK1 and GIRK3 subunits are unable to independently form 
functional channels (Chan et al., 1997; Woodward et al., 1997; Jelacic et al., 
1999; Mirshahi and Logothetis, 2004). Indeed, GIRK1 requires co-expression 
with another GIRK subunit to achieve membrane distribution (Krapivinsky et 
al., 1995; Hedin et al., 1996; Kennedy et al., 1996; Ma et al., 2002). GIRK1 and 
GIRK2 subunits can co-assemble with GIRK3 to form GIRK1/3 and GIRK2/3. 
Interestingly, it has been shown that GIRK2/GIRK3 heterotetramers have some 
activity, but reduced G0 sensitivity, compared with other heterotetramers 
containing GIRK1 subunits (Jelacic et al., 2000).
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Most neuronal GIRK channels are thought to be heteromeric, containing 
GIRK1 and GIRK2 subunits (Luscher et al., 1997; Signorini et al., 1997). 
Indeed, GIRK1 and GIRK2 knockout mice display similar behavioral 
phenotypes (Pravetoni and Wickman, 2008). Interestingly, the levels of GIRK1
subunit are decreased in GIRK2-/- mice (Signorini et al., 1997; Torrecilla et al., 
2002). However, several findings indicate that a wide array of GIRK subunit 
combinations may be relevant and exhibit specific functional properties. Thus, it 
has been shown that GIRK2/GIRK3 heterotetramers, which as previously 
mentioned exhibit reduced G0 sensitivity, could account for the GIRK currents 
in GABAergic neurons from VTA (Cruz et al., 2004). Also, the opiod-induced 
currents in noradrenergic neurons from LC are mediated by GIRK1, GIRK2,
and GIRK3 subunit-containing channels (Torrecilla et al., 2002). In the 
cerebellum, for example, there is a cell type-specific expression of GIRK 
channels, since there are at least seven distinct GIRK subunit expression 
patterns in several cell types (Aguado et al., 2008). In neurons from the 
hippocampus and spinal cord ultrastructural studies show that GIRK2, but not 
GIRK1, is present at post-synaptic specialization (Koyrakh et al., 2005; Marker 
et al., 2005). In dopamine neurons from the substantia nigra GIRK channels are 
formed by homomeric combination of splice variants of GIRK2 subunits 
(Inanobe et al., 1999), and in VTA the most typical combination is the assembly 
of distinct GIRK2 alternatively spliced isoforms with GIRK3 (Cruz et al., 2004; 
Labouebe et al., 2007). Three splice variants of GIRK2 (GIRK2a-c) exist in the 
brain, and splice variants of GIRK1 have also been reported, although its 
relevance is not well understood (Isomoto et al., 1996; Inanobe et al., 1999; 
Iwanir and Reuveny, 2008). No splice variants of GIRK3 and GIRK4 have been 
reported so far.
Despite its broad distribution in the CNS, the functional relevance of 
GIRK3 is uncertain. GIRK3 knockout mice are indistinguishable from wild-
type mice in some behavioral tests (Pravetoni and Wickman, 2008), have 
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similar agonist-induced GIRK currents, but exhibit less severe withdrawal from 
sedatives and reduced cocaine-self-administration (Morgan et al., 2003; Kozell 
et al., 2009). Interestingly, GIRK3 subunits, together with the major splice 
variant of GIRK2 which is GIRK2c, have been proposed to play a key role in 
regulating endosomal trafficking of GIRK channels (Ma et al., 2002; Lunn et 
al., 2007). 
In neurons, GIRK1 and GIRK2 subunits are localized at dendritic 
spines in the postsynaptic density, and also at presynaptic regions, whereas 
GIRK3 subunit has been detected in certain axons (Liao et al., 1996; Inanobe et 
al., 1999; Morishige et al., 1999; Grosse et al., 2003; Koyrakh et al., 2005; 
Kulik et al., 2006). In CA1 hippocampal pyramidal neurons GIRK channels are 
expressed in the soma, along the dendrites, and in dendritic spines (Chen and 
Johnston, 2005; Koyrakh et al., 2005; Kulik et al., 2006). In the cortex and 
cerebellum, they are also present at presynaptic sites in a subpopulation of 
excitatory axon terminals, close to GABAB receptors. Thus, GIRK channels 
may be involved not only in slow inhibitory postsynaptic potentials, but also in 
the presynaptic modulation of neuronal activity, although this idea still remains 
under debate.
Interestingly, differences in the subunit composition of GIRK channels 
have been detected between synaptic and extrasynaptic plasma membrane, 
suggesting that there is a compartmental molecular diversity. Only GIRK2 is 
detected in the spines in the postsynaptic density, whereas both GIRK1 and 
GIRK2 are located in the extrasynaptic membranes of the spine head, as well as 
in the dendritic shafts (Koyrakh et al., 2005).
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1.2.3. Physiology and regulation of GIRK channels 
As mentioned earlier, GIRK channels are members of the inwardly 
rectifying K+ channel family. The term “inward rectification” refers to a change 
in the slope of the current-voltage relationship of the channel at the reversal 
potential. At membrane potentials well above the equilibrium potential for K+,
the channel permits the efflux of K+, causing a very small outward current 
compared to the inward current caused at potentials well below equilibrium 
potential for K+. This rectification is due to the occlusion of the central pore by 
intracellular Mg2+ and polyamines at potential above equilibrium potential for 
K+ (Yamada et al., 1998). Under physiological conditions, the resting 
membrane potential of a typical neuron is positive to equilibrium potential for 
K+, and the small outward current through the channels decreases the 
excitability of the neuron. 
Postsynaptic inhibitory effects induced by activation of a wide range of 
pertussis toxin-sensitive Gi or Go type couple-receptors are mediated by direct 
binding of the G protein subunits G0 to the GIRK channel (Logothetis et al., 
1988). Thus, activation of GIRK channel by the binding of G0 complex permits 
the efflux of K+ ions and leads the cell to more hiperpolarized membrane 
potentials.
GIRK channels’ activity is dependent on interaction with several co-
assembled protein partners. In addition, GIRK channels undergo controlled 
subcellular trafficking that strongly regulates the GIRK-mediated signaling and 
contributes to their physiological roles (Lujan et al., 2009). Dysregulation of 
GIRK channels may contribute to particular human diseases and disorders. 
Given this, and because the efficacy of many clinically relevant and abused 
drugs relates to their actions on Gi/o-GIRK-dependent signaling, it is important 
to understand the cellular, subcellular, and molecular details of how GIRK 
channels and GIRK signaling are organized and regulated (Lujan et al., 2014).
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1.2.3.1. Regulation of ion conduction
As mentioned previously, GIRK channels are made up by four subunits 
which combine to form a K+ pore-forming TMD and a large CTD (Fig. 1.7). It 
is thought that ion conduction may be regulated by two functional gates in 
series: the inner helix gate, which is formed by the inner helices of the TMD, 
just inside the membrane; and the other gate, the G loop gate, which is formed 
by the G loop at the apex of the CTD, just outside the membrane (Doyle et al., 
1998; Jiang et al., 2002). For the complete activation of GIRK channels both 
gates have to be open (Pegan et al., 2005; Nishida et al., 2007). 
There are three main ligands that interact simultaneously with GIRK 
channels to regulate their activation: G protein, PIP2, and Na+ (Whorton and 
MacKinnon, 2011) (Fig. 1.8). Previous electrophysiological studies suggest that 
G proteins and Na+ function in a codependent manner with PIP2 to open GIRK 
channels (Huang et al., 1998). Recently, in reconstitution experiments using 
purified components, it has been proposed that these regulators individually 
activate GIRK channels partially, but in combination they activate the channels 
to a greater extent (Whorton and MacKinnon, 2011).
 G protein: when a G protein coupled receptor is stimulated through the 
binding of a neurotransmitter or drug on the outside of the cell membrane, it 
catalyzes guanine nucleotide exchange -GTP replaces GDP on the G subunit-
and releases G(GTP) and G0 subunit on the cytoplasmatic side (Gilman, 
1987). Then, G0 subunits can activate GIRK channels. Much evidence indicates
that G can also interact directly with GIRK channels (Huang et al., 1995; 
Rebois et al., 2006). It is suggested that direct binding of G subunit to GIRK 
channels is the responsible for their basal activity levels, even in the absence of 
receptor signaling, and that it also primes for activation by G0 (Peleg et al., 
2002; Clancy et al., 2005). It has been demonstrated that GDP-bound G can 
interact not only with GIRK1 and GIRK2, but also with a complex of G0-GIRK 
channels (Slesinger et al., 1995; Peleg et al., 2002; Ivanina et al., 2004). So, 
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even without agonist, GIRK channels make a complex with GDP-bound G and 
G0 called “preformed” complex (Hibino et al., 2010). It is proposed that, when 
the agonists bind to the receptor, G is released from the “preformed” complex 
and G0 stimulates the channels. In this condition, G0 may be always in close 
vicinity with GIRK channels and thus could quickly activate them. 
Accordingly, the formation of the “preformed” complex is suggested to be 
involved in rapid activation of GIRK channels in response to agonists (Slesinger 
et al., 1995; Peleg et al., 2002; Riven et al., 2006). Therefore, it is considered 
that whereas co-expression of G chelates G0 and reduces the basal activity of 
GIRK channels, it simultaneously augments the number of “preformed” 
complex and increases the pool of G0 available in the vicinity of the channels 
for their activation in response to agonists. Recently, the crystallization of a 
complex formed by G0 and the GIRK2 homomer has elucidated that GIRK2 
channels may have four binding sites for G0, one per subunit. These four 
binding sites are found at the well-conserved cytoplasmatic interfaces between 
the adjacent subunits that contribute to the formation of the extended 
cytoplasmatic pore. G0 alone only opens the G loop but not the inner helix gate 
of the channel, for the full gate opening PIP2 is also required (Whorton and 
MacKinnon, 2011).
 PIP2: like other Kir channels, GIRK channels also require PIP2, which 
stabilizes its functional integrity, to maintain their activity (Huang et al., 1998). 
In experiments where PIP2 is removed in inside-out patches, G0 cannot activate 
GIRK channels and therefore GIRK currents are absent (Sui et al., 1998). It has 
been suggested that one PIP2 lipid molecule binds to each subunit of the 
channels, near the TMD-CTD interface. The crystal structure of a GIRK2 
channels revealed that in the presence of PIP2, both the G loop gate and inner 
helix gate remain closed, and this is consistent with the observation that PIP2
alone is insufficient to open GIRK channels in electrophysiological experiments 
(Whorton and MacKinnon, 2011). Accordingly, a recent study shows that, when 
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PIP2 was added in bilayer membranes containing GIRK2 channel vesicles, the 
activity of GIRK channels was essentially unchanged, and similarly, addition of 
G0 subunits in the absence of PIP2 did not alter the channels activity. Only 
when both PIP2 and G0 were present, did they observe large K+ currents due to
robust GIRK2 channel opening (Wang et al., 2014).
As mentioned before, PIP2 is required for a full gate opening in GIRK channels. 
PIP2 alone binds but does not open either gate, and G0 alone opens the G loop 
gate but not the inner helix gate, but G0 in addition to PIP2 open both gates. 
Thus, PIP2 seems to play a facilitative role, this is, under conditions that favor 
channel opening, it presumably strengthens the interface between the CTD and 
the TMD, coupling tightly the two gates so upon G protein stimulation both 
gates open to activate the channel (Whorton and MacKinnon, 2011; Whorton 
and MacKinnon, 2013).
 Na+: certain GIRK channels, specifically those containing GIRK2 and 
GIRK4 subunits, are modulated by intracellular Na+ ions, which have their 
binding site near the TMD-CTD interface (Lesage et al., 1995; Sui et al., 1996; 
Sui et al., 1998; Ho and Murrell-Lagnado, 1999a; Ho and Murrell-Lagnado, 
1999b; Whorton and MacKinnon, 2011). A recent study in bilayer membranes 
containing GIRK2 channels shows that GIRK channels do open in the absence 
of internal Na+, but opening increases as the concentration of Na+ is increased 
(Wang et al., 2014). Thus, it seems that Na+ is not essential but augments the 
opening of the channels. This Na+ activation of GIRK channels is thought to 
serve an important physiological function by producing negative feedback on 
excessive electrical excitability. During excitation, Na+ entry elevates 
intracellular Na+ concentrations above the normal range, and this activates 
GIRK channels and drives the membrane potential negative again (Whorton and 
MacKinnon, 2011). 
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1.2.3.2. Regulation of GIRK signaling
Besides the regulation that the previously mentioned molecules exert on 
ion conductance of GIRK channels, there are other regulatory proteins and 
molecules that modulate GIRK channel activity through different mechanisms. 
Some of them are shown in figure 1.8.
 Regulators of G protein signaling (RGS) proteins: GPCR-GIRK 
signaling is negatively modulated by RGS proteins (Hibino et al., 2010; Luscher 
and Slesinger, 2010). They regulate various G protein-mediated signal pathways 
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formation of the inactive heterotrimeric G protein (Hepler, 1999; Ross and 
Wilkie, 2000; Lujan et al., 2009). Accordingly, RGS proteins primarily 
accelerate receptor-induced GIRK current deactivation kinetics, by as much as 
100-fold, among other influences (Doupnik et al., 1997). The increase in the 
rate of deactivation can be simply explained by the fact that activated RGS 
accelerate the hydrolysis of GTP on G, reduce the amount of free the G0 and 
decrease the activity of GIRK channels (Inanobe et al., 2001; Ishii et al., 2002). 
Discrete protein modules confer unique functionality to specific RGS proteins, 
and this, together with their unique cell and/or tissue expression patterns, 
appears to promote different interactions with GIRK channels (Sjogren, 2011; 
Lujan et al., 2014). For example, there is a selective gene expression of Rgs2 in 
VTA dopamine neurons that is preferentially associated with GIRK3 subunit 
containing channels. This association weakens the coupling between GABAB
receptors and GIRK2/3 heteromers (Labouebe et al., 2007). Indeed, it has been 
suggeste#"-hydroxybutyrate (GHB, GABAB receptor agonist) and 
morphine (µ-opioid receptor agonist) change the expression of Rgs2, leading to 
an alteration of the GABAB-GIRK signaling and possibly contributing to the 
development of tolerance to GHB. Recently, it has been demonstrated a novel 
role of RGS7 in hippocampal synaptic plasticity and memory formation. Mice 
lacking RGS7, which regulates GABAB-GIRK signaling in hippocampal 
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pyramidal neurons, exhibit deficits in learning and memory (Ostrovskaya et al., 
2014). It has been proposed that RGS7, in cooperation with its binding partner, 
R7BP, modulates the inhibitory effects of the GABAB-GIRK signaling, and that 
deletion of RGS7 sensitizes GIRK responses to GABAB receptor stimulation 
and slows channels deactivation kinetics, leading to a decreased neuronal 
excitability and disruption of inhibitory forms of synaptic plasticity.
 Sorting nexin 27 protein (SNX27): it is a GIRK3-interacting protein 
(Lunn et al., 2007) because it regulates the GIRK trafficking between the cell 
surface and endosome (Pfeffer, 2013). In the context of GIRK signaling, a 
proper function of SNX27 involves targeting GIRK3-containing channels to 
early endosomes, reducing the surface expression of GIRK channels and 
therefore enhancing the excitability of host neurons (Lunn et al., 2007; Balana 
et al., 2011; Balana et al., 2013). However, although GIRK2c can bind to 
SNX27, the surface distribution of homomeric GIRK2c channels is unaffected 
by SNX27 levels, suggesting that other unknown factors may influence the 
trafficking fates of GIRK channels (Nassirpour and Slesinger, 2007). SNX27 
has been implicated in Down’s syndrome and pscychostimulant addiction 
(Wang et al., 2013). Although an altered SNX27 expression and function 
impacts upon a wide array of cell signaling pathways, it has been suggested that 
an altered GIRK signaling may contribute to some of the cellular and behavioral 
deficits linked to these disorders. On one hand, in Down’s syndrome, there is a 
loss of SNX27 and interestingly, GIRK signaling is enhanced in the 
hippocampus and cortex of a mouse model of Down’s syndrome (Harashima et 
al., 2006; Best et al., 2007). Moreover, GIRK2 triploid mice display some of the 
neurological phenotypes associated with this syndrome (Cooper et al., 2012). 
On the other hand, there is an up-regulation of the b isoform of SNX27 in 
response to in vivo exposure to psychostimulants, such as cocaine and 
amphetamine. Interestingly, GABAB-GIRK signaling in VTA dopamine and 
GABA neurons is weakened after acute psychostimulant exposure and also 
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following chronic cocaine in layer 5/6 pyramidal neurons of the prelimbic 
cortex (Arora et al., 2011; Hearing et al., 2013).
 Neural cell adhesion molecule (NCAM): it regulates the trafficking and 
expression of GIRK channels. Cultured hippocampal neurons from mice 
lacking NCAM show larger GIRK currents, probably mediated by GIRK1/2 
subunit-containing GIRK channels. Co-expression of NCAM140 or NCAM180 
with GIRK1/2 in Xenopus oocytes led to a decrease in the surface expression of 
the cannels. Consistently, in cultured hippocampal neurons of NCAM-null mice 
the cell surface expression of GIRK1/2 is augmented, and this is not observed 
for GIRK1/4 channels (Delling et al., 2002). 
 GPCR linked to Gq-type may decrease GIRK channels activity through 
the activation of phospholipase C (PLC). It reduces PIP2 membrane levels and 
therefore its activation may reduce GIRK channel activity (Sadja et al., 2003).
 GPCR linked to Gs –type G proteins may increase GIRK channels 
activity, through the activation of protein kinase A (PKA). GIRK channels have 
a PKA phosphorylation site on the C-terminal domain that might mediate the 
effects of PKA on GIRK channels activity (Rusinova et al., 2009). 
It is noteworthy that the last two above mentioned pathways can 
modulate GIRK channel activity but do not induce channel activation and/or 
deactivation (Raveh et al., 2009). 
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Figure 1.8. Regulating mechanisms of the GIRK signaling complex. GIRK channels 
are activated following the activation of GPCRs associated with PTX-sensitive G 
proteins (Gi/o) that release G0 dimmers to couple to the channel directly (blue). PIP2 is 
in close vicinity to stabilize its functional integrity. GPCRs that are associated with Gq-
type G proteins (green) can reduce channel activity through activation of PLC, which 
breaks down PIP2. GPCRs that are associated with Gs -type G proteins (yellow) can 
increase channels’ activity through activation of PKA. Taken from Sadja et al. (2003).
- Macromolecular organization
It is thought that GIRK channels exist in a macromolecular multiprotein 
complex on the plasma membrane (Fig. 1.9). This complex is postulated to 
contain G proteins, GPCRs, GIRK channels and regulatory proteins (Doupnik et 
al., 1997; Hibino et al., 2010; Luscher and Slesinger, 2010). Although few 
protein-protein interactions involving GIRK channels have been demonstrated 
using the classical biochemical approaches or native system, some evidence 
support this established idea. First, because GIRK channels remain open as long 
as G0 (&(#" "&
* (&(#"  "##  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terminate GIRK channel activation (Luscher and Slesinger, 2010). Second, 
given that stimulation of GPCRs that couple to only PTX-sensitive (Gi/o type) G 
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proteins activate GIRK channels (Clancy et al., 2005; Geng et al., 2009), it has 
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associate directly with GIRK channels altering their gating (Schreibmayer et al., 
1996; Peleg et al., 2002; Ivanina et al., 2004; Clancy et al., 2005). Third, 
spectroscopic studies using fluorescence G proteins, GPCP and RGS proteins, 
have provided evidence regarding a special relationship between proteins within 
the macromolecular complex (Lavine et al., 2002; Fowler et al., 2007).
Moreover, some studies investigating the regulation and localization of 
GIRK channels in their native environment confirm the existence of this 
complex. Limiting the movement of µ opiod receptors does not alter the rate of 
GIRK activation in cerebellar granule cells, revealing that these signaling 
proteins are localized in membrane compartments and do not diffuse in the 
membrane (Lober et al., 2006). In addition, in PC12 neuronal cells chronic 
stimulation of M2 muscarinic receptors leads to a down-regulation of both M2
receptors and GIRK channels (Clancy et al., 2007), suggesting that they are co-
regulated in a complex. Furthermore, given that subunit 2 of the GABAB
receptor dimerizes with M2 receptors, it has been proposed the existence of a 
larger functional heteromeric complex (Boyer et al., 2009).
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Figure 1.9. Macromolecular signaling complex containing G proteins, G protein-
coupled receptors (GPCR), GIRK channels and regulatory proteins (RGS). 
Representation of the postulated macromolecular complex in which GIRK channels 
could exist. Note that RGS interacts selectively with GIRK channels whereas the 
heterotrimeric G protein associates directly with both GIRK and GPCR. Taken and 
modified from Lomazzi et al. (2008).
1.2.4. Physiological and pathophysiological aspects of GIRK channels
The physiological activation of GIRK channel can shape the neuronal 
network behavior at different levels. Their basal activity contributes to the 
resting membrane potential of neurons, shifting the membrane voltage by 
approximately -8 mV (Luscher et al., 1997; Torrecilla et al., 2002). In addition, 
receptor activation of GIRK channels provides another level of inhibition, to 
which three different changes in signaling can be generally ascribed: neuronal 
self-inhibition, neuron to neuron inhibition, and network level inhibition. 
As for neuronal self-inhibition or autaptic transmission, some neurons 
release a neurotransmitter to activate GPCR and in turn, GIRK channels on their 
own dendrites causing self-inhibition (Bacci et al., 2004). This is a well-known 
mechanism by which the firing rate of some neurons is autoinhibited. For 
example, in DR neurons, 5-HT or 5-HT1A receptor agonists activate 5-HT1A
autoreceptors. Their activation leads to inhibition of action potentials via 
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opening GIRK channels, resulting in an enhanced K+ conductance that leads to a 
hyperpolarization of the membrane potential and inhibition of 5-HT action 
potential (Sprouse and Aghajanian, 1987; Sinton and Fallon, 1988).
The second case is the neuron to neuron inhibition. When a 
neurotransmitter is released from neighboring neurons, it may also activate 
postsynaptic GIRK channels. Indeed, this occurs upon activation of 
postsynaptic GABAB receptors, D2 receptors, and group II metabotropic 
glutamate receptors by transmitters released to the synaptic cleft (Newberry and 
Nicoll, 1985; Dutar et al., 1999; Beckstead and Williams, 2007). While GABA 
spontaneously released produces a fast inhibitory postsynaptic potential 
mediated by GABAA receptors, strong or repetitive stimulation is required to 
elicit the slow inhibitory potential, suggesting that GABA released into the 
synaptic cleft diffuses and activates perisynaptic GABAB receptors coupled to 
GIRK channels. In the hippocampus generation of the slow inhibitory 
postsynaptic currents is important for regulating the rhythmic activity of the 
network (Scanziani, 2000). In addition to postsynaptic activation, recent 
characterization of GABAB receptor-mediated presynaptic inhibition suggests a 
presynaptic role for these channels in inhibiting GABA release (Ladera et al., 
2008; Michaeli and Yaka, 2010).
In the last case, the regulation of ambient levels of several endogenous 
G protein-coupled receptor agonists (for example, adenosine and somatostatin) 
may have a modulatory effect on large-scale neuronal networks through GIRK 
channel activation. This large-scale effect of neuromodulators is known as 
volume transmission. Moderate activation of GIRK channels in a population of 
neurons would be expected to reduce membrane excitability. For example, 
somatostatin acting onto somatostatin receptor subtype 5, might alter the 
oscillation behavior of thalamic networks through postsynaptic GIRK channel 
activation, together with presynaptic inhibition (Sun et al., 2002). Similarly, 
endogenous adenosine may suppress gamma oscillations in the hippocampus
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(Pietersen et al., 2009), possibly owing to the selective expression of adenosine 
A1 receptors on pyramidal neurons, which also activate GIRK channels. All 
these findings suggest a role for GIRK channels in signaling pathways beyond 
the direct membrane hyperpolarization. 
In this context, the use of GIRK mutant mice has been a key tool to 
study the roles of specific GIRK channel composition on neuronal physiology 
and animal behavior. Thus, GIRK channels functional relevance has been linked 
to susceptibility to seizures (Signorini et al., 1997), hyperalgesia and analgesia 
(Blednov et al., 2003; Marker et al., 2004; Marker et al., 2005), drug addiction, 
and alcohol-related behavioral effects (Kobayashi et al., 1999; Blednov et al., 
2001b; Morgan et al., 2003; Cruz et al., 2008), as well as motor activity, co-
ordination, and reward- and anxiety-related behaviors (Pravetoni and Wickman, 
2008) (see table 1 to observe the most studied implications of GIRK mutation in 
physiology). 
The first mutant mice regarding GIRK channels were the weaver mice 
(GIRKwv). These mice carry an spontaneous mutation in the pore region of 
GIRK2 subunit (GIRK2wv) (Patil et al., 1995), leading to a loss of K+ selectivity 
and G protein insensitivity (Kofuji et al., 1996; Navarro et al., 1996; Slesinger 
et al., 1997). Upon receptor activation, GIRK2wv depolarizes rather than 
hyperpolarizes neurons. Homozygous mice are characteristic because they have 
an abnormal walk as a consequence of the lost of granular neurons in 
cerebellum (Rakic and Sidman, 1973). They also show motor hyperactivity, 
spontaneous temblor, ataxia, and male sterility by the degeneration of dopamine 
neurons of the substantia nigra (Lane et al., 1977; Liao et al., 1996; Roffler-
Tarlov et al., 1996). In weaver mice it is showed an important decrease of 
GIRK2 subunit as well as GIRK1 subunits (Liao et al., 1996). Therefore, this 
mutation could have different qualitative effects in different neuronal 
populations depending on GIRK2 and GIRK1 expression levels. 
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One of the aspects in which GIRK channels might be relevant in the 
physiology is analgesia or pain perception.GIRK1 knockout and GIRK2 
knockout mice, as well as wild-type mice given intrathecal injection of the 
GIRK channel blocker tertiapin-Q, exhibit thermal hyperalgesia and blunted 
analgesic responses to intrathecal morphine (Marker et al., 2004; Marker et al., 
2005). Interestingly, GIRK channels make a dose-dependent contribution to the 
#'" )) )  4-opioid receptors agonist. In this sense, the effect of 
high, but not low doses of the opioid agonist, is selectively blunted after 
pharmacologic or genetic ablation of spinal GIRK channels. Morphine and the 
" 5-opioid agonist, U-50488, which are known to activate GIRK2 
containing channels through their coupling to opioid receptors, reduce pain 
perception in wild-type mice but not in the weaver mice (Ikeda et al., 2000). 
Moreover, in GIRK2-/- mice, for example, the dose–response curve for analgesia 
( & "# # #""# # 2-adrenergic receptor agonist) is 
shifted to higher concentrations, but the maximal effect is preserved (Mitrovic 
et al., 2003). This finding was confirmed in a study using double knockout mice 
for GIRK2 and GIRK3. In LC neurons of these mice, the potency (coupling 
efficiency) of opioid-induced analgesia is reduced, but the efficacy (maximal 
response) is intact (Cruz et al., 2008). Similarly, in LC neurons from GIRK2 
mutant mice opioid-induced currents were reduced in both in vivo and in vitro
studies (Torrecilla et al., 2002; Torrecilla et al., 2013). 
GIRK channels have also been implicated in opioid tolerance and 
dependence, as the channels undergo adaptive changes during chronic exposure 
to morphine, such as desensitization. In neurons of the LC inhibiting the 
signaling by both G protein coupled receptor kinase 2 and extracellular signal-
regulated kinase significantly reduces the met-enkephalin-induced GIRK 
current desensitization that normally occurs within minutes of drug application 
(Dang et al., 2009). However, GIRK current desensitization may not occur 
#4-opioid receptors are activated by morphine. Morphine causes less GIRK 
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channel desensitization in vitro and in vivo than met-enkephalin (Whistler et al., 
1999). In addition, in wild-type animals strong withdrawal signs are induce by 
the opioid receptor antagonist, naloxone, after chronic exposure to morphine. 
However, mice lacking GIRK2 and GIRK3 have strongly reduced withdrawal 
signs, fail to display an increase in LC neuron firing rate, which is an 
established electrophysiological hallmark of withdrawal, and morphine-induced 
GIRK-dependent postsynaptic currents are absent in LC neurons in these 
mutant mice (Cruz et al., 2008).
Regarding drug dependence, GIRK channels are thought to have a role 
in the acute rewarding effects and/or the adaptation that occurs with chronic 
exposure to addictive drugs that work through GPCR, such as opioids, the ‘club 
drug’ GHB, and cannabinoids. The initial target for addictive drugs in reward 
pathway is the VTA. Based on in vivo and in vitro experiments, distinct cellular 
mechanisms have been proposed for different classes of drugs (Luscher and 
6#'
 $	 "# "( 4-opioid receptors that are selectively 
expressed on GABAergic interneurons of the VTA and activates GIRK 
channels, reducing the firing of these cells and eventually leading to 
disinhibition of dopamine neurons (Johnson and North, 1992). It is suggested 
that GHB selectively activates GIRK currents in GABAergic interneurons, 
leading to desinhibition of dopamine neurons. This indirect effect is probably 
due to the fact that GABAB receptors in GABAergic interneurons are more 
efficaciously coupled to GIRK channels than those in dopamine neurons (Cruz 
et al., 2004). In addition, dopamine neurons in the VTA selectively express 
RGS proteins, and this could account for the lower sensitivity of GABAB
receptors for GIRK channels in these neurons (Labouebe et al., 2007). 
Furthermore, chronic drug exposure can dynamically regulate the expression 
levels of RGS proteins. In fact, it has been demonstrated that chronic morphine 
or GHB enhances the coupling efficiency of GABAB receptors and GIRK 
channels by decreasing RGS protein levels in dopamine neurons from VTA, 
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and therefore low drug concentrations are sufficient to inhibit dopamine 
neurons, losing the rewarding properties and becoming aversive (Lomazzi et al., 
2008). 
GIRK channels are also involved in alcohol-induced behavior and 
addiction, as alcohol directly binds and activates GIRK channels (Kobayashi et 
al., 1999; Mullner et al., 2000; Aryal et al., 2009). Indeed, weaver mice lack 
ethanol analgesia (Kobayashi et al., 1999). In GIRK2-/- mice some effects 
induced by ethanol, as stimulation of home cage motor activity, anxiety, and 
handling-induced convulsions are absent (Blednov et al., 2001b). GIRK3-/- mice 
display less severe withdrawal from ethanol and barbiturates (Pravetoni and 
Wickman, 2008). Moreover, it has been demonstrated that ethanol increases 
GABAB receptor-induced GIRK currents in VTA neurons, decreasing 
excitability of dopamine neurons (Federici et al., 2009). 
Memory and learning processes are also altered in mutant mice. Mice 
with low levels of GIRK1 have difficulties in learning and memory (Kourrich et 
al., 2003). In the same line, GIRK4-/- mice have difficulties with spatial learning 
(Wickman et al., 2000).
Regarding the implication of GIRK channels in the pathophysiology of 
several diseases, two broad principles should be taken into account. First, the 
loss of GIRK function can lead to excessive neuronal excitability, such as in 
epilepsy, whereas a gain of GIRK function can considerably reduce neural 
activity, such as is postulated to occur in Down’s syndrome. Second, the loss of 
selectivity can cause aberrant ion fluxes across GIRK channels, such as aberrant 
Na+ influx that triggers cell death, which is exemplified in a model of 
Parkinson’s disease. In epilepsy, GIRK2-/- mice develop spontaneous 
convulsions and show a propensity for generalized seizures when injected with 
a pro-convulsive GABAA receptor antagonist (Signorini et al., 1997). In Down’s 
syndrome, two mouse models have been generated that carry either a partial or 
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full segment duplication of the mouse chromosome 16, the orthologue of human 
chromosome 21 (Reeves et al., 1995; Sago et al., 1998). In both cases GIRK2 
protein is up-regulated, resulting in a larger slow inhibitory postsynaptic current 
mediated by GABAB receptors (Siarey et al., 1999). Moreover, hippocampal 
long term potentiation is reduced and long-term depression is enhanced in both 
models, and therefore synaptic plasticity of glutamatergic transmission is 
altered.
Additionally, cell death is implicated in Parkinson’s disease. The 
involvement of GIRK channels in Parkinson’s disease was first inferred from 
the weaver mouse (Patil et al., 1995), in which constitutively active GIRK2wv 
channels produce chronic depolarization and cell death in a subset of neurons in 
the brain (Kofuji et al., 1996; Navarro et al., 1996; Slesinger et al., 1996), 
mimicking the neuronal degeneration observed in Parkinson’s disease (Schein 
et al., 2005). The gain-of-function phenotype in dopamine neurons of weaver
mice is of clinical interest owing to the progressive degeneration of dopamine 
neurons in the substantia nigra. However, other mechanisms are also implicated 
in Parkinson’s cell death such as the nerve growth factor receptor (also known 
as p75NTR). The nerve growth factor mediates the programmed cell death in 
dorsal root ganglion neurons, which represents an important step in the 
development of the nervous system. In this sense, it has been reported that 
activation of p75NTR increases PIP2 plasma membrane levels, activating GIRK 
channels and creating a sustained K+ efflux that stimulates programmed cell 
death (Coulson et al., 2008). 
Moreover, although GIRK channels have a relatively well characterized 
role in controlling neuronal excitability by mediating the actions of inhibitory 
neurotransmitters in adult neurons, the role of GIRK channels before the 
development of mature neuronal circuitry has not been fully investigated. It has 
been suggested that GIRK channel action during early postnatal development 
regulates maturation of functional circuits at a time when activity is primarily 
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excitatory (Karschin et al., 1996; Sickmann and Alzheimer, 2002). In addition, 
it has been proposed that GIRK channels participate in the fundamental process
of neuronal selection that occurs both in development and in neurodegenerative 
disease, as a checkpoint in the p75NTR-mediated death pathway (Coulson et al., 
2008) (Table 1.1).
Introduction
50 
 
Table 1.1. Physiological and pathophysiological relevance of Girk gene 
mutation on GIRK signaling. Taken and modified from Lujan et al. (2014). 
Girk gene(s) Mutation Phenotype References
Nociception
Thermal 
Girk1, Girk2 Knockout Hyperalgesia Mitrovic et al., 2003 
Marker et al., 2004
Mechanical Girk2 Knockout Hyperalgesia Mitrovic et al., 2003
Chemical Girk2 Knockout Hyperalgesia Mitrovic et al., 2003
Antinociception
Opiod
Girk1, Girk2 Knockout Decreased 
analgesia
Mitrovic et al., 2003
Cruz et al., 2008
Girk3 Knockout Decreased 
sensitivy
Smith et al., 2008
GIRK2 Polymorphism Increased dose 
requirement
Nishizawa et al., 2009
Lotsch et al., 2010
2 Adrenergic Girk2, Girk3 Knockout Decreased 
analgesia
Blednov et al., 2003
Mitrovic et al., 2003
Smith et al., 2008
GABAB Girk2 Knockout Decreased 
analgesia
Blednov et al., 2003
Cholinergic Girk2 Knockout Decreased 
analgesia
Blednov et al., 2003
Cannabinoid Girk2, Girk3 Knockout Decreased 
sensitivity
Blednov et al., 2003, 
Smith et al., 2008
Reward
Motor activity
Girk1, Girk2 Knockout Enhanced basal 
and cocaine-
induced
Blednov et al., 2002
Morgan et al., 2003
Arora et al., 2010
Natural rewards
Girk2, Girk4 Knockout Elevated 
responding for 
food
Perry et al., 2008
Pravetoni and Wickman, 
2008
Girk2 Triploid Enhanced 
sucrose intake
Cooper et al., 2012
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Girk gene(s) Mutation Phenotype References
Girk2, Girk3 Knockout Decreased 
(cocaine)
Morgan et al., 2003
Self-administration Girk2 Knockout Enhanced 
consumption 
(ethanol)
Blednov et al., 2001b
Girk2/3 Knockout Decreased opiod 
withdrawal
Cruz et al., 2008
Dependence/withdrawal Girk3 Knockout Decreased 
sedative-
hypnotic 
withdrawal
Kozell et al., 2009
GIRK2 Polymorphism Associated with 
ethanol intake 
and stress Clarke et al., 2011
Learning and memory
Spatial 
learning/memory Girk4 Knockout Decreased recall Wickman et al., 2000
Fear conditioning Girk2 Triploid Decreased 
contextual recall
Cooper et al., 2012
Anxiety Girk2 Knockout Anxiolysis Blednov et al., 2001aPravetoni and 
Wickman, 2008
Schizophrenia GIRK1 Polymorphism Genetic 
association
Yamada et al., 2012
Seizure/epilepsy Girk2 Knockout Increased 
spontaneous and 
PTZ-induced
Signorini et al., 1997
Thermoregulation Girk2 Knockout Decreased drug-
induced 
hypothermia
Costa et al., 2005
Neurodevelopment Girk2 Weaver Loss of granule 
and dopamine 
neurons
Gregerson et al., 2001
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1.2.5. Pharmacology
Although GIRK channels are activated or inhibited by an array of 
psychoactive compounds, most of these compounds usually have other primary 
molecular targets (Lujan et al., 2014).
Antipsychotic drugs like tiorizadine, clozapine, pimozide, and 
haloperidol inhibit GIRK channels to different levels of efficacy. Risperidone 
has a lower inhibitory effect onto GIRK channels (Kobayashi et al., 2000; 
Kobayashi et al., 2004b). Antidepressants, especially those that inhibit NA or 5-
HT transporter, have important implications on the efficacy of GIRK channels, 
although they do not represent their primary target. As an example, fluoxetine 
has been shown to indirectly inhibit GIRK channels when they are over-
expressed on Xenopus oocytes (Kobayashi et al., 2003). Similarly, in studies 
conducted in GIRK2 weaver aberrant channel mutant mice, where the channels 
have less selectivity for K+ ions, fluoxetine also inhibits the activity of these 
channels (Takahashi et al., 2006). In contrast, in native systems containing 
GIRK channels, antidepressants as fluoxetine are expected to indirectly increase 
GIRK conductance given their coupling to 5-HT1A receptors. In addition, 
fluoxetine derivates have been also identified as selective agonists and 
antagonists of GIRK channels (Nishizawa et al., 2009). Tricyclic 
antidepressants including imipramine, desipramine, amitriptiline, nortriptiline, 
clomipramine, and maprotiline also inhibit over-expressed GIRK channels in 
Xenopus oocytes (Kobayashi et al., 2004a). Furthermore, it has also been 
described that fluoxetine and other tricyclic antidepressants are able to inhibit 
GIRK current induced by ethanol at clinical concentrations (Kobayashi et al., 
2003; Kobayashi et al., 2004a). Moreover, antitussives including caramiphen, 
which in addition show antidepressant-like effect in the forced swimming test, 
have an inhibitory action in the activated GIRK currents (Kawaura et al., 2010). 
Altogether, these investigations suggest that the modulation of GIRK channels 
by antidepressants could contribute to some therapeutic and secondary effects.
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Ethanol and methanol increase GIRK channel function. Ethanol effect is 
independent of G protein activation and secondary to cytolitic messengers 
(Kobayashi et al., 1999; Lewohl et al., 1999). Nowadays, it is well known that 
the activation of GIRK2 subunits-containing GIRK channels mediates the 
behavioral effects of the ethanol (Blednov et al., 2001b). Some other 
compounds, as for example halothane, isoflurane, and enfluorane, which are 
volatile anesthetics, or the bioflavonoid found in the grapefruit, naringin can 
also activate GIRK channels in a G protein-independent manner (Weigl and 
Schreibmayer, 2001; Yamakura et al., 2001; Yow et al., 2011). In addition, the 
mechanism of analgesic action of flupirtine is believed to be related to the 
activation of GIRK channels (Kornhuber et al., 1999).
Regarding GIRK channel inhibitors, some other drugs, such as 
verapamil, a Ca2+ channel blocker, have been described as inhibitors of the 
channels. However, the most selective GIRK channel blocker is tertiapin-Q
(Lesage et al., 1995). This peptide obtained from the honey bee venom is a high 
affinity blocker for GIRK channels and it is widely used in investigations 
studying GIRK signaling (Jin and Lu, 1998).
The pharmacologic manipulation of GIRK channels should evoke a 
wide range of undesirable consequences given their broad distribution, 
contribution and roles in the nervous system and cardiac and endocrine 
physiology. In this sense, new GIRK agents or strategies associated with 
enhancing or inhibiting GIRK signaling are likely to achieve their full 
therapeutic potential if they act selectively in a specific region and/or GIRK 
subunit. Recently, a new class of subunit-selective, efficacious, potent, and 
direct-acting GIRK channel agonists and antagonists has been identified 
(Kaufmann et al., 2013; Ramos-Hunter et al., 2013; Wen et al., 2013). Among
them, it is interesting the novel G protein-independent GIRK channel 
modulator, ML297, which is a potent agonist selective for GIRK1 subunit-
containing channels (Kaufmann et al., 2013). This small molecule was firstly 
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described as being efficacious in mice in delaying seizure onset in a maximal 
electroshock model of epilepsy, and it is also able to prevent convulsions and 
lethality in a chemically induce epilepsy model (Kaufmann et al., 2013). Further 
behavioral investigations have revealed that, in addition to its antiseizure 
efficacy, ML297 also has anxiolytic effects, since it decreases the anxiety-
related behavior without sedative or addictive liabilities (Wydeven et al., 2014). 
The recent identification of the subunit-selective, efficacious and potent
direct modulators of GIRK signaling represents a step forward in this field. 
These compounds, when available will greatly facilitate the efforts directed at 
understanding the physiological relevance of GIRK channels at the same time it 
will allow to reduce the use of mutant mice.
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1.3. Novel antidepressant treatments: ketamine as a rapid-acting 
antidepressant
Depression standard of care for the last 50 years has focused on 
monoamine neurotransmitters, including such treatments as selective serotonin 
reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors (Zarate et 
al., 2013). However, the efficacy of these medications is limited, with a 
substantial proportion of patients failing to achieve a sustained remission (Rush 
et al., 2006). In addition, the full clinical benefit of these traditional 
antidepressants is only achieved following weeks to months of treatment (Katz, 
2004). Therefore, there is a clear need for rapid-acting antidepressants with 
robust efficacy. In this regard, ketamine has turned out to be the prototype for a 
new generation of antidepressants that rapidly alleviate depression symptoms
and display efficacy in patients who are refractory to currently available 
treatments (Abdallah et al., 2015). 
Ketamine is a non-competitive NMDA receptor antagonist that has been 
widely used for induction and maintenance of anesthesia. The implication of the 
NMDA receptor in the pathophysiology and treatment of depression was first 
described in 1996 by Skolnick et al. By the late-1990s, it was found that low 
(subanesthesic) doses of this drug administered intravenously began to reduce 
depression symptoms within 4 hours of administration in severely treatment-
resistant depressed patients (Berman et al., 2000). The striking finding in this 
study was the rapid emerge and the persistence for so long of the antidepressant 
effects following a single dose of ketamine. The antidepressant effects tend to 
emerge 1-2 hours after the acute perceptual disturbances of ketamine have 
abated, and can persist for two weeks or longer in some patients. To date, five 
placebo-controlled studies have replicated the rapid antidepressant effects of 
ketamine in major depression and bipolar depression (Berman et al., 2000;
Zarate et al., 2006; Diazgranados et al., 2010; Valentine et al., 2011; Zarate et 
al., 2013). In these studies, the antidepressant effects were evident within 4 
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hours of treatment and sustained for 3-7 days. Little is known about the long-
term safety and efficacy of repeated ketamine dosing, which appears to extend 
the benefits of a single ketamine infusion. However, it seems that repeated 
ketamine infusions may safely extend the benefits for several months or even a 
year or more (Blier et al., 2012; Szymkowicz et al., 2013). In this line, the 
results of a larger controlled study of repeated ketamine administration 
(NCT01627782) will be published in the coming months.
Studies in animals using several behavioral models confirmed the rapid-
antidepressant effect of ketamine (Maeng et al., 2008; Li et al., 2010; Koike et 
al., 2013). These included a significant decrease in immobility in the forced 
swimming test (FST), a decreased escape failure and latency to escape in the 
learned helplessness paradigm, and a decreased latency to feed in the novelty 
suppressed feeding test (NSFT). The large body of evidence highlighting the 
antidepressant effect of ketamine led to establish the general idea that during 
depression there might be alterations in the glutamatergic transmission 
controlling the synaptic connectivity in different brain regions such as the PFC. 
Convergent evidence has highlighted the involvement of synaptic
plasticity alterations in the pathophysiology and treatment of depression (Popoli 
et al., 2002; Duman and Aghajanian, 2012). In fact, this altered synaptic 
plasticity represents the link between the neurobiology of depression and the 
therapeutic effects of ketamine. Synaptic plasticity, which can be “local”, such 
as long term potentiation, or “global” such as homeostatic plasticity 
(Turrigiano, 2012), regulates the excitability and connectivity of neuronal 
circuits in the context of adaptation, and it is accomplished by modulating the 
synaptic strength and synaptic number. This means changing the number of 
AMPA receptors and the synaptic and extrasynaptic number of NMDA 
receptors, which promote and reduce synaptic strength, respectively 
(Hardingham and Bading, 2010). The global synaptic plasticity is of particular 
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interest in depression given that clinical depression is associated with a reduced 
prefrontal synaptic connectivity. 
Prolonged stress and depression have been associated with neuronal 
atrophy and overall synaptic depression or dysfunction in the PFC and the 
hippocampus (Bessa et al., 2009; Kang et al., 2012; Yuen et al., 2012). 
However, the amygdala and nucleus accumbens show neuronal hypertrophy and 
synaptic potentiation (Vyas et al., 2004; Bessa et al., 2013). These changes are 
thought to result from the altered glutamate release induced by prolonged stress 
and the astroglial loss, leading to deficits in neurotrophic factors and to a 
sustained increase in extracellular glutamate. In the PFC, this excess in 
glutamate precipitates excitotoxicity, altered synaptic strength, dendritic 
retraction, and reduction in spine density and branching (Popoli et al., 2011; 
Krystal et al., 2013), leading to a down-regulation of PFC activity. 
Consecutively, this reduced activity leads to a gain of function in the amygdala,
which is negatively controlled by the PFC and associated with increased anxiety 
and hypothalamic-pituitary-adrenal axis reactivity (Savitz and Drevets, 2009). It 
has been found that the stress-related prefrontal synaptic dysfunction is 
precipitated by reduction in the brain-derived neurotrophic factor (BDNF) 
(Duman and Monteggia, 2006), and also by inhibition of the mammalian target 
of rapamycin complex 1 (mTORC1) (Ota et al., 2014). Data from preclinical 
studies and studies in animal models of depression propose that the 
enhancement of BDNF and mTORC1 signaling, leading to prefrontal 
synaptogenesis and reversal of stress and depression-induced neuronal atrophy 
and synaptic disconnectivity, are required for efficacious antidepressant 
treatment (Duman and Monteggia, 2006; Ota et al., 2014). 
Although antidepressants targeting monoaminergic systems were found 
to increase BDNF and synaptogenesis (Duman and Monteggia, 2006; Popoli et 
al., 2011), these effects were evident only after chronic treatment. Therefore, a 
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rapid acting antidepressant should directly target the mTOR and BDNF to 
ultimately increase the PFC synaptogenesis. 
Studies conducted in rodents have begun to elucidate the downstream 
effects of ketamine that may underlie the beneficial effects in depressed 
patients. In the cascade of effects, the first step is ketamine’s antagonism of the 
glutamatergic NMDA receptor. Specifically, low-dose ketamine administration
rapidly triggers three consecutive effects: first, a presynaptic disinhibition of 
glutamatergic neurons owing to a blockade of NMDA receptors on GABAergic 
interneurons, leading to a glutamate surge in the PFC; second, an increased 
activation of AMPA receptors (Maeng et al., 2008; Koike et al., 2011; Tizabi et 
al., 2012); and third, a postsynaptic activation of neuroplasticity-related 
pathways involving the mTORC1 and BDNF, resulting in synaptogenesis and 
synaptic potentiation (Homayoun and Moghaddam, 2007; Li et al., 2010; Autry 
et al., 2011). Together, these data show that these acute effects of ketamine 
rapidly oppose the stress- and depression-induced PFC neuronal atrophy and 
synaptic disconnectivity (Li et al., 2011) (Fig. 1.10). 
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Figure 1.10. Representation of the prefrontal synaptic connectivity during normal 
mood, depression, and remission of depression, and the postulated mechanism of 
action of ketamine on the glutamatergic neurotransmission. In euthymic individuals, 
stimuli and activity maintain and regulate synaptic strength. Following stress or 
depression, a synaptic disconnectivity is observed together with a reduction in the 
glutamatergic transmission, excitatory aminoacid transporters (EAAT), brain-derived 
neurotrophic factor (BDNF), and the mammalian target of rapamycin (mTOR) 
signaling. Remission, characterized by synaptic formation, is believed to arise from 
blockade of NMDA receptors located extrasynaptially on GABAergic interneurons, 
leading to a glutamate surge, activation of AMPA receptors, and an increase in BDNF 
release and mTOR signaling. Activation of mTOR signaling, ultimately, leads to 
increased synaptic proteins, spine densities and synaptogenesis (Jourdi et al., 2009; 
Akinfiresoye and Tizabi, 2013). Taken and modified from Naughton et al. (2014) and 
Abdallah et al. (2015).
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Similar to SSRIs, acute administration of ketamine increases 5-HT 
levels in the PFC (Amargos-Bosch et al., 2006) and the stimulated 5-HT efflux 
in the DR (Tso et al., 2004). Traditional antidepressants, including SSRIs, have 
been found to increase BDNF and synaptogenesis as ketamine does (Popoli et 
al., 2002; Duman and Monteggia, 2006). Besides this, it has been suggested that 
the effects of SSRIs may also involve alterations in NMDA function (Dutta et 
al., 2015). Therefore, it seems evident and consistent that there is an 
involvement of the 5-HT system in the antidepressant effect of ketamine and, 
obviously, as confirmed by a large body of studies, in the neurobiology of 
depression. Li et al. (2010) reported that a low dose of ketamine resulted in a 
rapid induction of spine formation in layer 5 pyramidal neurons of the PFC, 
which was correlated with an increase in the frequency and amplitude of 5-HT-
induced excitatory postsynaptic currents (EPSCs), which in turn, indicates an 
increase in cortico-cortical connections. As previously indicated, ketamine 
produces rapid antidepressant effects in various behavioral models including the 
FST (Li et al., 2010). Interestingly, this effect seen in the FST was later 
demonstrated to be via a 5-HT-dependent mechanism, since depletion of 5-HT, 
using the tryptophan hydroxylase inhibitor para-chlorophenylalanine, abolished 
the behavioral antidepressant effect of ketamine (Gigliucci et al., 2013).
Moreover, 5-HT1A receptors have been also specifically involved in the 
antidepressant effect of ketamine in the NSFT (Fukumoto et al., 2014). In this 
study, pretreatment with the 5-HT1A receptor antagonist, WAY100635 blocked 
the effect of ketamine in the NSFT, suggesting 5-HT1A receptor stimulation 
upon the AMPA receptor-dependent 5-HT release. Recently, it has been 
demonstrated that ketamine induces prefrontal 5-HT release through the 
activation of AMPA receptors and 42-nicotinic acetylcholine receptors in the 
DR (Nishitani et al., 2014). In this study, the direct stimulation of DR AMPA 
receptors significantly increased the 5-HT levels in the PFC, mimicking the 
effect of ketamine. Also, a microinjection of the AMPA receptor antagonist, 
DNQX, directly into the DR, attenuated the ketamine-induced 5-HT release. In 
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addition, a microinjection of the 42-nicotinic acetylcholine receptor 
antagonist, DHE, into the DR attenuated the ketamine-induced 5-HT release in 
the PFC. Consistently, 42-nicotinic acetylcholine receptor agonist increased 
5-HT levels in the rat PFC. The DR is innervated by glutamatergic neurons 
from several brain regions including the PFC. Thus, it seems possible that 
indirect activation of glutamatergic neurons in the PFC might induce glutamate 
release in the DR leading to a 5-HT release in the PFC. It is also postulated that 
the resulting 5-HT release in the PFC is because ketamine may disinhibit 5-HT 
neurons in the DR through the blockade of NMDA receptors on GABA 
interneurons, which suppress 5-HT neuronal activity (Boothman et al., 2006). 
Altogether, it is an established factor that ketamine administration induces 
alterations at the 5-HT neurotransmission level and/or its major source the DR, 
confirmed also by behavioral studies in animal models of depression (Fukumoto 
et al., 2014). In spite of these reports, to our knowledge, it has not been fully 
investigated whether a single dose of ketamine induces alterations in the 
glutamatergic activity and mTOR activation within the DR, and in that case, the 
time duration of the effects. 
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2. HYPOTHESIS AND OBJECTIVES
Depression is a highly disabling mood disorder with a big impact on 
public health, social, and economic aspects. It is well known that the 
monoaminergic systems have long been implicated in the etiology of this 
pathology. In this sense, much evidence indicates that depression is related to a 
decreased serotonergic neurotransmission, and as a result most of the 
antidepressants are aimed at increasing the extracellular levels of serotonin. 
Thus, the serotonergic system and its main biological substrate, the DR, are 
considered important therapeutic targets in this disorder. 
The activity of the DR is primarily controlled by 5-HT1A receptors, 
which play a critical role in the negative feedback regulation of serotonergic 
neurotransmission (Barnes and Sharp, 1999; Stamford et al., 2000). In fact, the 
SSRIs, which nowadays are the first-line therapies in depression, activate DR 5-
HT1A receptors by increasing 5-HT levels (Trivedi et al., 2006; Duman and 
Aghajanian, 2012). Microdialysis and electrophysiological studies using chronic 
administrations of SSRIs have indicated that desensitization of 5-HT1A receptors
correlates with the delayed onset of the clinical response to these drugs, which 
takes several weeks to appear (Sanchez et al., 2015). In addition to the delayed 
response, these medications have limited efficacy (Duman, 2014).
GIRK channels are coupled to inhibitory G protein coupled receptors, 
such as 5-HT1A receptors. It has been described that they control the 
electrophysiological properties of neurons and some neurotransmitter systems 
in different brain areas, as well as some animal behaviors (for review see 
Luscher et al., 2010). Specifically, the deletion of GIRK2 subunit promotes
important electrophysiological and biochemical alterations in different brain 
regions including the noradrenergic LC (Torrecilla et al., 2013). Regarding 
behavior, GIRK2 deficient mice display a reduced anxiety compared to wild-
type mice (Blednov et al., 2001a; Pravetoni and Wickman, 2008). Thus, the 
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selective manipulation of GIRK channels offers hope to treat a variety of 
debilitating afflictions (for review see Lujan et al., 2014).
Central serotonergic transmission is also influenced by the synaptic 
excitatory and inhibitory inputs to the DR (Nitz and Siegel, 1997; Gervasoni et 
al., 2000; Adell et al., 2002; Judge et al., 2004). In this sense, dysregulation of 
the GABAergic system has been considered to play a key role in the etiology of 
depression (Krystal et al., 2002; Sanacora et al., 2012). For example, it has been 
reported that SSRIs alter, ultimately, the GABAergic transmission (Zhong and 
Yan, 2004; Luscher et al., 2011). Likewise, alterations in the glutamatergic 
system have also been linked to depression. In fact, the glutamatergic antagonist 
ketamine produces fast antidepressant actions in depressed patients, including 
treatment-resistant patients (Zarate et al., 2006). The specific effects of this drug 
on the glutamatergic activity of the prefrontal cortex (PFC) have been well 
described (Moghaddam and Adams, 1998; Li et al., 2010; Aan Het Rot et al., 
2012). However, it is likely that ketamine also has effects on glutamate 
synapses of other brain regions related to the pathophysiology of depression, 
such as the DR. In fact, some studies point out the DR and serotonergic system 
as key targets of the biochemical and antidepressant-like effects of ketamine in 
rodents (Fukumoto et al., 2014; Nishitani et al., 2014). 
All this highlights that there is a major need for a better understanding 
and identification of novel strategies and targets for depression to develop new 
safer rapid acting agents with greater efficacy. Thus, we stated two hypotheses 
based on two alternative approaches in the field of depression therapy. First, 
GIRK2 subunit-containing GIRK channels are controlling the basal activity and 
regulation of DR neurons, and therefore restraining the serotonergic 
neurotransmission and impacting on depression-like behaviors and other 
functional aspects related to depression, such as adult neurogenesis. As a 
consequence, the electrophysiological, physiological and behavioral responses 
to serotonergic agents and antidepressants are altered in GIRK2 mutant mice 
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compared to wild-type mice. Secondly, the actions of ketamine related to its 
antidepressant effects extend to the DR, and therefore electrophysiological and 
biochemical alterations are observed in DR neurons of wild-type mice after 
ketamine administration.
The global aim of this study was to study in the DR two alternative 
approaches in the field of depression therapy, which are GIRK2 subunit 
containing GIRK channels as potential therapeutic targets, and the novel rapid-
acting antidepressant ketamine. To this end, we proposed two main objectives; 
first, to characterize the neurophysiology of DR neurons and the behavioral 
response in depression-related tests of mice lacking GIRK2 subunits; and 
second, to characterize the effect of ketamine in the glutamatergic transmission 
of the DR.
The specific objectives of the present study were:
I. To investigate in vivo the contribution of GIRK2 subunit-
containing GIRK channels to the electrophysiological properties of central 
serotonergic transmission. For this purpose, we measured the basal electrical 
activity of DR neurons and its modulation by serotonergic drugs, such as the 5-
HT1A receptor agonist 8-OH-DPAT, and the selective serotonin reuptake 
inhibitor citalopram, in GIRK2 mutant mice.
II. To study the involvement of GIRK2 subunit-containing GIRK 
channels in depression-related behaviors and in the behavioral response to the
SSRI citalopram. For this purpose, we assessed the depression-related behavior 
in the tail suspension test and novelty suppressed feeding test, as well as the 
citalopram-induced behavioral response in the tail suspension test in GIRK2 
mutant mice.
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III. To investigate in vitro the involvement of GIRK2 subunit-
containing GIRK channels in the regulation of the activity of DR neurons. For 
this purpose, we performed patch-clamp recordings of passive and active 
membrane properties and 5-HT1A receptor-mediated whole-cell currents, as well 
as of the glutamatergic and GABAergic pre- and postsynaptic transmissions in 
DR neurons of GIRK2 mutant mice.
IV. To study the electrophysiological and biochemical effects of 
ketamine on the glutamatergic transmission in the DR, as well as its impact on 
the mTOR activity in this brain area. To this end, we carried out in vitro patch-
clamp recordings to investigate the acute and sustained effects of ketamine on 
the glutamatergic transmission in DR neurons. In addition, we measured the 
mTOR activation after ketamine administration in DR neurons using the 
western blot technique. 
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3. MATERIALS AND METHODS
3.1. Materials
3.1.1. Animals
C57BL6/J wild-type mice (WT), GIRK2+/- (heterozygous), and GIRK2-/-
(homozygous) mice derived from heterozygote crossing (Signorini et al., 1997) 
were used. Initial breeding pairs were kindly provided by Dr. Kevin Wickman 
from the University of Minnesota (Minneapolis, USA). From this initial source 
a stable colony of GIRK2 mutant mice was grown. Animals were maintained at 
22±2 ºC in a 12-h light/dark cycle with food and water provided ad libitum.
Mice were genotyped by PCR screening as previously described by Torrecilla et 
al. (2002) at the Department of Neurochemistry Research of the Basque Health 
Service (Zamudio, Spain). Male and female adult mice (3-4 months) were used 
for the behavioral tests and electrophysiological procedures (4-8 weeks old for 
in vitro recordings). Male mice were used for the immunohistochemistry, 
physiological tests, and western blotting experiments (3 months). Every effort 
was made to minimize the animals’ suffering and to reduce the number of 
animals used to a minimum. All procedures were conducted in accordance with 
European Community Council Directive on ‘The Protection of Animals Used 
for Experimental and Other Scientific Purposes’ (86/609/EEC) and the Spanish 
Law (RD 1201/2005) for the care and use of laboratory animals. Experimental 
protocols were reviewed and approved by Local Committee for Animal 
Experimentation at the University of the Basque Country.
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3.1.2. Drugs and antibodies
The drugs and antibodies used in this study are shown in table 3.1.
Table 3.1. Pharmacological activity of the drugs and antibodies used in this 
study
Drug Activity Pursached from
Baclofen
(R)-4-Amino-3-(4-chlorophenyl)butanoic 
acid
GABAB receptor 
agonist
Sigma-Aldrich
Chloral hydrate Anesthetic Sigma-Aldrich
CGP55845
(2S)-3-[[(1S)-1-(3,4-
Dichlorophenyl)ethyl]amino-2-
hydroxypropyl](phenylmethyl)phosphinic 
acid hydrochloride
GABAB receptor 
antagonist
Tocris Bioscience
Citalopram
1-[3-(dimethylamino)propyl]-1-(4-
fluorophenyl)-1,3-dihydro-5-
isobenzofurancarbonitrile hydrobromide
SSRI
Tocris Bioscience
5-CT
5-Carboxamidotryptamine maleate salt 5-HT1A receptor agonist
Sigma-Aldrich
D-AP5
D-2-Amino-5-phosphonovaleric acid NMDA receptor antagonist
Tocris Bioscience
DNQX
6,7-Dinitroquinoxaline-2,3-dione Non-NMDA receptor antagonist
Abcam
GABA
-Aminobutyric acid Inhibitory neurotransmitter
Abcam
Isoflurane Inhalatory 
anesthetic
Abbott
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Drug Activity Pursached from
Ketamine
2-(2-Chlorophenyl)-2-
(methylamino)cyclohexanone
Non-competitive 
NMDA receptor 
antagonist
Ketamidor ®
Richter
Pharma AG
Kynurenic acid
Hydroxyquinoline-2-carboxylic acid Excitatory amino acidantagonist Sigma-Aldrich
MK801 
(5S,10R)-(+)-5-Methyl-10,11-dihydro-
5H-dibenzo[a,d]cyclohepten-5,10-imine 
maleate
NMDA receptor 
antagonist
Abcam
8-OH-DPAT
(±)-8-Hydroxy-2-
(dipropylamino)tetralin hydrobromide
5-HT1A receptor 
agonist Sigma-Aldrich
Pentobarbital
5-Ethyl-5-(1-methylbutyl)-2,4,6-
trioxohexahydropyrimidine
Anesthetic Sigma-Aldrich
Picrotoxin
GABAA receptor 
antagonist
Abcam
PP242
2-[4-Amino-1-(1-methylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-3-yl]-1H-
indol-5-ol
mTOR inhibitor Tocris Bioscience
Tertiapin-Q
GIRK channel 
blocker
Tocris Bioscience
WAY100635
N-[2-[4-(2-Methoxyphenyl)-1-
piperazinyl]ethyl]-N-2-
pyridinylcyclohexanecarboxamide 
maleate salt
5-HT1A receptor 
antagonist
Sigma-Aldrich
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The following antibodies were used in this study:
Antibody Activity Pursached from
Rabbit polyclonal 
antiserum for 
phosphorylated Histone 
H3 (HH3)
Primary antibody raised 
against HH3
Merck Millipore
(Upstate)
Mouse monoclonal 
antiserum for glial 
fibrillary acidic protein 
(GFAP)
Primary antibody raised 
against GFAP
Sigma-Aldrich
Biotinylated donkey anti-
rabbit IgG
Secondary antibody 
generated against rabbit 
IgG
Stratech Scientific
Biotinylated horse anti-
mouse IgG
Secondary antibody 
generated against mouse 
IgG
Vector Laboratories
Rabbit monoclonal 
antibody anti-phospho-
mTOR (Ser2448)
Primary antibody raised 
against phosphor-mTOR 
(Ser2448; Akt 
phophorylation site)
Cell signaling
Rabbit polyclonal 
antibody anti- phospho-
mTOR (Ser2481)
Primary antibody raised 
against phosphor-mTOR 
(Ser2481;
autophophorylation site)
Cell signaling
Rabbit monoclonal 
antibody anti-mTOR
Primary antibody raised 
against mTOR
Cell signaling
Rabbit monoclonal 
antibody anti-Raptor
Primary antibody raised 
against Raptor (regulatory 
associated protein of 
mTOR)
Cell signaling
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Antibody Activity Pursached from
Rabbit monoclonal 
antibody anti-  Primary antibody raised '"#*0! (mediates 
rictor-mTOR signaling to 
378	
Cell signaling
Rabbit polyclonal 
antibody anti-actin
Primary antibody raised 
'"#0-actin
Sigma-Aldrich
Goat polyclonal anti-
rabbit IgG
Secondary antibody 
generated against rabbit 
IgG
Cell signaling
For intraperitoneal administrations chloral hydrate, citalopram, 8-OH-
DPAT, and WAY100635 were prepared in physiological saline (0.9% NaCl). 
For intracerebroventricular administrations tertiapin-Q was dissolved in 
artificial cerebrospinal fluid (ACSF) containing (in mM): 125 NaCl, 2.5 KCl, 
1.2 MgCl2, 26 NaH2CO3, 1.25 NaH2PO4, 2.4 CaCl2, and 11 D-glucose (pH 7.3-
7.4). With the exception of chloral hydrate, drugs were freshly prepared 
immediately prior to the use.
For the in vitro recordings drug stocks were prepared in either 
distilled water (baclofen, 5-CT, D-AP5, GABA, ketamine, and WAY100635) or 
dimethyl sulfoxide (CGP55845, DNQX, MK801, and PP242), and diluted in
ACSF right before application. Kynurenic acid and picrotoxin were directly 
dissolved in ACSF before bath-perfusion. 
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3.2. Methods
3.2.1. Electrophysiological procedures
3.2.1.1. In vivo single-unit extracellular recordings of dorsal raphe neuronal
activity in anesthetized mice 
Preparation for electrophysiological procedures was performed as 
previously described (Torrecilla et al., 2013).
A) Animal preparation and surgery
Mice were anesthetized with chloral hydrate (400 mg/kg, i.p.) and
placed in a sterotaxic frame. A catheter (Terumo Surflo) was inserted in the 
peritoneum for additional administrations of anesthetic and other systemic 
drugs. In order to maintain a full anesthetic state, characterized by the absence 
of a nociceptive reaction to a paw/tail pinch and eye blink response to pressure, 
supplemental doses of chloral hydrate (100 mg/kg, i.p.) were periodically 
administered. Body temperature was maintained at ~ 37 º C for the entire 
experiment by means of a heating pad. For the recordings, the head was 
oriented in the horizontal plane. A bur hole (3 mm diameter approximately) was 
drilled and an electrode was lowered into the DR (relative to bregma: AP -4.5 
mm, ML -1.0 mm, DV -2.5 to -4.0 mm) (Franklin and Paxinos, 1997) with a 
lateral angle of 20° in order to avoid the damage of the sagital sinus. 
Intracerebroventricular administrations (tertiapin-Q 100 pmol in 1µL, 
dissolved in ACSF; or ACSF used as a control group) were performed using a 
""#' 94
 :"#
 ;#(<
 /"<#	 ##   =-gauge 
stainless-steel needle that was perpendicularly inserted into the right lateral 
ventricle (relative to bregma: AP -0.5 mm, ML -1.0 mm, DV -2.0 mm). 
Intracerebroventricular administrations were performed 10 min prior to the 
recordings.
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B) Recording and neuronal identification
For the preparation of the recording electrode, an Omegadot single 
barrel micropipette was stretched using an automatic vertical electrode stretcher. 
After that, the electrode was filled with 2 % solution of Pontamina Sky Blue in 
0.5 % sodium acetate, previously filtered in a 0.22 µm pore diameter filter. The 
tip of the electrode was broken under microscope inspection (40X 
magnification) to obtain a tip diameter of 1-2 µm. The electrode was lowered 
into the DR (found in the above mentioned sterotaxic coordinates) by means of 
a hydraulic microdrive (David Kopf Instruments, California, USA).
The extracellular signal from the electrode was preamplified (10X), 
amplified later (10X) by means of a high-input impedance amplifier, and 
monitored with an oscilloscope and an audioanalyzer. The extracellular signal 
was bandpass-filtered at 30-5000 Hz in a second amplifier and digitalized by an 
interface (CED micro 1401) (Fig. 3.1). Firing patterns were analyzed off-line, 
using the computer software Spike2 (Cambridge Electronic Design, UK). The 
following parameters were calculated: firing rate, coefficient of variation, 
percentage of cells exhibiting burst firing, firing rate of burst firing neurons, 
number of burst, percentage of spikes in burst, mean spikes per burst, and 
response to drug administration. Only one cell was studied in each animal when 
any drug was administered. 
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Figure 3.1. Schematic illustration of extracellular electrophysiological procedure in 
anesthetized mice. Briefly, the extracellular signal recorded was passed through a high-
input impedance amplifier, displayed in an oscilloscope, and monitored with an 
audioanalyzer. Individual (single-unit) neuronal spikes were isolated and analyzed by 
means of PC-based software Spike2.
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DR neurons were identified using established criteria, which included 
slow (0.5-2.5 Hz) and regular firing rate, and characteristic spikes with a long-
lasting and long duration (0.8-1.2 ms) positive-negative waveform. A burst was 
defined according to (Gartside et al., 2000), and burst-firing neurons in mice 
were identified as described previously (Gobbi et al., 2007), including a first 
interspike interval of 20 ms or less and a termination interspike interval greater 
than or equal to 160 ms (Fig. 3.2).
Figure 3.2. Example of a single spike from a dorsal raphe neuron recorded in vivo.
Picture was taken from Spike2 recordings. The abscise and ordinate axes represent 
duration (ms) and amplitude (volt) of the action potential, respectively.
C) Histological verification procedure 
At the end of some experiments, a Pontamine Sky Blue mark was 
" "#  "#'"&"#'94"(# ),"#
through the recording electrode (FICTE 10, Cibertec, Spain). This procedure 
left a discrete spot of Pontamine Sky Blue at the recording site. Afterwards, 
brains were carefully dissected and sliced to visually localize the Pontamine 
Sky Blue mark within the DR, which was identified on the midline and ventral 
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to the aqueduct. Only measurements from cells within the DR were included in 
the analyses. 
3.2.1.2. In vitro patch-clamp recordings of dorsal raphe neuronal activity in 
mice brain slices
Whole-cell patch-clamp recordings were performed as previously 
described (Torrecilla et al., 2008; Bruzos-Cidón et al., 2015).
A) Brain slice preparation
Male and female wild-type and GIRK2 mutant mice (4-8 weeks old) 
were anesthetized with isoflurane and killed by decapitation. Immediately 
afterwards, brains were removed quickly and mounted in a vibratome chamber 
(Leica VT 1200S or Microm HM 650V). Coronal slices (220 µm) were 
prepared in ice-cold artificial cerebrospinal fluid (ACSF, external bath solution) 
containing the following (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 2.6 CaCl2,
1.2 NaH2PO4, 11 D-Glucose, and 21.4 NaHCO3. ASCF was oxygenated and 
maintained at pH 7.4 by bubbling 95 % O2/5 % CO2 gas. Slices were stored in 
glass vials at 34ºC with oxygenated (95 % O2 /5 % CO2) ACSF. In order to 
reduce the neuronal damage, MK801 (10 µM) was included in the cutting and 
initial incubation solution to block NMDA receptors. To record excitatory 
synaptic activity, MK801 was substituted with kynurenic acid (2 mM). After an 
incubation period of at least 40 min, slices were transferred to the recording 
chamber for recording. 
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B) Neuronal identification and recording
The DR was located in slices that were rostral to the level where the 
aqueduct begins to meet the fourth ventricle and caudal to the decussation of the 
cerebellar peduncle. The slice containing DR was mounted on the recording 
chamber attached to a microscope (Eclipse FN1, Nikon), and was continuously 
perfused with ACSF at 1.5–3 ml/min at 32 - 34°C, maintained by an in-line 
solution heater (TC-324; Warner Instruments). Cells were visualized under 60X 
water-immersion objective with an upright microscope with infrared 
illumination. The image from the microscope was enhanced using a CCD 
camera and a camera controller (C2741-62; Hamamatsu), and ultimately 
displayed on a computer monitor (Fig. 3.3). DR neurons selected for recordings 
were located on the midline, which is identified the translucent area between the 
medial longitudinal fasciculus and the aqueduct, and ventral to the aqueduct. 
Only neurons that exhibited membrane properties typical of putative 5-HT 
neurons were included in this study (Haj-Dahmane and Shen, 2009; Gocho et 
al., 2013; Levitt et al., 2013). The recorded neurons, apart from being in the 
midline, had a large cell body and met the previously published properties of 5-
HT cells (see results section). Schematic illustration of the patch-clamp 
electrophysiological procedure is shown in figure 3.4.
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Figure 3.3. Microphotograph (60X magnification) illustrating a DR cell being 
recorded. The recording pipette patching the cell is also shown.
 "("<    "  
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established, and the cell membrane ruptured to obtain a whole-cell recording. 
Patch-clamp recordings made in current or voltage-clamp mode (Vh = -70 mV) 
were detected with a Multiclamp 700B amplifier. Signals were then digitized by 
Digidata 1440A analog-to-digital converter, and data were acquired and stored 
on-line using pClamp 10 software (all from Molecular Devices) (sampled at 10 
kHz, filtered at 5 kHz). Recording pipettes pulled from glass capillaries (1.7–3
 >3""#?#(#	()xperiments. 
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Figure 3.4. Schematic illustration of the patch-clamp procedure carried out in 
mouse DR slices. Briefly, data from the recordings were acquired using a Multiclamp 
700B amplifier, digitized with a digidata, and stored on-line using the pClamp 10 
software (all from Molecular Devices). To visualize the cells, the image from the 
microscope was enhanced with a CCD camera and a camera controller ,and displayed 
on a TV monitor.
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To record the electrophysiological intrinsic membrane properties, 
characteristics of action potentials, and 5-CT- and baclofen-induced currents 
recording pipettes were filled with internal solution containing the following (in 
mM): 130 K-Gluconate, 5 NaCl, 1 MgCl2, 1 EGTA, 10 HEPES (K), 2 Mg-ATP, 
0.5 Na-GTP and 10 Na2-phosphocreatine (pH: 7.3 - 7.4, 280 mOsm). Series 
resistance was not compensated and was monitored with a 5 mV depolarizing 
steps (200 ms) given every 60 s to ensure sufficient and stable electrical access 
   ('(  @"# A,9  ) "nclusion). Immediately 
after gaining access to the cell, membrane capacitance and input resistance were 
measured using the Clampex application of pClamp 10 software. In some 
experiments the resting membrane potential (Vm) was also recorded (I = 0). 
Afterwards, in current-clamp mode firing rate and active electrophysiological 
properties were measured by current injection (50 – 200 pA, 2 s). For current-
voltage (I/V) analysis voltage steps were applied. With this protocol the 
presence of an inwardly rectifying potassium current was detected by a typical 
current-voltage relationship obtained when the membrane potential was 
hyperpolarized from - 60 to -140 mV in -10 mV increments (100 ms per step) 
(Williams et al., 1982). Activation of GIRK currents induced by 5-CT and 
baclofen was also detected using the I/V protocol before and during drug 
administration. 
Junction potential between the pipette internal solution and the ACSF 
was ~ 15 mV and was not corrected. Slices used for recording were discarded 
after each experimental procedure, and no recording was performed more than 6 
h after animal’s decapitation. 
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 Recordings of inhibitory postsynaptic currents 
In order to study the spontaneous inhibitory postsynaptic currents 
(sIPSCs) and the evoked inhibitory postsynaptic currents (eIPSCs) we added 
DNQX (10 µM) to the external solution (ACSF) to block AMPA/kainate 
receptors. Recording electrodes were filled with the following internal solution 
(in mM): 70 K-Gluconate, 70 KCl, 2 NaCl, 4 EGTA, 10 HEPES (K), 4 Mg-
ATP, and 0.3 Na-GTP (pH: 7.3 - 7.4, 280 mOsm). To analyze sIPSCs, we 
voltage-clamped the cells at – 70 mV and the spontaneous activity of the cells 
was recorded for at least 3 min once the recording was steady and stable. To 
evoke eIPSCs,a monopolar stimulating electrode was positioned 100 - 4
&"#'#")""(",4
20 Hz, interpulse interval 100 ms, interpair interval 20 s) were delivered with an 
Iso-Flex stimulus isolator (A.M.P.I.). In some cells (in both spontaneous and 
evoked IPSC experiments), the GABAA receptor mediation of IPSC was 
verified at the end of the experiment with the addition of the GABAA receptor 
antagonist picrotoxin (100 µM). 
 Recordings of excitatory postsynaptic currents 
To isolate the spontaneous excitatory postsynaptic currents (sEPSCs) 
and the evoked inhibitory postsynaptic currents (eEPSCs) picrotoxin (100 4M) 
was added in the ACSF to block GABAA receptors. Glass pipettes were filled 
with an internal solution containing (in mM): 70 Cs2SO4, 20 CsCl, 20 NaCl, 15 
MgCl2, 5 HEPES (K), 1 EGTA, 2 Mg-ATP and 0.5 Na-GTP (pH: 7.3 - 7.4, 280 
mOsm). To study the sEPSCs, we recorded the spontaneous activity of the cells 
(Vh = – 70 mV) for at least 3 min, once the recording was steady and stable. To 
evoke eEPSCs, holding potential was held at + 40 mV in order to evoke both 
AMPA receptor- and NMDA receptor- mediated eEPSCs (AMPAR-eEPSCs 
and NMDAR-B3/8
"	"#'"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Hz) (Iso-Flex stimulus isolator, A.M.P.I.) was applied every 30 s using a 
monopolar stimulating electrode positioned 100 -  4   
cell being recorded. Once the evoked events were stable, the NMDA receptor 
antagonist D-AP5 (50 4M) was applied during 5-7 min in order to isolate 
AMPA-eEPSCs and calculate the AMPA/NMDA ratio. In some cells (in both 
spontaenous and evoked EPSC experiments), the AMPA receptor mediation of 
EPSC was verified at the end of the experiment with the addition of the 
AMPA/kainate receptor antagonist DNQX (10 µM). Under these conditions, 
DNQX eliminated all EPSC activity (for example, see Fig. 4.21A).
3.2.2. 8-OH-DPAT-induced hypothermia 
Animals were singly housed in clean cages 1 h before testing. Body 
temperature was assessed intrarectally, inserting a lubricated probe (BIO-
BRET-3, Cibertec, Spain) approximately 2 cm and monitored with a digital 
thermometer (CITEC, Cibertec, Spain). Three baseline body temperature 
measurements were taken as a control value before drug administration. 10 min 
after the third baseline measurement, animals received 8-OH-DPAT (0.5 mg/kg 
i.p.) or 0.9% physiological saline (i.p.) in equivalent volumes, and body 
temperature was monitored and measured the subsequent 10, 20, 30 and 60 min.
3.2.3. Behavioral tests
All tests were performed between 9:00 and 13:00 h. Mice were 
transferred to a noise free and temperature-controlled testing room at least 1 h 
before the tests for environmental habituation. No more than one test was 
performed in each mouse. 
3.2.3.1. Novelty suppressed feeding test 
The novelty suppressed feeding test (NSFT) is a conflict test that elicits 
competing motivations between the drive to eat and the fear of venturing into 
the center of brightly lit arena. The NSFT was performed as previously 
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described (Santarelli et al., 2003). Briefly, animals were food-deprived 24 h 
prior to the test (water ad libitum). The testing apparatus consisted of a plastic 
box (45x45x20 cm) with wooden bedding covered floor (approximately 2 cm) 
illuminated by a 70W lamp and with a white paper platform where a food pellet 
was placed in the centre. Mice were tested individually, placing them in the 
corner of the box and a stopwatch was immediately started. The test was carried 
out during 10 min and the latency to eat was timed. Only one mouse was 
studied at each time. Afterwards, animals were transferred to their home cages 
and the amount of food consumed by each mouse in the subsequent 5 min was 
measured as a control for change in appetite as a possible confounding factor.
3.2.3.2. Tail suspension test
In the tail suspension test (TST) mice were suspended 60 cm from the 
surface and secured by adhesive tape placed approximately 2 cm from the tip of 
the tail. Animals, both acoustically and visually isolated, were monitored by 
video camera for subsequent blind analysis. The total duration of the test was 6 
min, and mice were considered immobile when they stood completely 
motionless or hung passively. A decreased immobility time is considered an 
antidepressant-like activity according to Cryan et al. (2005). Intraperitoneal 
administration of citalopram (10 mg/kg) was carried out 30 min prior to the 
experiment in the same testing room. When the effect of citalopram was tested 
in a group of animals, another group of mice was injected with 0.9% saline in 
identical time and volume as a control group.
3.2.4. Immunohistochemistry procedures
3.2.4.1. Fixation and tissue processing
Male adult mice (n = 6 - 10/group) were anesthetized with an 
intraperitoneal injection of sodium pentobarbital (200 mg/kg). Animals were 
perfused through the aortic arch with 3.75 % acrolein (25 mL, TAAB, UK) in a 
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solution of 2 % paraformaldehyde and 0.1 M phosphate buffer (PB) pH 7.4, 
followed by 2 % paraformaldehyde (75 mL). Brains were removed and cut into 
coronal blocks that were post-fixed in 2 % paraformaldehyde for 24 h and kept 
in 0.1 M PB pH 7.4. Coronal sections were cut into 40 µm thickness using a 
vibrating microtome (VT1000 S, Leica, Milton Keynes, UK). Free floating 
sections in 0.1 M PB pH 7.4, were collected and stored in cryoprotectant 
solution containing 25% sucrose and 3.5% glycerol in 0.05 M PB, pH 7.4. 
Coronal sections at levels -1.34 mm/ -2.30 mm posterior to bregma and 1.18 
mm/ 0.26 mm anterior to bregma from hippocampus (HPP) and subventricular 
zone (SVZ), respectively, were selected for immunohistochemistry according to 
the stereotaxic mouse brain atlas of Franklin and Paxinos (1997). 
3.2.4.2. Antibodies
A polyclonal affinity-purified rabbit antibody raised against 
phosphorylated Histone H3 (HH3) and a monoclonal mouse antiserum 
generated against glial fibrillary acidic protein (GFAP) from pig spinal cord 
were used for the determination of proliferating cells and glia. We determined 
the number of proliferating cells by the presence of HH3 that were not co-
localized with GFAP to exclude glial phenotype. A series of control 
experiments were previously performed to asses for the non-specific 
background labeling or cross reactivity between antibodies derived from 
different host species. Furthermore, omission of primary and/ or secondary 
antibodies resulted in a total absence of target labeling (Rodriguez et al., 2008; 
Rodriguez et al., 2009).
3.2.4.3. Immunohistochemistry
To minimize methodological variability, sections containing HPP and 
SVZ from both hemispheres of all animals were processed at the same time 
using precisely the same experimental conditions. For this procedure, as 
previously reported (Rodriguez et al., 2008; Rodriguez et al., 2009), the sections 
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were first incubated for 30 min in 30% methanol in 0.1 M PB and 30% 
hydrogen peroxide (H2O2). Sections were then rinsed with 0.1 M PB for 5 min 
and placed in 1% sodium borohydride for 30 min. The sections were then 
profusely washed with 0.1 M PB before rinsing in 0.1 M Trizma base saline 
(TS) for 10 min. Brain sections were then incubated in 0.5% bovine serum 
albumin, in 0.1 M TS and 0.25% Triton X-for 30 min. Sections were incubated 
for 68 h at room temperature in 0.1% bovine serum albumin, in 0.1 M TS and 
0.25% Triton X-100 containing rabbit polyclonal antiserum for HH3 (1:1000) 
and mouse monoclonal antiserum for GFAP (1:60000). After the incubation, 
sections were rinsed in 0.1 M TS for 30 min. Subsequently, the HH3 and GFAP 
antibodies were detected in a sequential manner on the same sections. For HH3 
labeling, sections were placed in 0.1 M TS and 0.25% Triton X-100 containing 
(1) 1:400 dilutions of biotinylated donkey anti-rabbit IgG (Jackson 
Immunoresearch, Stratech Scientific Ltd., Soham, UK) for 1 h at room 
temperature and (2) avidin-bioctin peroxidase complex for 30 min at room 
temperature. The peroxidase reaction product was visualized in a solution 
prepared from SGZ kits for 2-3 min. For GFAP labeling, sections were the 
rinsed again in 0.1 M TS for 30 min and incubated in 0.1 M TS and 0.25% 
Triton X-100 containing (1) 1:400 dilution of biotinylated horse anti-mouse IgG 
(Vector Laboratories, Peterborough, UK) for 1 h at room temperature and (2) 
avidin-biocytin peroxidase complex for 30 min at room temperature. The GFAP 
peroxidase reaction was visualized by incubation in a solution containing 
0.022% 3,3´diaminobenzidine (DAB) and 0.003% H2O2 for 1-2 min. With this 
procedure, the GFAP labeling was seen in brown, allowing us to differentiate it 
from the HH3 labeled cells (blue). After stopping the reaction by rinsing the 
sections in 0.1 M TS for 5 min followed by 0.1 M PB for 15 min, sections were 
mounted onto gelatinized slides and allowed to dry overnight. Sections were 
then dehydrated in increasing concentrations of ethanol (50%, 70%, 80%, 90%, 
95% and 100%) and finally, xylene. Coverslips were applied using Entellan and 
slides were left overnight before counting.
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3.2.4.4. Cell quantification
The number of HH3-immunoreactive neurons and HH3/GFAP co-
localized cells was determined by counting the labeled cells in both 
hemispheres in coronal sections taken through representative sections of dentate 
gyrus (DG) of the HPP, and of the SVZ, at levels previously mentioned. Cells 
were counted and images obtained using light microscopy (Nikon Eclipse 80i). 
The number of HH3 positive cells and the area measurements of the DG and 
SVZ, bounded by the lateral ventricles, corpus callosum and caudate-putamen 
nucleus, were determined blindly to ensure consistency and reproducibility.
3.2.5. Western Blotting
Fresh tissue samples from the DR region were collected at 30 min and 
24 h after injection of the ketamine 30 mg/kg (i.p.) or vehicle (0.9% saline). All 
the samples were homogenized in 25 mM Tris-HCl (pH 7.4) and 0.32 M 
sucrose, supplemented with a phosphatase and protease inhibitor cocktails
(Sigma Chemical Co., Spain). To detect the proteins in the tissue homogenates, 
C((#)"#=4'	"#/D/-PAGE gels and then 
transferred to a polyvinylidene difluoride membrane (BioRad Laboratories). 
After washing in Tris-buffered saline containing 0.1% Tween-20 (TBST), the 
blots were blocked with 5% bovine serum albumin (Sigma) in TBST and 
incubated overnight at 4°C in rabbit anti-phospho-mTOR (Ser2448), rabbit anti-
phospho-mTOR (Ser2481), rabbit anti-mTOR, rabbit anti-Raptor, rabbit anti-
*0! ,E,  8 /"'#"#' %#'	 # &&" #"-0-actin (1:250000; 
Sigma-Aldrich) antibodies diluted in 5% bovine serum albumin–TBST. 
After thorough washing, these primary antibodies were detected by 
incubating for 1h at room temperature with IRDye 800CW goat anti-rabbit 
secondary antibody (1:10000; LI-COR Biosciences). After three final washes 
with TBST, the antibody binding was detected by using a LI-COR Odyssey 
two-channel quantitative fluorescence imaging system (LI-COR Biosciences). 
Materials and methods
91 
 
Digital images of Western blots were analyzed by densitometry using the 
ImageJ free access software (National Institutes of Health, Bethesda, MD). The 
)"(#&"#'#"<'"#0-actin. No protein 
bands were detected when the primary antibody was omitted.
3.2.6. Data and statistical analysis
Statistical analyses were performed using the GraphPad Prism Software 
(v.5.01; GraphPad Software Inc., USA).
3.2.6.1. Analysis of the in vivo electrophysiological data
The analysis of the in vivo electrophysiological data was carried out by 
means of the software Spike2 (Cambridge Electronic Design, UK). The 
following parameters were estimated:
A. Firing rate: Defined as the number of neuronal discharges per 
second. Data were represented in a bar histogram that showed the mean firing 
rate each 10 s. Basal firing rate was recorded for 180 s and mean firing rate after 
drug administration for 60 - 300 s (depending on plateau effect for each dose of 
drug).
B. Coefficient of variation: This parameter is related to the interval 
between consecutive discharges (inter-spike interval) and gives an idea of the 
regularity of the firing. The representation of the inter-spike interval histogram 
followed by the analysis ran by Spike 2 (script meaninx.s2s) led to the 
numerical value. Data was represented in percentage, as the division between 
the standard deviation and the mean value. The recording period analyzed (3 
min) was the same as that one used for the analysis of the firing rate.
C. Burst spikes: Some neurons of the DR show burst firing activity 
(first interspike interval F ; termination interspike interval G,$	?#
those neurons the firing rate, number of burst, percentage of spikes in burst and 
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mean spikes per burst was analyzed. The analysis of the burst firing was 
performed using the Spike 2 software (script w_burst.s2s) in the same period as 
the previous parameters.
D. Dose-effect curve: Dose - effect curves were analyzed for the best 
non-linear fit to a logistic three-parameter equation (Parker and Waud, 1971) as 
described previously (Miguelez et al., 2009).
The following equation was used:
E= Emax [A]n / (EDn50+ [A]n),
Where [A] is the concentration of the drug, E is the effect on the firing 
rate induced by A, Emax is the maximal effect, ED50 is the effective dose for 
eliciting 50 % of the Emax and n is the slope factor of the dose-response curve. 
Extra sum-of-squares F test (GraphPad Prism Software, San Diego, USA) was 
used for statistical comparison of the response to a drug in dose-response curves 
and for comparison of ED50 among groups.
Spontaneous firing rate and coefficient of variation were analyzed in 
selected pair comparisons using two-tailed unpaired t-test. Two-" H2
analysis of contingency tables was used to evaluate differences in the 
percentage of neurons presenting burst firing. Other parameters derived from 
burst pattern were analyzed by the non-parametric Kruskal-Wallis test followed 
by Dunn’s post-hoc test. The level of significance was considered as p < 0.05.
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3.2.6.2. Analysis of the in vitro electrophysiological data
Recordings were post-hoc filtered at 1 kHz and visually inspected. 
Analyses were carried out off-line using Clampfit application of pClamp 10 
software.
Electrophysiological intrinsic membrane properties (membrane 
capacitance, input resistance and resting membrane potential) were measured 
immediately after gaining access to the cell. A period of 1 s was taken for the 
analysis of the electrophysiological properties of action potentials at each 
current injection step (50 - 200 pA, 2 s steps). To this end a semi-automated 
sliding event detection procedure was used (Clampfit 10.3 software). We 
measured the frequency of the spikes at each current step, as well as parameters 
derived from the action potential (AP) waveform (AP threshold and AP 
amplitude) and AP kinetic parameters (AP half-width, AP rise time, and AP
decay time) at the minimum depolarizing current injection (50 pA).
To calculate the effect of 5-CT, baclofen, and GABA on DR cells, the 
amplitude of the currents induced by these drugs was measured when the 
maximal effect was reached, only in those cells where there was a complete 
washout after drug perfusion. 
One minute period was taken for off-line analysis of the spontaneous 
activity. Frequency, amplitude, and half-width of the events were analyzed. 
Single peak spontaneous synaptic currents were detected using a semi-
automated sliding template detection procedure (Clampfit 10.3 software). The 
template was generated by averaging multiple spontaneous currents (different 
templates for sIPSCs and sEPSCs), and the selection was fitted to 4 threshold of 
the template. Each detected event was visually inspected and discarded if the 
amplitude was < 7 pA. 
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Duration of synaptic events was determined by measuring the width at 
50 % of the peak amplitude (half-width). 
The amplitude of eIPSCs and eEPSCs was calculated by measuring the 
average current at the peak of each evoked event and subtracted from the 
current obtained during the 10 ms window taken immediately before the 
stimulus artifact. Other parameters such as half-width and decay time 
(calculated from 10 to 90 % of the decay phase) of the evoked currents were 
also inspected. 
To analyze the eIPSCs, paired stimuli were given at 20 s intervals 
(interpulse interval 100 ms), and the ratios of the amplitudes of the second and 
the first eIPSC were averaged for at least 10 trials (200 s). By analyzing the 
paired pulse ratio we studied if there was a paired-pulse facilitation or 
depression pattern in each DR cell, which is related to changes in the probability 
of GABA release (Bonci and Williams, 1997). Decay time and half-width of 
eIPSCs were also inspected.
To analyze the eEPSCs, a total of 30 evoked synaptic currents were 
recorded (15 min) before the application of D-AP5 (50 µM). Glutamatergic 
total response and AMPA-eEPSCs were calculated from the average of 5 
consecutive events. NMDA-eEPSCs was calculated by subtraction of AMPA 
receptors-mediated response to total eEPSCs. Peak currents of isolated AMPA-
and NMDA-eEPSC were used to calculate the AMPA/NMDA ratio.
When possible, data were compared through groups by one-way 
analysis of variance (ANOVA) followed by Newman-Keuls post-hoc test, 
otherwise two-tailed t-test (paired or unpaired t-test according to the data). 
Repeated measures one-way ANOVA followed by Newman-Keuls post-hoc test 
was also used in some cases. Two-"H2 analysis of contingency tables was 
used to evaluate differences in the percentage of neurons presenting paired-
pulse facilitation. The level of significance was considered as p < 0.05.
Materials and methods
95 
 
3.2.6.3. Analysis of the behavioral, immunohistochemical, hypothermic 
response, and western blotting data
In the NSFT the latency to eat (s) was measured over a total duration of 
10 min. Scoring for the measure of interest did not begin until the mouse 
reached for the food with its forepaws and began eating. Afterwards, the amount 
of food consumed (g) during 5 min was measured. 
In the TST the immobility time (s) was measured over a 6 min period. 
To investigate the effect induced by citalopram on the immobility time we 
calculated the immobility time reduction. Data was presented in percentage, as 
the division between the immobility time after citalopram injection for each 
individual mouse and the mean basal immobility time value obtained in its 
group. 
Data compiled from the TST, immunohistochemical and western 
blotting experiments were compared through groups by one-way ANOVA
followed by Newman-Keuls post-hoc test. For the analysis of the latency to eat
obtained from the NSFT Kruskal-Wallis nonparametric test followed by Dunn’s 
post-hoc test was used. For the 8-OH-DPAT hypothermic response analysis, 
two-way ANOVA followed by Bonferroni post-hoc test was used for statistical 
comparison among genotypes. The level of significance was considered as p <
0.05.
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4. RESULTS
4.1. STUDY I: Deletion of GIRK2 subunit of GIRK channels alters the  
5-HT1A receptor-mediated signaling and results in a depression-resistant 
behavior
4.1.1. Electrophysiological properties of dorsal raphe neurons of GIRK2 
mutant mice
To examine the contribution of GIRK2 subunit-containing GIRK 
channels to the spontaneous activity of dorsal raphe (DR) neurons, the firing 
pattern in GIRK2 mutant mice was studied (firing rate, coefficient of variation 
and burst activity).
All neurons recorded from wild-type (WT n = 86), GIRK2 
heterozygous (GIRK2+/- n = 79), and GIRK2 homozygous mice (GIRK2-/- n = 
45) fitted the standard criteria previously mentioned (see methods section 
3.2.1.1.). 
Spontaneous firing rate of DR neurons in GIRK2-/- mice was higher 
than in wild-type (1.99 ± 0.15 Hz, n = 45; 1.68 ± 0.08 Hz, n = 86; for GIRK2-/-
and WT mice, respectively. p < 0.05, unpaired two-tailed t-test). No changes 
were seen either in the coefficient of variation or in the burst activity among the
groups (Table 4.1). A more extended study of the burst pattern done by 
analyzing the mean firing rate, number of bursts, the percentage of spikes firing 
in bursts, and mean spikes in burst showed no differences among groups. 
Next, the effect of the high affinity GIRK channel blocker, tertiapin-Q
(100 pmol, i.c.v.) (Jin and Lu, 1998; Kanjhan et al., 2005) on the 
electrophysiological properties of DR neurons was assessed. The firing rate of 
DR neurons in tertiapin-Q-injected wild-type mice (WT TPN-Q) was 
statistically higher (38 %) than in wild-type group (WT TPN-Q: 2.32 ± 0.27 Hz, 
n = 15 and WT: 1.68 ± 0.08 Hz, n = 86. p < 0.001, unpaired two-tailed t-test). 
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However, no significant changes were seen either in the coefficient of variation 
or in any of the burst parameters, compared to wild-type mice. In order to 
clarify if the intracerebroventricular injection was producing an effect by itself, 
an intracerebroventricular ACSF-injected WT group was added as a control. No 
differences were observed in firing rate (1.80 ± 0.27 Hz, n = 7), coefficient of 
variation (35.13 ± 4.42 %, n = 7) or number of burst firing neurons (14 %) in 
this group compared to wild-type (data not shown).
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Table 4.1. In vivo electrophysiological properties of dorsal raphe neurons 
recorded under basal conditions in wild-type and GIRK2 mutant mice
Each cell was recorded for at least 3 min (180 seconds were taken for 
subsequent analysis). All data are presented as the mean ± S.E.M of n experiments. WT: 
wild-type; GIRK2+/-: GIRK2 heterozygous mice; GIRK2-/-: GIRK2 homozygous mice.
WT TPN-Q: tertiapin-Q-injected WT mice. *p < 0.05 and **p < 0.01 vs WT, unpaired 
two-tailed t-test. 
Results
104 
 
4.1.2. Effect of Girk2 gene deletion on the 5-HT1A receptor-mediated 
inhibition of dorsal raphe neuronal activity
To investigate the role of GIRK2 subunit in the 5-HT1A receptor-
mediated signaling, we compared the inhibitory effect of cumulative increasing 
doses of the 5-HT1A receptor agonist, 8-OH-DPAT (12.5 - 300 µg/kg, i.p.) onto 
firing rate of DR neurons of wild-type and GIRK2 mutant mice. In all the 
groups, 8-OH-DPAT caused a progressive and dose-dependent inhibition of the 
firing rate (Fig. 4.1A, B). In GIRK2+/- mice, the dose-response curve was shifted 
to the right, so that the ED50 mean value was significantly higher than the one 
obtained in wild-type mice (ED50: 42.15 ± 2.89 µg/kg, n = 8; ED50: 34.93 ± 
3.41 µg/kg, n = 15, for GIRK2+/- mice and WT, respectively. p < 0.05, 
nonlinear fit analysis, extra sum-of-squares F test). In GIRK2-/- mice, the shift in 
the dose-response curve was even greater and so ED50 mean value increased 2-
fold compared to wild-type mice (ED50: 69.50 ± 8.57 µg/kg, n = 5. p < 0.01, 
nonlinear fit analysis, extra sum-of-squares F test) (Fig. 4.1C). The following 
administration of the 5-HT1A receptor antagonist, WAY100635 (1 - 1.5 mg/kg, 
i.p.), completely recovered the firing activity in the three groups (WT: 86.22 ± 
7.04 %, n = 13; GIRK2+/-: 92.54 ± 12.98 %, n = 6; GIRK2-/-: 122.20 ± 23.27 %, 
n = 3). No significant differences were found among the groups.
Next, the sensitivity of the 5-HT1A receptor to the SSRI citalopram (0.5-
3 mg/kg, i.p.), in GIRK2 mutant groups was evaluated. For this purpose, 
citalopram dose-response curves obtained from GIRK2 mutant mice were 
compared to those obtained in wild-type mice. In all the groups, cumulative 
doses of citalopram caused a progressive and dose-dependent inhibition of the 
firing rate. However, citalopram showed less potency inhibiting DR neurons in 
GIRK2-/- mice, so that ED50 mean value for this group was significantly greater 
than the values obtained for GIRK2+/- and wild-type mice (ED50: 1.36 ± 0.04 
mg/kg, n = 6; ED50: 1.04 ± 0.04 mg/kg, n = 7; ED50: 0.97 ± 0.03 mg/kg, n = 13, 
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for GIRK2-/- , GIRK2+/-, and WT mice, respectively. p < 0.0001, nonlinear fit 
analysis, extra sum-of-squares F test) (Fig. 4.1D). 
Figure 4.1. The inhibitory effect of 8-OH-DPAT and citalopram on the firing rate 
of dorsal raphe neurons in wild-type and GIRK2 mutant mice. (A) Representative 
firing rate histograms illustrate the inhibitory effect of 8-OH-DPAT (12.5 - 300 µg/kg, 
i.p.) on dorsal raphe (DR) basal activity in wild-type (WT) and (B) GIRK2-/- mice. 
Following adminitration of the 5-HT1A receptor antagonist WAY100635 (1-1.5 mg/kg, 
i.p.) completely reversed the 8-OH-DPAT-induced inhibitory effect. (C) Dose-response 
curves for 8-OHDPAT and (D) citalopram (0.5 - 3 mg/kg, i.p.) on DR firing rate in WT, 
GIRK2+/- and GIRK2-/- mice. Each point represents the mean ± S.E.M. of n experiments 
(n = 5 - 15 mice/group).
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4.1.3. Effect of WAY100635 on the citalopram inhibitory effect in dorsal 
raphe neurons of wild-type and GIRK2+/- mice
In addition, we wanted to assess if the inhibitory effect of citalopram 
was mediated through 5-HT1A receptors. For this purpose, we performed 
experiments where we first blocked the 5-HT1A receptor with the 5-HT1A
receptor antagonist WAY100635 (25 µg/kg, i.p.), and recorded the firing rate 
for 10 min to observe whether the antagonist was altering the firing rate of DR 
neurons. After this, the inhibitory effect of two different doses of citalopram 
was studied in wild-type and GIRK2+/- mice. The doses were those 
corresponding to the ED50 and Emax mean values previously obtained for each 
group.
First, we observed that the administration of WAY100635 did not alter 
the firing rate of DR neurons in wild-type (Before WAY: 2.83 ± 0.41 Hz; After 
WAY: 3.26 ± 0.59 Hz, n = 7) or in GIRK2+/- mice (Before WAY: 2.60 ± 0.27 
Hz; After WAY: 2.44 ± 0.36 Hz, n = 10) (Fig. 4.2A). Additionally, 
WAY100635 attenuated the inhibitory effect produced by citalopram on the 
firing rate of DR neurons in both groups (Fig. 4.2B). In wild-type mice in the 
presence of WAY100635, the inhibitory effect of citalopram (1 mg/kg, i.p.; 
ED50 value for this group) was significantly smaller (11.84 ± 1.99 %, n = 5) 
than that obtained in the absence of WAY100635 (53.63 ± 4.67 %, n = 10) (p <
0.0001, unpaired two-tailed t-test). Similarly, in GIRK2+/- mice in the presence 
of WAY100635, the inhibitory effect of citalopram (1 mg/kg, i.p.; ED50 value 
for this group) was statistically smaller (15.97 ± 5.94 % n = 7) than that 
obtained in the absence of WAY100635 (49.36 ± 6.50 %, n = 5) (p < 0.01, 
unpaired two-tailed t-test). However, in wild-type the firing rate inhibition 
obtained with the Emax dose (1.5 mg/kg, i.p.) in the presence of WAY100635 
(74.86 ± 11.75 %, n = 7) was smaller, but not statistically different, than that 
obtained in the absence of WAY100635 (81.51 ± 6.15 %, n = 11). In GIRK2+/-
mice the firing rate inhibition obtained with the dose of citalopram 
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corresponding to the Emax value for this group (2 mg/kg, i.p.) was statistically 
smaller in the presence of WAY100635 (53.24 ±7.82 %, n = 7) than that 
obtained in the absence of WAY100635 (97.16 ± 2.54 %, n = 3) (p < 0.01, 
unpaired two-tailed t-test). 
Figure 4.2. Effect of WAY100635 on the firing rate and citalopram-induced 
inhibitory effect of dorsal raphe neurons in wild-type and GIRK2+/- mice. (A) Bar 
graphs showing that WAY100635 (25 µg/kg, i.p.) had no effect in the firing rate of 
dorsal raphe neurons in wild-type (WT) and GIRK2+/- mice. (B). Bar graphs showing 
that the blockade of the 5-HT1A receptor with WAY100635 decreased the inhibitory 
effect of the of citalopram in both groups. Bars represent means ± S.E.M. of n
expermiments (n = 10 - 3 cells/group).
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4.1.4. Effect of pharmacological blockade of GIRK channels on the 
citalopram-induced inhibition of dorsal raphe neuronal activity
To further investigate the 5-HT1A-GIRK signaling pathway, we 
performed a pharmacological blockade of GIRK channels with tertiapin-Q and 
the sensitivity of the 5-HT1A receptor to the effect of citalopram was evaluated 
in this group. For this purpose, we studied the inhibitory effect of citalopram on 
WT TPN-Q mice and also on the wild-type control group (ACSF-injected 
group, WT control). In both groups, citalopram (0.5-3 mg/kg, i.p ) caused a 
progressive and dose-dependent inhibition of the firing rate (Fig. 4.3A, B), but 
showed less potency inhibiting DR neurons in WT TPN-Q so that ED50 mean 
value for this group was significantly greater than the value obtained for WT 
control (ED50: 1.25 ± 0.04 mg/kg, n = 5; ED50: 0.99 ± 0.06 mg/kg, n = 4 for 
WT TPN-Q and WT control, respectively. p < 0.0001, nonlinear fit analysis, 
extra sum-of-squares F test) (Fig. 4.3C). Interestingly, ED50 mean values were 
similar between GIRK2-/- mice and WT TPN-Q, indicating that citalopram had 
the same potency in both groups (ED50: 1.25 ± 0.04 mg/kg, n = 5; ED50: 1.36 ± 
0.04 mg/kg, n = 6; for WT TPN-Q and GIRK2-/- mice, respectively). As 
expected, WT control showed similar ED50 values to the WT group. 
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Figure 4.3. The inhibitory effect of citalopram on the firing rate of dorsal raphe
neurons in wild-type and tertiapin-Q injected mice. (A) Representative firing rate 
histograms illustrate the inhibitory effect of citalopram (0.5 - 2.5 mg/kg, i.p.) on dorsal
raphe (DR) basal activity in artificial cerebrospinal fluid-injected mice (WT control, 
i.c.v.) and (B) tertiapin-Q injected mice (WT TPN-Q, 100 pmol, i.c.v.). (C) Dose-
response curves for citalopram (0.5 - 3 mg/kg, i.p.) on DR firing rate in wild-type (WT),
WT control, and WT TPN-Q. Each point represents the mean ± S.E.M. of n experiments 
(n = 4 - 5 mice/group).
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4.1.5. Characterization of 8-OH-DPAT-induced hypothermia in GIRK2 
mutant mice
To further study the functional status of 5-HT1A receptors in GIRK2 
mutant mice, we evaluated the 8-OH-DPAT-induced hypothermic response. In 
all the groups, 8-OH-DPAT (0.5 mg/kg, i.p.) caused a decrease in temperature 
(n = 6-7 per group). GIRK2-/- mice showed a reduced 8-OH-DPAT-induced 
hypothermia in every different time point, compared to wild-type mice. A two-
way ANOVA revealed that in the minute 30, the temperature decrease induced 
by 8-OH-DPAT was significantly smaller in GIRK2-/- mice compared to wild-
type ([F(2,68) = 10.30, p < 0.05]) (Fig. 4.4). In addition, another three groups of 
GIRK2+/-, GIRK2-/-, and wild-type mice were injected with 0.9% saline (saline 
groups, i.p.), in order to check if the manipulation of the animals or the 
intraperitoneal injection were causing an effect on the response. No significant 
changes in the temperature were observed in these groups. 
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Figure 4.4. The hypothermic response induced by 8-OH-DPAT in wild-type and 
GIRK2 mutant mice. The temperature decrease induced by 8-OH-DPAT (0.5 mg/kg, 
i.p.) was significantly lower in GIRK2-/- mice relative to wild-type (WT) in minute 30. 
Mice of each genotype injected with 0.9% saline (saline groups) were used as controls.
Each point represents the mean ± S.E.M of n animals (n = 6 - 7 mice/group; *p < 0.05 
vs WT, two-way ANOVA followed by Bonferroni post-hoc test). 
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4.1.6. Behavioral characterization of GIRK2 mutant mice and the response 
to citalopram
To evaluate whether GIRK2 subunit ablation impacts on depressive-
related behavior, GIRK2 mutant mice were evaluated using two well-
established behavioral models of antidepressant activity, the NSFT and TST 
(Santarelli et al., 2003; Cryan et al., 2005; Heurteaux et al., 2006). 
In the NSFT, both GIRK2-/- and GIRK2+/- mice showed a decreased 
latency to eat, compared to wild-type mice (GIRK2-/-: 145.60 ± 19.63 s, n = 9; 
GIRK2+/-: 154.60 ± 14.30 s, n = 20; WT: 212.00 ± 14.85 s, n = 22. p < 0.05,
Kruskal-Wallis nonparametric test following Dunn’s post-hoc test) (Fig. 4.5A). 
This decrease in the latency to eat observed in the mutant groups was not due to 
an increased appetite (Fig. 4.5B).
When evaluating the behavioral characteristics in the TST, GIRK2-/-
mice showed a lower immobility time than GIRK2+/- and wild-type mice 
(GIRK2-/-: 115.10 ± 9.08 s, n = 16; GIRK2+/-: 189.10 ± 3.24 s, n = 16; WT: 
191.80 ± 8.87 s, n = 14. p < 0.0001, one-way ANOVA following Newman-
Keuls test) (Fig. 4.5C). Next, we examined the effect of citalopram on the 
immobility time in the TST. In all the groups, the administration of citalopram 
(10 mg/kg, i.p.) 30 min prior to the test caused a reduction of the immobility 
time (Fig. 4.5D). However, in GIRK2-/- and GIRK2+/- mice this reduction was 
significantly lower than that observed in wild-type mice (GIRK2-/-: 53.2 ± 9.5 
%, n = 7; GIRK2+/-: 50.5 ± 5.9 %, n = 7; WT: 79.2 ± 5.1 %, n = 10. p < 0.05, 
one-way ANOVA following Newman-Keuls post-hoc test). 
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Figure 4.5. Behavioral characterization of GIRK2 mutant mice. (A) In the novelty 
suppressed feeding test (NSFT), both GIRK2+/- and GIRK2-/- mice displayed a lower 
latency to eat compared to wild-type (WT) mice (n = 9 - 22 mice/group; *p < 0.05 vs 
WT, Kruskal-Wallis nonparametric test following Dunn’s post-hoc test). (B) No 
changes among groups in the amount of food consumed after the NSFT (n = 9 - 22
mice/group). (C) In the tail suspension test (TST), GIRK2-/- mice displayed a lower 
immobility time compared to GIRK2+/- mice and WT (n = 14 - 16 mice/group; ***p <
0.001 vs WT, one-way ANOVA followed by Newman-Keuls post-hoc test). (D) In the 
TST, 30 min after the citalopram injection (10 mg/kg, i.p.), both GIRK2+/- and GIRK2-/-
mice showed a lower reduction of the immobility time compared to WT (n = 7 - 10
mice/group; *p < 0.05 vs WT, one-way ANOVA followed by Newman-Keuls post-hoc
test). Bars represent means ± S.E.M. of n animals.
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4.1.7. Basal neurogenesis in GIRK2 mutant mice
We next investigated whether GIRK2 subunit is involved in basal adult 
neurogenesis measuring the area density (#cells/mm2, Sv) of new proliferating 
cells in the DG of the HPP and in the SVZ of GIRK2 mutant mice compared to 
wild-type mice.
In the DG of the HPP and SVZ of all the groups newly generated cells 
were visualized, as indicated by HH3 immunoreactiviy (HH3-IR). GFAP 
immunoreactivity was detected throughout both areas, but less than 2% of HH3-
IR cells expressed GFAP. Quantitative analysis of the Sv of HH3-IR cells 
showed no differences among genotypes either in the DG (WT: 17.18 ± 1.89, 
GIRK2+/-: 16.69 ± 1.36, and GIRK2-/-: 14.71 ± 1.51. (Fig. 4.6A, B, C) or in the 
SVZ (WT: 152.43 ± 8.81; GIRK2+/-: 154.34 ± 6.10; GIRK2-/-: 139.99 ± 16)
(Fig. 4.6D).
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Figure 4.6. Brightfield micrographs showing phosphorilated Histone H3 (HH3, a 
proliferating mitotic marker) labelled cells within the dentate gyrus and 
subventricular zone of wild-type and GIRK2 mutant mice. (A - B) Dual labeling of 
HH3 positive cells (arrows) and glial cells (GFAP, brown) in the hippocampal dentate 
gyrus (DG) of (A) wild-type (WT) and (B) GIRK2-/- mice. Bar graphs showing no 
differences among groups in the area density of HH3 positive cells within (C) the DG 
(all layers included) and (D) the subventricular zone (SVZ) of WT and GIRK2 mutant 
mice. Bars represent means ± S.E.M. of n animals (n = 6 - 10 mice/group). GCL: 
Granular Cell Layer, ML: Molecular Layer. 
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4.2. STUDY II: Altered inhibitory pre- and postsynaptic activity in dorsal 
raphe neurons of GIRK2 mutant mice
4.2.1. In vitro electrophysiological properties of dorsal raphe neurons of 
GIRK2 mutant mice
DR neurons were found ventral to the aqueduct in slices that were 
rostral to the level where the aqueduct begins to meet the fourth ventricle and 
caudal to the decussation of the cerebellar peduncle. Whole-cell recordings 
were carried out in voltage- (Vh = -70 mV) or current-clamp mode from 
preumed 5-HT DR neurons. These cells were confined and densely present 
within the midline DR, which is an area where non serotonergic cells are hardly 
observed (Gocho et al., 2013). Putative 5-HT neurons were initially identified 
by midline location and large cell body. Moreover, the electrophysiological 
properties of the recorded neurons from wild-type mice in this study were 
similar and consistent with previously reported of tryptophan hydroxylase 
positive, non-GABAergic median dorsal raphe neurons from mice (Gocho et 
al., 2013; Levitt et al., 2013). 
Thus, we analyzed the intrinsic membrane properties of DR neurons 
from wild-type, GIRK2+/-, and GIRK2-/- mice. Membrane capacitance and 
resting membrane potential of DR neurons did not change among genotypes. 
However, input resistance values obtained in GIRK2-/- mice were statistically 
higher than those in GIRK2+/- and wild-type mice (p < 0.05 and p < 0.01 vs 
GIRK2+/- and WT mice, respectively, one-way ANOVA followed by Newman-
Keuls post-hoc test) (Table 4.2).
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Table 4.2. Electrophysiological intrinsic membrane properties of dorsal 
raphe neurons of wild-type and GIRK2 mutant mice.
WT GIRK2+/- GIRK2-/-
Membrane capacitance (pF) 52.29 ± 2.24
(23)
51.55 ± 3.18
(17)
52.33±2.37
(38)
?#("#	 479.40±31.07 
(24)
448.70±38.93 
(16)
667.00±55.25#**
(35)
Resting membrane 
potential (mV)
-57.71±0.73 
(56)
-54.48±1.50
(29)
-55.58± 1.19 
(43)
Values represent the mean ± S.E.M of (n) cells. WT: wild-type; GIRK2+/-:
GIRK2 heterozygous mice; GIRK2-/-: GIRK2 homozygous mice. #p < 0.05 and **p <
0.01 vs GIRK2+/- and WT mice, respectively. One-way ANOVA followed by Newman-
Keuls.
Since the differences in the electrophysiological properties were found 
between wild-type and GIRK2-/- mice, posterior analyses of the action potential 
(AP) characteristics were performed in these two genotypes.
In current-clamp mode, DR neurons were sometimes active (50 % of 
the total number of neurons recorded in wild-type and 58 % in GIRK2-/- mice),
and injection of current (50 – 200 pA) produced slow, regular firing of long-
duration action potentials (AP half-width) that increased in frequency with 
larger current injections (WT 50 pA = 9.63 ± 0.49 Hz; 100 pA = 15.13 ± 0.68 
Hz ; 150 pA = 19.57 ± 0.88 Hz; 200 pA = 23.71 ± 1.14 Hz; n = 24. GIRK2-/- 50 
pA = 10.32 ± 0.58 Hz; 100 pA = 16.32 ± 0.79 Hz; 150 pA = 21.28 ± 1.03 Hz;
200 pA = 24.97 ± 1.2 Hz; n = 35) (Fig. 4.7A, B, C). In this sense, neurons from 
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GIRK2-/- and wild-type mice had a similar sensitivity to injected currents (Fig. 
4.7C).
Then, we analyzed the AP properties in each group. As shown in figure 
4.7D, GIRK2-/- cells had similar AP amplitudes and threshold compared to those 
of wild-type cells. Regarding AP kinetics, such as half-width, rise time, and 
decay time, GIRK2-/- neurons had significantly narrower AP compared to wild-
type neurons (Table 4.3), shown by a shorter AP half-width and decay time (p <
0.05, unpaired two-tailed t-test).
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Figure 4.7. Electrophysiological properties of action potentials of dorsal raphe
neurons of wild-type and GIRK2-/- mice. (A and B) Action potential (AP) waveforms 
of dorsal raphe (DR) neurons from wild-type (WT) and GIRK2-/- mice elicited by 
current injections of 50, 100 and 200 pA (black, green and orange, respectively). (C) 
Input-output relationship curves of DR neurons from WT (n = 24) and GIRK2-/- mice (n
= 35). Means ± S.E.M. To calculate the firing frequency, APs were elicited by 
application of current steps from 0 to 200 pA in 50 pA increments (2 seconds per step). 
(D) Representative AP waveforms of DR neurons in WT and GIRK2-/- mice elicited 
with the minimum depolarizing current injection.
A B
C D
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Table 4.3. Electrophysiological properties of action potentials of dorsal 
raphe neurons of wild-type and GIRK2 mutant mice
WT GIRK2-/-
AP threshold (mV) -32.26 ± 1.94 (16) -35.73 ± 0.97 (35)
AP amplitude (mV) 71.48 ± 1.09 (17) 72.70 ± 1.06 (35)
AP half-width (ms) 1.55 ± 0.08 (17) 1.33 ± 0.05 *(36)
Rise time 10 – 90 % (ms) 0.55 ± 0.03 (14) 0.62 ± 0.03 (25)
Decay time 10 – 90 % (ms) 1.42 ± 0.08 (17) 1.16 ± 0.06 *(36)
Values represent the means ± S.E.M of (n) cells. WT: wild-type; GIRK2-/-:
GIRK2 homozygous mice. *p < 0.05, unpaired two-tailed t-test. 
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4.2.2. Role of GIRK2 subunit-containing GIRK channels in 5-HT1A- and 
GABAB receptor-mediated whole currents in dorsal raphe neurons
We studied the role of GIRK2 subunit-containing GIRK channels in 
mediating the postsynaptic actions of 5-HT and GABA through the activation of 
5-HT1A and GABAB receptors, respectively.
In the first series of experiments, in order to evaluate the 5-HT1A
receptor-mediated postsynaptic transmission on DR neurons of GIRK2 mutant 
mice, we examined the action of 5-CT, a high-affinity full agonist of 5-HT1A
receptors on the holding current of DR cells. Whole-cell voltage-clamp 
recordings performed in wild-type mice revealed that the application of 5-CT 
(100 nM) elicited an outward current that reached the steady-state in 1 - 2 min 
and slowly returned to baseline as the compound was washed from the slice 
(Fig. 4.8A). The amplitude of the 5-CT induced current ranged from 15.70 to 
104.00 pA (mean = 54.21 ± 7.23 pA, n = 13). Voltage steps (-60 to -140 mV, 
100 ms) were applied to determine the identity of the 5-CT induced-outward 
current before and during drug application. For this purpose, the current 
produced by 5-CT at each voltage was determined by subtracting the 
corresponding control current at baseline conditions, before the perfusion of 5-
CT. The 5-CT-induced current displayed inward rectification shown as a change 
in the slope of the current-voltage relationship, being more pronounced at more 
hyperpolarized potentials (Fig. 4.8B), and reversed at the potassium equilibrium 
potential. This is consistent with the activation of GIRK channels. In this sense, 
in wild-type animals the slope conductance between - 70 and - 80 mV (G1) was 
5.44 ± 0.43 nS, and statistically increased to 8.79 ± 0.41 nS (n = 9) when 
measured between - 110 and - 120 mV (G2) (p < 0.01, paired two-tailed t-test) 
(Fig. 4.8D). Thus, in wild-type mice, 5-CT activated 5-HT1A somatodendritic 
receptors resulting in an increase in GIRK conductance in DR neurons. In line 
with this, the 5-CT-induced current was reduced in DR neurons of GIRK2+/-
mice (34.18 %), and even more in GIRK-/- mice (68.75 %) compared that in 
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wild-type mice. In GIRK2+/- DR neurons, the amplitude of the outward current 
ranged from 12.10 to 67.90 pA (mean = 35.68 ± 3.84 pA, n = 18), and from 
2.90 to 59.60 pA (mean = 16.94 ± 5.28 pA, n = 12) in GIRK2-/- DR neurons 
(Fig. 4.8C). Therefore, mean amplitudes of the 5-CT-induced currents in 
GIRK2+/- and GIRK2-/- mice were statistically smaller than in wild-type mice (p
< 0.05 and p < 0.001 for GIRK2+/- and GIRK2-/- mice, respectively. One-way 
ANOVA followed by Newman-Keuls post-hoc test). Voltage steps were also 
performed in GIRK2 mutant mice before and after 5-CT application. In 
GIRK2+/- mice current-voltage analysis of the 5-CT induced currents showed 
inward rectification revealing activation of GIRK channels (GIRK2+/- G1 = 5.09 
± 0.43 nS; GIRK2+/- G2 = 6.38 ± 0.68 nS, n = 10. p < 0.05, paired two-tailed t-
test). However, no inward rectification was displayed in GIRK2-/- mice 
(GIRK2-/- G1= 2.58 ± 0.24 nS; GIRK2-/- G2 = 3.03 ± 0.56 nS, n = 7) (Fig. 
4.8D). Values obtained for G1 and G2 in GIRK2-/- were statistically different to 
those obtained for G1 and G2 in wild-type mice (p < 0.05 and p < 0.0001 for G1 
and G2 in GIRK2-/- mice vs G1 and G2 in WT mice, respectively. One-way 
ANOVA followed by Newman-Keuls post-hoc test). These results suggest a 
lack of function of GIRK channels in GIRK2-/- DR neurons.
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Figure 4.8. 5-CT-induced outward currents in dorsal raphe neurons of wild-type 
and GIRK2 mutant mice. (A) Representative whole-cell recordings illustrating the 
outward current induced by 5-CT (100 nM) in dorsal raphe (DR) neurons of wild-type 
(WT) mice, and the diminished 5-CT-induced outward current in GIRK2-/- mice. 
Voltage steps (-60 to -140 mV) were performed before and during 5-CT perfusion. (B) 
Summary graph of 5-CT induced current (pA) vs potential (mV) in DR neurons of WT, 
GIRK2+/- and GIRK2-/- mice. Note that 5-CT-induced currents showed inward 
rectification in DR neurons of WT and GIRK2+/- mice but not in GIRK2-/- mice. (C) 
Summary bar graph showing the amplitudes of the 5-CT-induced outward currents in 
WT, GIRK2+/- and GIRK2-/- mice. (D) Summary bar graphs showing the conductance 
between – 70 to – 80 mV (G1) and -110 to – 120 mV (G2) in DR neurons of the three 
groups. Bars represent the means ± S.E.M. of n experiments (n = 13 for WT; n = 18 for 
GIRK2+/-; and n = 12 for GIRK2-/- mice). *p < 0.05 and ***p < 0.001 vs WT, one-way 
ANOVA followed by Newman-Keuls post-hoc test. #p < 0.05 and ##p < 0.01, paired 
two-tailed t-test.
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Besides to 5-HT1A receptors, GIRK channels are coupled to GABAB
receptors in the DR. Thus, in the second set of experiments, we studied the 
GABAB receptor-mediated postsynaptic transmission on DR neurons of GIRK2 
mutant mice. Figure 4.9A shows that the application of the selective GABAB
agonist baclofen (30 µM), which activates GIRK channels (Andrade et al., 
1986; Thompson and Gahwiler, 1992), elicited an outward current that was 
reduced in GIRK2+/- (40 %) and in GIRK2-/- (78 %) compared to wild-type
mice. The mean amplitudes of the baclofen-induced currents were statistically 
smaller in GIRK2 mutant mice compared to wild-type mice (WT = 34.97 ± 5.79 
pA, n = 11; GIRK2+/- = 21.15 ± 2.39 pA, n = 11; and GIRK2-/- = 7.60 ± 0.79 
pA, n = 13. p < 0.0001 and p < 0.001 for GIRK2+/- and GIRK2-/- mice
respectively. One-way ANOVA followed by Newman-Keuls post-hoc test)
(Fig. 4.9B). Current-voltage analysis derived from voltage steps made before 
and during baclofen perfusion revealed that in wild-type and GIRK2+/- mice 
baclofen induced an inward rectification consistent with GIRK channels 
activation, although GIRK2-/- mice did not display inward rectification (data not
shown).
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Figure 4.9. Baclofen-induced outward currents in dorsal raphe neurons of wild-
type and GIRK2 mutant mice. (A) Representative whole-cell recordings in dorsal 
raphe (DR) neurons illustrating the outward current induced by the bath perfusion of 
baclofen (30 µM) in wild-type (WT), and the diminished baclofen-induced outward 
current in GIRK2-/- mice. (B) Summary bar graph showing the amplitudes of the 
baclofen-induced outward currents in DR neurons of WT, GIRK2+/- and GIRK2-/- mice. 
Bars represent means ± S.E.M. of n experiments (n = 11 for WT; n = 11 for GIRK2+/-;
and n = 13 for GIRK2-/- mice). **p < 0.001 and ***p < 0.0001 vs WT, one-way ANOVA 
followed by Newman-Keuls post-hoc test.
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4.2.3. Role of GIRK2 subunit-containing GIRK channels in the GABAergic 
synaptic activity in dorsal raphe neurons
To study the fast GABAergic synaptic activity we first blocked the 
glutamatergic transmission and isolated the GABAA activity by adding the 
AMPA/kainate receptor antagonist, DNQX (10 µM), to the external solution.
We investigated the spontaneous and evoked GABAergic presynaptic activity,
as well as the GABA-induced postsynaptic currents in GIRK2 mutant mice.
First, we evaluated if Girk2 gene mutation alters the GABAergic 
synaptic activity by studying the spontaneous and evoked inhibitory 
postsynaptic currents (sIPSCs and eIPSCs, respectively). Regarding sIPSCs, 
GIRK2 mutant mice displayed a statistically significant reduction, compared to 
those in wild-type, in both the mean frequency (GIRK2+/- = 2.01 ± 0.14 Hz, n =
32; GIRK2-/- = 2.55 ± 0.20 Hz, n = 44; and WT = 3.56 ± 0.31 Hz, n = 31. p <
0.0001 for GIRK2+/- and p < 0.001 for GIRK2-/- vs WT. One-way ANOVA 
followed by Newman-Keuls post-hoc test) (Fig. 4.10A, C), and the mean 
amplitude of the events (GIRK2+/- = 33.63 ± 2.55 pA, n = 32; GIRK2-/- = 34.88 
± 2.04 pA, n = 41; and WT = 49.66 ± 3.51 pA, n = 31. p < 0.0001 for GIRK2+/-
and GIRK2-/- vs WT. One-way ANOVA followed by Newman-Keuls post-hoc 
test) (Fig. 4.10B, C). However, no differences were found in the mean duration 
of the sIPSC (sIPSCs half-width) among genotypes (GIRK2+/- = 3.04 ± 0.09 ms, 
n = 32; GIRK2-/- = 3.07 ± 0.08 ms, n = 41; and WT = 2.89 ± 0.09 ms, n = 31) 
(Fig. 4.10C).
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Figure 4.10. Spontaneous GABAergic synaptic activity in dorsal raphe neurons of 
wild-type and GIRK2 mutant mice. (A) Representative current traces showing 
spontaneous inhibitory postsynaptic currents (sIPSCs) in dorsal raphe (DR) neurons of 
wild-type (WT), GIRK2+/- and GIRK2-/- mice. (B) Representative magnified sIPSCs in 
DR neurons illustrating the amplitudes of the sIPSCs in WT, GIRK2+/- and GIRK-/-
mice. (C) Summary bar graph showing the frequency, amplitude, and half-width of 
sIPSCs in DR neurons of WT, GIRK2+/- and GIRK2-/- mice. Bars represent the means ± 
S.E.M. of n experiments (n = 31 for WT; n = 32 for GIRK2+/-; and n = 41 - 44 for 
GIRK2-/- mice). **p < 0.001 and ***p < 0.0001 vs WT, one-way ANOVA following 
Newman-Keuls post-hoc test.
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Then, we evaluated the role of GIRK2 subunit-containing GIRK 
channels in the presynaptic inhibition of GABA release. For this purpose, 
GABA release was evoked by pairs of electrical stimuli (paired-pulse 
stimulation, 100 µs at 20 Hz) every 20 seconds (Fig. 4.11A). In wild-type mice, 
a 22% of the DR neurons showed paired-pulse facilitation, being the mean 
amplitude of the peak 1 855.50 ± 89.59 pA, and the mean amplitude of peak 2 
766.80 ± 80.10 pA (n = 17). Thus, the paired-pulse ratio, which is the ratio of 
the amplitudes between peak 2 and peak 1, was 0.89 ± 0.04 (n = 17). Compared 
to wild-type, GIRK2+/- mice showed a similar number of cells displaying 
paired-pulse facilitation (30 %) and no significant changes were found either in 
the mean values of the amplitude of peak 1 and peak 2 (654.60 ± 94.90 pA, and 
567.70 ± 71.80 pA, respectively. n = 19), or in the paired-pulse ratio (0.94 ± 
0.03, n = 19). However, GIRK2-/- mice displayed a statistically significant 
increase in the number of cells that showed paired-pulse facilitation (59 %) (p <
0.0001 vs WT, chi-square test). In addition, the mean amplitude of the peak 1 
was statistically smaller than in wild-type (534.00 ± 72.77 pA, n = 18) (p <
0.05, one-way ANOVA followed by Newman-Keuls post-hoc test). No changes 
were found in the mean amplitude of peak 2 (555.90 ± 71.60 pA, n = 18) 
compared to wild-type mice. Paired-pulse ratio was statistically greater in DR 
neurons of GIRK2-/- mice (1.05 ± 0.05, n = 17) compared to that obtained for 
DR neurons in wild-type mice (p < 0.05, one-way ANOVA followed by 
Newman-Keuls post-hoc test) (Fig. 4.11B, C, D). 
Other kinetic parameters such as half-width and decay time of the peak 
1 (Fig. 4.11E) were also analyzed and were similar among genotypes (WT peak 
1 mean half-width: 5.04 ± 0.43 ms, n = 14, and WT peak 1 mean decay time: 
16.29 ± 1.14 ms, n = 18; GIRK2+/- peak 1 mean half-width: 5.75 ± 0.73 ms, n =
14, and GIRK2+/- peak 1 mean decay time: 20.58 ± 2.32 ms, n = 19; GIRK2-/-
peak 1 mean half-width: 5.60 ± 0.54 ms, n = 15, and GIRK2-/- peak 1 mean 
decay time: 18.88 ± 2.39 ms, n = 15).
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Figure 4.11. Electrophysiological parameters of evoked inhibitory postsynaptic 
currents in dorsal raphe neurons of wild-type and GIRK2 mutant mice. (A) 
Representative traces of the recordings of evoked inhibitory postsynaptic currents 
(eIPSCs) in dorsal raphe (DR) neurons of wild-type (WT), GIRK2+/-, and GIRK2-/-
mice, showing a different pattern in the response to the paired-pulse stimulation in DR 
neurons of GIRK2 mutant mice compared to WT. (B) Summary bar graph comparing 
percent of DR neurons that display paired-pulse facilitation in WT, GIRK2+/-, and 
GIRK2-/- mice. (C) Summary bar graphs showing the mean amplitudes of the peak 1
(top), and peak 2 (bottom) of eIPSCs in DR neurons of WT GIRK2+/- and GIRK2-/-
mice. (D) Paired-pulse mean ratios of DR neurons in WT, GIRK2+/-, and GIRK2-/- mice 
summarized in a bar graph. (E) Summary bar graphs showing half-width (top) and 
decay time (bottom) of the peak 1 of eIPSCs in DR neurons of WT, GIRK2+/,- and 
GIRK2-/- mice. Bars represent the means ± S.E.M. of n experiments (n = 17 - 18 for 
WT; n = 19 - 20 for GIRK2+/-; and n = 17 - 18 for GIRK2-/- mice). *p < 0.05 vs WT, 
one-way ANOVA followed by Newman-Keuls post-hoc test. ***p < 0.0001 vs WT, chi-
square test.
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 Control of the GABAergic presynaptic activity by 5-HT1A
and GABAB presynaptic receptors in GIRK2 mutant mice
Once having detected that Girk2 gene mutation promotes alterations in 
the GABAergic activity at the presynaptic level, we studied whether the control 
that 5-HT1A and GABAB receptors exert on the GABAergic presynaptic activity 
was normal in GIRK2 mutant mice. 
In the first set of experiments we evaluated the control of the 
GABAergic presynaptic activity exerted by presynaptic 5-HT1A receptors in DR 
neurons of GIRK2 mutant mice. For this purpose, we recorded the sIPSCs in 
basal and stable conditions, when the frequency and amplitude of the events and
the holding current remained steady. Then, the 5-HT1A receptor antagonist, 
WAY100635 (10 nM and 1 µM), was perfused during 5 min, and frequency and 
amplitude of the sIPSCs were analyzed before and after drug perfusion (Fig. 
4.12A).
In DR neurons of wild-type mice, WAY100635 10 nM and 1 µM 
caused a significant increase (50 % and 47 %, respectively) in sIPSCs frequency 
that was similar at both concentrations (WT WAY 10 nM ratio: 1.50 ± 0.25, n =
6; WT WAY 1 µM ratio: 1.47 ± 0.18, n = 9). However, in GIRK2-/- mice, 
WAY100635 10 nM and 1 µM caused only a slight increase (10% and 5%, 
respectively) in the frequency of sIPSCs (GIRK2-/- WAY 10 nM ratio: 1.10 ± 
0.09, n = 8; GIRK2-/- WAY 1 µM ratio: 1.05 ± 0.08, n = 9) that was statistically 
smaller at the higher concentration compared to that in wild-type (p < 0.05, 
unpaired two-tailed t-test) (Fig. 4.12A, B). 
Regarding the effect of WAY100635 on the amplitude of sIPSCs, no 
statistical changes were seen either in wild-type (WT WAY 10 nM ratio: 1.06 ± 
0.08, n = 6; WT WAY 1 µM ratio: 1.19 ± 0.15, n = 8) or in GIRK2-/- mice 
(GIRK2-/- WAY 10 nM ratio: 1.24 ± 0.21, n = 6; GIRK2-/- WAY 1 µM ratio: 
1.60 ± 0.27, n = 7) after perfusion of WAY100635 (Fig. 4.12C).
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In addition, no statistical differences were found in the effect of 
WAY100635 on the amplitude of the sIPSCs between genotypes.
Figure 4.12. Effect of the 5-HT1A receptor antagonist, WAY100635, on the 
spontaneous GABAergic presynaptic activity in dorsal raphe neurons of wild-type 
and GIRK2 mutant mice. (A) Representative current traces showing spontaneous 
inhibitory postsynaptic currents (sIPSCs), before and after WAY100635 (1 µM) 
perfusion, in dorsal raphe (DR) neurons of wild-type (WT) and GIRK2-/- mice. (B) 
Summary bar graph showing the effect of WAY100635 (10 nM and 1 µM) on the 
frequency of the sIPSCs, normalized to basal values, in DR neurons of WT and 
GIRK2-/- mice. (C) Summary bar graph showing the effect of WAY100635 (10 nM and 
1 µM) on the amplitude of the sIPSCs, normalized to basal values, in DR neurons of 
WT and GIRK2-/- mice. Bars represent the means ± S.E.M. of n experiments (n = 6 - 9
for WT, n = 8 - 9 for GIRK2-/- mice). *p < 0.05 vs WT WAY 1 µM, unpaired two-tailed 
t-test.
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In the second group of experiments, the control of the GABAergic 
presynaptic activity by presynaptic GABAB receptors in DR neurons was 
studied. For this purpose, we recorded the sIPSCs in basal conditions and then 
we applied the GABAB receptor antagonist, CGP55845 (1 µM) during 5 min 
(Fig. 4.13A). Frequency and amplitude of the sIPSCs were analyzed before and 
after drug perfusion. In wild-type mice, CGP55845 caused a significant increase 
(81 %) in the frequency of sIPSCs compared to basal frequency (WT CGP ratio: 
1.81 ± 0.21, n = 12). However, in GIRK2-/- mice, CGP55845 perfusion caused a 
slight increase (24 %) in the frequency (GIRK2-/- CGP ratio: 1.24 ± 0.09, n = 9), 
and this increment in the frequency was statistically smaller than that produced 
by CGP55845 in DR neurons of wild-type mice (Fig. 4.13A, B) (p < 0.05, 
unpaired two-tailed t-test). Perfusion of CGP55845 did not change the 
amplitude of the sIPSCs either in wild-type mice (WT CGP ratio: 1.11 ± 0.09, n
= 11) or in GIRK2-/- mice (GIRK2-/- CGP ratio: 1.17 ± 0.08, n = 8) and therefore 
no differences were obtained between genotypes (Fig. 4.13C).
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Figure 4.13. Effect of the GABAB receptor antagonist, CGP55845, on the 
spontaneous GABAergic presynaptic activity in dorsal raphe neurons of wild-type 
and GIRK2 mutant mice. (A) Representative current traces showing spontaneous 
inhibitory postsynaptic currents (sIPSCs) before and after CGP55845 (1 µM) perfusion 
in dorsal raphe (DR) neurons of wild-type (WT) and GIRK2-/- mice. (B) Summary bar 
graph showing the effect of CGP55845 on the frequency of the sIPSCs, normalized to 
basal values, in DR neurons of WT and GIRK2-/- mice. (C) Summary bar graph showing 
the effect of CGP55845 on the amplitude of the sIPSCs, normalized to baseline values, 
in DR neurons of WT and GIRK2-/- mice. Bars represent the means ± S.E.M. of n
experiments (n = 11 - 12 for WT; and n = 8 - 9 for GIRK2-/- mice). *p < 0.05, unpaired 
two-tailed t-test.
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Additionally, we investigated whether GIRK2 subunit ablation could 
cause alterations in the GABAergic postsynaptic activity. Whole-cell currents of 
DR neurons induced by two different concentrations of the neurotransmitter 
GABA (100 and 300 µM) were recorded at a holding potential of -70 mV. In 
both wild-type and GIRK2-/- DR neurons, GABA elicited fast onset inward 
currents in a concentration dependent manner ([F(1,64) = 15,75, p < 0.001]. 
Two-way ANOVA followed by Bonferroni post-hoc test) that reached the 
steady-state in 1-2 min and slowly returned to baseline as the compound was 
washed from the slice (Fig. 4.14A). However, in GIRK2-/- mice the amplitude of 
the inward currents induced by GABA 100 µM (58.81 ± 9.21 pA, n = 18) was 
statistically smaller than in wild-type (106.30 ± 18.65 pA, n = 17) (p < 0.05, 
unpaired two-tailed t-test). Similarly, in GIRK2-/-, the perfusion of GABA 300 
µM induced an inward current (137.80 ± 21.53 pA, n = 15) that was statistically 
smaller that the GABA-induced current in wild-type mice (331.20 ± 59.62 pA, 
n = 16) (p < 0.01, unpaired two-tailed t-test) (Fig. 4.14A, B).
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Figure 4.14. GABA-induced inward currents in dorsal raphe neurons of wild-type 
and GIRK2 mutant mice. (A) Representative whole-cell recordings illustrating the 
inward currents induced by the bath perfusion of GABA (300 µM) in dorsal raphe (DR) 
neurons of wild-type (WT) and the diminished GABA-induced inward current in DR 
neurons of GIRK2-/- mice. (B) Summary bar graph showing the amplitudes of the 
GABA-induced inward currents (100 and 300 µM) in DR neurons of WT and GIRK2-/-
mice. Note that GABA induced inward currents in a concentration dependent manner in 
WT and GIRK2-/- mice. ***p < 0.0001, **p < 0.001, & p < 0.05, and && p < 0.01, unpaired 
two-tailed t-test. Bars represent the means ± S.E.M. of n experiments (n = 16 - 17 for 
WT; n = 15 - 18 for GIRK2-/- mice). 
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4.2.4. Role of GIRK2 subunit-containing GIRK channels in the 
glutamatergic synaptic activity in dorsal raphe neurons
To evaluate the role of GIRK2 subunit in the control of the 
glutamatergic presynaptic activity in DR neurons, we studied the spontaneous 
and evoked excitatory postsynaptic currents (sEPSCs and eEPSCs, respectively) 
in GIRK2 mutant mice. To ensure the blockade of GABAA transmission we 
continuously bath perfused picrotoxin (100 µM) during the experiments.
Regarding the sEPSCs, compared to those in wild-type, no differences 
were observed in GIRK2-/- mice either in the mean frequency (GIRK2-/- = 4.77 ± 
0.45 Hz, n = 28 and WT = 5.86 ± 0.46 Hz, n = 38) (Fig. 4.15A, C) or in the 
mean amplitude of the events (GIRK2-/- = 22.43 ± 1.53 pA, n = 28; and WT = 
24.56 ± 1.18 pA, n = 32) (Fig. 4.15B, C). In addition, the kinetic of the sEPSCs 
remained similar since the mean duration of the events (sEPSCs half-width) in 
GIRK2-/- mice was similar to that obtained in the wild-type group (GIRK2-/- =
1.16 ± 0.04 ms, n = 28; and WT = 1.17 ± 0.04 ms, n = 32) (Fig. 4.15C).
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Figure 4.15. Spontaneous glutamatergic synaptic activity in dorsal raphe neurons 
of wild-type and GIRK2 mutant mice. (A) Representative current traces showing 
spontaneous excitatory postsynaptic currents (sEPSCs) of dorsal raphe (DR) neurons 
from wild-type mice (WT), and GIRK2-/- mice. (B) Representative magnified sEPSCs 
of DR neurons illustrating the amplitudes of the sEPSCs in DR neurons of WT and 
GIRK2-/- mice. (C) Summary bar graph showing the frequency, amplitude, and half-
width of sEPSCs in DR neurons of WT and GIRK2-/- mice. Bars represent the means ± 
S.E.M. of n experiments (n = 32 – 38 for WT and n = 28 for GIRK2-/- mice).
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Next, glutamate release was evoked by a single electrical stimulus (100 
µs at 10 Hz) every 30 seconds at a holding potential of +40 mV in order to 
trigger simultaneously both AMPA and NMDA receptor-dependent eEPSCs 
(Fig 4.16A). No differences were observed between genotypes either in the 
mean amplitude of the eEPSCs (GIRK2-/- = 450.90 ± 92.46 pA, n = 14; and WT 
= 460.10 ± 87.64 pA, n = 24) or in the mean half-width (GIRK2-/- = 2.24 ± 0.26 
ms, n = 12; and WT = 3.08 ± 0.34 ms, n = 21). We further studied possible 
differences in the balance of AMPA/NMDA mediation of eEPSCs. In order to 
do this, 5 min after evoking the first eEPSC, we bath-perfused the NMDA 
receptor antagonist, D-AP5 (50 µM) to block NMDA receptor dependent 
eEPSCs. No differences were observed between groups either in the mean 
amplitude of the AMPA-eEPSCs (GIRK2-/- = 345.80 ± 79.85 pA, n = 14; and 
WT = 327.70 ± 50.29 pA, n = 24) or in the mean amplitude of the NMDA-
eEPSCs (GIRK2-/- = 141.40 ± 30.16 pA, n = 14; and WT = 126.60 ± 32.47 pA, 
n = 24). Therefore, no differences were found in the AMPA/NMDA mean ratio 
of the amplitude between groups (GIRK2-/- = 3.84 ± 1.11, n = 14; and WT =
4.37 ± 1.23, n = 24) (Fig. 4.16A, B).
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Figure 4.16. Electrophysiological parameters of evoked excitatory postsynaptic 
currents in dorsal raphe neurons of wild-type and GIRK2 mutant mice. (A) 
Representative traces of the recordings of evoked excitatory postsynaptic currents 
(eEPSCs) in dorsal raphe (DR) neurons of wild-type (WT) and GIRK2-/- mice. The 
relative contribution of AMPA- and NMDA-eEPSCs is also shown. (B) Summary bar 
graph showing the eEPSCs amplitude, AMPA-eEPSCs amplitude, NMDA-eEPSCs 
amplitude and AMPA/NMDA ratio of the amplitude in DR neurons of WT and 
GIRK2-/- mice. Bars represent the means ± S.E.M. of n experiments (n = 21 - 24 for 
WT, n = 12 - 14 for GIRK2-/- mice).
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4.3. SUDY III: Ketamine promotes electrophysiological and biochemical 
alterations in the glutamatergic transmission in the dorsal raphe
4.3.1. Behavioral effect of ketamine in the tail suspension test
To evaluate whether ketamine promotes an antidepressed-like behavior, 
we performed the TST, a well recognized animal model for assessing the 
antidepressant activity (Cryan et al., 2005). For this purpose, wild-type animals 
were acutely treated with ketamine (30 mg/kg, i.p.), 30 min or 24 h prior to the 
test. Injections of 0.9% saline were carried out in the control group in order to 
work in the same conditions in all the groups. 
Ketamine administered 30 min prior to the test (ket 30 min) 
significantly reduced the immobility time in the TST (control: 195.10 ± 7.49 s, 
n = 18; ket 30 min: 84.30 ± 6.64 s, n = 10. p < 0.0001, one-way ANOVA 
following Newman-Keuls post-hoc test) (Fig. 4.17). Interestingly, this 
antidepressant-like effect was maintained when ketamine was administered 24 h 
before the TST (ket 24 h). Thus, the immobility time was statistically smaller in 
ket 24 h (ket 24 h: 152.10 ± 9.50 s, n = 10) compared to that in control group (p
< 0.0001, one-way ANOVA followed by Newman-Keuls post-hoc test),
although the antidepressant-like effect was more pronounced when ketamine 
was administered 30 min prior to the test than 24 h before the test (p < 0.001, 
one-way ANOVA followed by Newman-Keuls post-hoc test).
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Figure 4.17. Effect of ketamine on the immobility time in the tail suspension test. 
Summary bar graph showing the effect of ketamine (30 mg/kg i.p.) on the immobility
time of wild-type mice in the tail suspension test. The administration of ketamine 30 
min (ket 30min) prior to the test significantly decreased the immobility time compared 
to control group. ***p < 0.0001, one-way ANOVA followed by Newman-Keuls post-hoc
test. In the same line, ketamine (30 mg/kg, i.p.) administered 24 hours (ket 24h) prior to 
the test significantly reduced the immobility time compared to control group. ***p <
0.0001, one-way ANOVA followed by Newman-Keuls post-hoc test. The immobility 
time reduction was significantly more pronounced in the ket 30min group than in the ket 
24h group. ##p < 0.001 vs ket 24h, one-way ANOVA followed by Newman-Keuls post-
hoc test. Bars represent mean ± S.E.M. of n experiments (n = 10 - 18 mice/group).
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4.3.2. In vitro electrophysiological effects of ketamine administration 24 
hours prior to the recordings on the glutamatergic synaptic activity in 
dorsal raphe neurons 
In order to study if ketamine could produced sustained alterations on 
excitatory synaptic activity of DR neurons, we examined whether a single 
injection of ketamine 24 hours prior to the recordings (ket 24h, 30 mg/kg, i.p.), 
could have any effect on the sEPSCs and eEPSCs of DR neurons. For these
recordings, picrotoxin (100 µM) was added to the external solution to block 
GABAA receptors. 
First, we examined the sEPSCs of DR neurons in control mice and in 
mice treated with ketamine 24 hours prior to the recordings (Fig. 4.18A, B). For 
this purpose, sEPSCs were recorded during at least 3 min and the frequency and 
amplitude of the events were evaluated. Ketamine injection produced no 
alterations either in the frequency (ket 24 h: 6.05 ± 0.61 Hz, n = 13) or in the 
amplitude (ket 24 h: 25.15 ± 1.64 pA, n = 13) of the events, compared to those 
obtained in the control group (control sEPSC frequency: 5.86 ± 0.46 Hz, n = 38; 
control sEPSC amplitude: 24.42 ± 1.00 pA, n = 38) (Fig. 4.18C, D).
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Figure 4.18. Effect of ketamine on spontaneous excitatory postsynaptic currents in 
dorsal raphe neurons. (A) Representative current traces showing sEPSCs in dorsal 
raphe (DR) neurons of control mice (control) and mice treated with ketamine (30 
mg/kg, i.p.) 24 hours prior to the recordings (ket 24h). (B) Representative magnified 
sEPSCs of DR neurons illustrating similar amplitudes in control and ket 24h mice. (C) 
Summary bar graph showing similar sEPSC frequency and (D) amplitude between 
control and ket 24h mice. Bars represent mean ± S.E.M. of n experiments (n = 38 cells 
for control group; n = 13 for ket 24h group).
Results
149 
 
Then, we studied the specific mediation of the sEPSCs by AMPA 
receptors of DR neurons. For this purpose, in these experiments the selective 
NMDA receptor antagonist, D-AP5 (50 µM), was added to block excitatory 
transmission via NMDA receptors (Fig. 4.19A, B). On one hand, in control 
animals, D-AP5 produced no changes either in the sEPSCs frequency (control 
basal: 6.79 ± 0.52 Hz, n = 6; control D-AP5: 5.74 ± 1.05 Hz, n = 6) (Fig. 4.19C) 
or in the sEPSCs amplitude (control basal: 22.31 ± 0.67 pA, n = 6; control D-
AP5: 20.66 ± 1.30 pA, n = 6) (Fig. 4.19D), demonstrating that sEPSCs in DR 
neurons are predominantly mediated by AMPA receptors in control animals. On 
the other hand, in mice treated with ketamine, the perfusion of D-AP5 did not 
alter the sEPSCs frequency (ket 24 h basal: 6.87 ± 0.88 Hz, n = 13; ket 24 h D-
AP5: 6.09 ± 0.55 Hz, n = 13) or amplitude (ket 24 h basal: 25.55 ± 1.72 pA, n =
13; ket 24 h D-AP5: 23.14 ± 1.86 pA, n = 13).Therefore, the injection of 
ketamine 24 hours prior to the recordings did not alter the AMPA receptor-
mediation of the frequency of the sEPSCs (control D-AP5: 5.74 ± 1.05 Hz, n =
6; ket 24 h D-AP5: 6.09 ± 0.55 Hz, n = 13. p = 0.7846, unpaired two-tailed t-
test) (Fig. 4.19C, D).
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Figure 4.19. Effect of D-AP5 on spontaneous excitatory postsynaptic currents in 
dorsal raphe neurons of control mice and mice treated with ketamine. (A) 
Representative current traces showing sEPSCs, before and after D-AP5 perfusion (50
µM), in dorsal raphe (DR) neurons of control mice (control) and in (B) mice treated 
with ketamine (30 mg/kg, i.p.) 24 hours prior to the recordings (ket 24h). (C) Summary 
bar graph showing similar sEPSCs frequency and (D) amplitude before (control basal 
and ket 24h basal), and after D-AP5 perfusion (control D-AP5 and ket 24h D-AP5). 
Bars represent mean ± S.E.M. of n experiments (n = 6 for control groups; n = 13 for ket 
24h groups).
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Next, we assessed if ketamine was producing any effect on the eEPSCs 
of DR neurons. For this purpose, glutamate release was electrically evoked by a 
single-stimulus (100 µs at 10 Hz) application every 30 seconds at a holding 
potential of +40 mV in order to trigger simultaneously both AMPA and NMDA 
receptor-dependent eEPSCs (Fig. 4.20A). No differences were observed in the 
eEPSCs amplitude between groups (control: 460.10 ± 87.64 pA, n = 24; ket 
24h: 415.10 ± 46.54 pA, n = 25). To further study whether ketamine was 
producing any alteration in the balance of AMPA/NMDA mediation of eEPSC, 
we studied the AMPA and NMDA receptor-dependent-eEPSCs separately in 
both groups (AMPA-eEPSCs and NMDA-eEPSCs). In order to do this, 15 min 
after evoking the first eEPSC, we bath-perfused the NMDA receptor antagonist, 
D-AP5 (50 µM), to block NMDA receptor dependent eEPSCs. No differences 
were observed between groups either in the AMPA-eEPSC amplitude (control: 
332.3 ± 49.45 pA, n = 24; ket 24h: 296.00 ± 30.46 pA, n = 25) or in the 
NMDA-eEPSC amplitude (control: 101.51 ± 17.43 pA, n = 24; ket 24h: 132.82 
± 19.51 pA, n = 25). Therefore, no differences were found in the 
AMPA/NMDA ratio of the amplitude between groups (control: 3.86 ± 0.72, n =
24; ket 24h: 2.81 ± 0.36, n = 25) (Fig. 4.20B).
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Figure 4.20. Effect of ketamine on the electrically-evoked excitatory postsynaptic 
currents in dorsal raphe neurons. (A) Representative recordings of eEPSCs in dorsal 
raphe (DR) neurons of control mice (control) and mice treated with ketamine (30 
mg/kg, i.p.) 24 hours prior to the recordings (ket 24 h). The relative contribution of 
AMPA- and NMDA-eEPSCs is also shown. (B) Summary bar graph showing the 
eEPSCs amplitude, AMPA-eEPSCs amplitude, NMDA-eEPSCs amplitude, and 
AMPA/NMDA ratio of the amplitude in DR neurons of control (n = 24) and ket 24 h (n
= 25) groups. Bars represent the means ± S.E.M. of n experiments.
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4.3.3. In vitro electrophysiological acute effects of ketamine on the 
glutamatergic synaptic activity in dorsal raphe neurons
Next, we investigated if ketamine perfusion could alter the excitatory 
synaptic transmission of DR neurons. Thus, we bath-perfused ketamine (50 
µM) during 10 min and examined the sEPSCs and eEPSCs in DR slices.
Regarding the sEPSCs of DR neurons, perfusion of ketamine during 10 
min produced a statistically significant increase in the sEPSCs frequency at 
minute 5 (ket 5 min: 7.38 ± 0.97 Hz, n = 8) and at minute 10 (ket 10 min: 8.34 ± 
1.69 Hz, n = 8), compared to the sEPSCs frequency prior to the ketamine 
perfusion (basal: 5.43 ± 1.08 Hz, n = 8. p < 0.001 for ket 5 min and p < 0.0001 
for ket 10 min vs basal, repeated measures one-way ANOVA following 
Newman-Keuls post-hoc test) (Fig. 4.21A, C). Moreover, at minute 10, this 
increase in the frequency was significantly greater than the increase at minute 5 
(p < 0.001, repeated measures one-way ANOVA following Newman-Keuls 
post-hoc test). Ketamine perfusion produced no changes in the sEPSCs 
amplitude either at minute 5 (ket 5 min: 16.83 ± 1.67 pA, n = 8) or at minute 10 
(ket 10 min: 15.07 ± 1.34 pA, n = 8) compared to the sEPSC amplitude prior to 
the ketamine perfusion (basal: 15.98 ± 1.66 pA, n = 8) (Fig. 4.21B, D).
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Figure 4.21. Effect of ketamine on spontaneous excitatory postsynaptic currents in 
dorsal raphe neurons. (A) Representative current traces showing sEPSCs, before 
(basal) and after 5 min (ket 5 min) and 10 min (ket 10 min) of ketamine perfusion (50
µM) in dorsal raphe (DR) neurons. The blockade of sEPSCs after ketamine perfusion 
by DNQX (10 µM) is also shown. (B) Representative magnified sEPSCs of DR neurons 
illustrating similar amplitudes in basal, ket 5 min and ket 10 min groups. (C) Summary 
bar graph showing the sEPSC frequency in basal, ket 5 min and ket 10 min groups. (D) 
Summary bar graph showing the sEPSC amplitude in basal, ket 5 min, and ket 10 min 
groups. Bars represent mean ± S.E.M. of n experiments (n = 8 for all the groups). **p <
0.001 and ***p < 0.0001 vs basal. ###p < 0.001 vs ket 5 min, repeated measures one-way 
ANOVA following Newman-Keuls post-hoc test.
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Moreover, by comparison of the effect of ketamine to the previously 
described effect of D-AP5 on sEPSCs frequency, we could rule out the NMDA 
receptor antagonism as the mechanism by which ketamine is increasing 
glutamate release. In this sense, D-AP5 perfusion did not produce any change in 
sEPSCs frequency and amplitude, but the perfusion of ketamine did increase the 
sEPSCs, suggesting that ketamine is producing an increase in the excitatory 
synaptic through a NMDA-receptor independent mechanism (Fig. 4.19C and 
4.21C). Moreover, the effect of ketamine perfusion on sEPSCs was completely 
blocked by the AMPA receptor antagonist DNQX (10 µM), demonstrating that 
the ketamine-induced effect increasing glutamate release is mediated by AMPA 
receptors (Fig. 4.21A).
Additionally, we assessed if ketamine could produce any effect on the 
eEPSC of DR neurons. Given that ketamine acts as an NMDA antagonist we 
did not measure the NMDA receptor-dependent eEPSCs. No changes were 
found in the AMPA-eEPSCs amplitude at minute 10 (ket 10 min: 330.3 ± 93.41 
pA, n = 8) compared to control group (control: 332.2 ± 49.45 pA, n = 24) (Fig. 
4.22).
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Figure 4.22. Effect of ketamine on the electrically-evoked excitatory postsynaptic 
currents in dorsal raphe neurons. Summary bar graph showing the AMPA receptor-
mediated eEPSCs amplitude in dorsal raphe (DR) neurons in the absence of ketamine 
(control), and 10 min after ketamine perfusion (50 µM) (ket 10 min). Bars represent 
means ± S.E.M. of n experiments (n = 24 for control group and n = 8 for ket 10 min 
group).
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4.3.4. In vitro electrophysiological effects of the mTOR inhibitor, PP242, on 
the glutamatergic synaptic activity in dorsal raphe neurons. Partial 
blockade by PP242 of the ketamine-induced effects on the spontaneous 
excitatory postsynaptic currents
It has been suggested that mammalian target of rapamycin (mTOR) 
activation positively regulates excitatory synaptic function (Schratt et al., 2004; 
Jaworski et al., 2005; Kumar et al., 2005), although mTOR activation has also 
been linked to depression of excitatory synaptic function (Hou and Klann, 
2004). In addition, it has been also reported that ketamine produces some of its 
effects, including the antidepressant effects, by activation of the mTOR pathway 
(Li et al., 2010). Therefore, our aims were to evaluate the effect of the selective 
active-site mTOR inhibitor PP242 (Apsel et al., 2008; Choo and Blenis, 2009; 
Feldman et al., 2009; Dowling et al., 2010; Janes et al., 2010) on the 
glutamatergic synaptic activity of DR neurons, as well as to investigate if the 
observed increased sEPSCs frequency produced by ketamine was due to an 
activation of the mTOR in DR neurons.
4.3.4.1. Effect of PP242 on the glutamatergic synaptic activity in dorsal 
raphe neurons
We first incubated DR slices for at least 45 min with the mTOR 
inhibitor PP242 (2.5 µM) and examined the frequency and amplitude of 
sEPSCs. In the presence of PP242, frequency of sEPSCs in DR neurons 
remained unaltered compared to the frequency of sEPSCs in control animals 
(PP242: 7.98 ± 1.14 Hz, n = 17; control: 8.80 ± 1.14 Hz, n = 5) (Fig. 4.23A, C). 
However, the amplitude of sEPSCs in the presence of PP242 was statistically 
smaller than that in control animals (PP242: 20.99 ± 2.49 pA, n = 17; control: 
34.07 ± 5.38 pA, n = 5. p < 0.05, unpaired two-tailed t-test) (Fig. 4.23B, D).
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Figure 4.23. Effect of the mTOR inhibitor, PP242, on spontaneous excitatory 
postsynaptic currents in dorsal raphe neurons. (A) Representative current traces 
showing sEPSCs in dorsal raphe (DR) neurons of control mice (control) and DR slices 
incubated with the mTOR inhibitor PP242 (2.5 µM). (B) Representative magnified 
sEPSCs of DR neurons illustrating sEPSCs amplitude in control and PP242 groups. (C) 
Summary bar graph showing sEPSCs frequency in control and PP242 groups. (D) 
Summary bar graph showing sEPSCs amplitude in control and PP242 mice. Bars 
represent means ± S.E.M. of n experiments (n = 5 cells for control group and n = 17 for 
PP242 group). *p < 0.05, unpaired two-tailed t-test.
Results
159 
 
4.3.4.2. Effect of PP242 on the ketamine-induced increase in the frequency 
of spontaneous excitatory postsynaptic currents in dorsal raphe neurons
Then, we studied the effect of PP242 on the increase in sEPSCs 
frequency induced by ketamine perfusion. For this purpose, we incubated DR 
slices with PP242 (2.5 µM) for at least 45 min, and recorded the spontaneous 
excitatory activity in DR neurons for at least 3 min. Then, we bath perfused 
ketamine (50 µM) for 10 min and examined the frequency and amplitude of 
sEPSCs in DR neurons. The perfusion of ketamine in the presence of PP242 did 
not significantly increase the sEPSCs frequency at minute 5 (PP242 + ket 5 
min: 7.591 ± 0.88 Hz, n = 14) or at minute 10 (PP242 + ket 10 min: 8.338 ± 
1.06 Hz, n = 14) compared to the sEPSC frequency prior to the ketamine 
perfusion (PP242 basal: 6.891 ± 1.17 Hz, n = 14) (Fig. 4.24A, B). Neither the 
sEPSC amplitude was different with the perfusion of ketamine at minute 5 
(PP242 + ket 5 min: 27.41 ± 2.64 pA, n = 14) or at minute 10 (PP242 + ket 10 
min: 25.44 ± 2.40 pA, n = 14), compared to the sEPSC amplitude prior to the 
ketamine perfusion (PP242 basal: 33.00 ± 3.64 pA, n = 14) (Fig. 4.24C). Taking 
into account the ketamine-induced increase in sEPSC frequency observed in 
control conditions (see section 4.3.3), and comparing it to the effect in the 
presence of PP242 (Fig. 4.24D), it seems that the mTOR activation mediates, at 
least in part, the effect of ketamine on glutamatergic synaptic activity of DR 
neurons.
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Figure 4.24. Effect of the mTOR inhibitor, PP242, on the ketamine-induced 
increase in frequency of spontaneous excitatory postsynaptic currents in dorsal 
raphe neurons. (A) Representative current traces showing sEPSCs before (PP242 
basal), after 5 min (PP242 + ket 5 min), and after 10 min (PP242 + ket 10 min) of 
ketamine perfusion (50 µM) in dorsal raphe (DR) slices incubated with PP242 (2.5 
µM). (B) Summary bar graph showing the sEPSC frequency in PP242 basal, PP242 + 
ket 5 min, and PP242 + ket 10 min mice. (C) Summary bar graph showing the sEPSCs 
amplitude in PP242 basal, PP242 + ket 5 min, and PP242 + ket 10 min mice. (D) 
Summary sEPSCs frequency-time plots normalized to basal values for the control group 
(ketamine perfusion without PP242, see section 4.3.3) and PP242 group, showing the 
effect of the perfusion of ketamine in both groups. Bars and dots represent mean ± 
S.E.M. of n experiments (n = 14 cells for PP242 basal, PP242 + ket 5 min, and PP242 + 
ket 10 min groups; n = 8 for control group). *p < 0.05 and **p < 0.01 vs control at min 0, 
repeated measures one-way ANOVA following Newman-Keuls post-hoc test. 
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4.3.5. Effect of ketamine administration on phospho-mTOR levels in the 
dorsal raphe
Finally, we investigated whether a single injection of ketamine (30 
mg/kg; i.p.) produces acute and/or sustained effects on the mTOR pathway in 
the DR. For this purpose we studied the Ser 2448 (phospho-mTOR 2448) and 
Ser 2481 (phosphor-mTOR 2481) phophorylation sites of the mTOR, which are
the Akt phophorylation site and the autophophorylation site of mTOR, 
respectively (Peterson et al., 2000; Hay and Sonenberg, 2004). In addition, we 
*0!@"#
"#"(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
(Kim et al., 2003), mTOR expression, and Raptor expression, in mice injected 
with ketamine or with physiological saline (0.9 % NaCl, control mice). 
Ketamine administration produced an increase in the expression of 
phospho-mTOR 2448 in the DR, being the expression levels 24 hours after the 
injection significantly higher than the levels obtained in control mice (ket 24 h: 
0.6945 ± 0.05915, n = 7; ket 30 min: 0.6089 ± 0.03973, n = 7; control: 0.5180 
± 0.01971, n = 7. p < 0.05, one-way ANOVA followed by Newman-Keuls post-
hoc test) (Fig. 4.25A). In addition, this increase was not due to a ketamine-
induced increase in the expression of phospho-mTOR 2481 
(autophophorylation site) or in the expression of no phosphorilated mTOR (Fig. 
4.25B, E), suggesting that ketamine administration produced an activation of 
the Akt/mTOR pathway in the DR.
When examining the expression levels of the rest of the proteins 
studied, we showed that ketamine did not change the expression levels of any of 
them either 30 min or 24 hours after the injection (Fig. 4.25C, D, E).
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Figure 4.25. Effect of ketamine on phospho-mTOR 2448, phospho-mTOR 2481, 
	
	  
dorsal raphe. (A) Ketamine produced a 
statistically significant increase in the phospho mTOR 2448 levels in dorsal raphe (DR) 
24 h after the injection. (B-E) Ketamine did not produce significant alterations in the 
expression levels of (B) phospho-%IJK,
8	*0!
D	
#B	%IJ"#
DR neurons, either 30 min or 24 h after the injection. Below the graphs are images of 
the blots showing phospho-mTOR 2448 (289 kDa), phosphor-mTOR 2481 (289 kDa),
*0! =.D	
  ,9D	
 %IJ K-D	
 #0-actin (42 kDa) expression 
from each experimental group. Bars represent mean ± SEM of n animals (n = 7
mice/group). *p < 0.05 vs control group, one-way ANOVA following Newman-Keuls 
post-hoc test.
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5. DISCUSSION
5.1. Deletion of GIRK2 subunit of GIRK channels alters 5-HT1A receptor-
mediated signaling and results in a depression-resistant behavior
The goal of our study was to determine the role that GIRK2 subunit-
containing GIRK channels play in depression-related behaviors as well as in the 
control of 5-HT1A-mediated inhibitory effects. We found that mice lacking 
GIRK2 subunits of GIRK channels display a depression-resistant phenotype 
combined with a reduced behavioral response to citalopram, an increase in the 
firing rate of DR neurons and a reduction of 5-HT1A receptor-mediated 
responses. In addition, GIRK2 subunit deletion does not affect basal adult 
neurogenesis. 
Our findings suggest that Girk2 gene deletion promotes a depression-
resistant behavior and determines the response to the antidepressant citalopram. 
Thus, GIRK2-/- mice showed a marked decrease in the immobility time in the 
tail suspension test (TST), and both GIRK2+/- and GIRK2-/- mice presented a 
lower latency to eat in the novelty suppressed feeding test (NSFT), that was not 
correlated with an increase in appetite. It is important to remark that general 
locomotor activity status is a confusing factor in these tests (Blednov et al., 
2001a). Previous studies showed that GIRK2-/- mice, but not GIRK2+/- mice, 
have signs of hyperactivity (Blednov et al., 2001a; Cruz et al., 2008; Arora et 
al., 2010) that has been attributed to D1 receptor activation (Blednov et al., 
2002). Given that GIRK2+/- mice do not have hyperactivity but showed 
depression-resistant phenotype in the NSFT, these results might be due to a less 
depressive-like behavior rather than to a more active state. We suggest that the 
5-HT1A-GIRK signaling may be mediating this depression-resistant phenotype: 
first, studies in 5-HT1A receptor knockout mice show that they display an 
antidepressant-like phenotype under baseline conditions (Heisler et al., 1998; 
Mayorga et al., 2001), as we observed in GIRK2 mutant mice. Secondly, here 
citalopram was less potent in reducing the immobility in the TST. Similarly, it 
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has been reported that the expression of the antidepressant-like behavioral 
response of SSRIs in the TST requires the presence of functional 5-HT1A
receptors (Mayorga et al., 2001). Additionally, our observations are in line with 
those showing that chronic administration of fluoxetine exerts a beneficial 
influence on a rodent model of depression through suppression of GIRK-
dependent signaling in the DR (Cornelisse et al., 2007). Interestingly, the 
depression-resistant phenotype that we observed here is combined with the 
previously reported reduced anxiety-like behavior that GIRK2 mutant mice 
display (Blednov et al., 2001a; Pravetoni and Wickman, 2008). Therefore, this 
phenotype represents a great advance over the classic antidepressed-like 
phenotype of 5-HT1A knockout mice, since they display a robust anxiety-like 
behavior (Heisler et al., 1998; Parks et al., 1998; Ramboz et al., 1998). Given 
the constitutive and global nature of the Girk2 gene deletion, it is not possible to 
completely identify the circuit(s) or neurotransmitter system(s) that explain this 
“antidepressive” phenotype. However, we can rule out the involvement of the 
GABAB-GIRK2 signaling, since GABAB mutant mice showed elevated anxiety-
related behaviors (Mombereau et al., 2004). 
The implication of GIRK2 subunit-containing GIRK channels in the 5-
HT1A receptor-mediated neurotransmission is also supported by our in vivo
electrophysiological findings. First, we observed that the lack of GIRK2 
subunits induces an increase in the firing rate of DR neurons. This increase was 
also observed by the total blocking of GIRK channels with tertiapin-Q. On one 
hand, these results suggest that the intrinsic activity of GIRK2 subunit-
containing GIRK channels controls the transmission in the DR. Similar findings 
have been obtained in LC neurons, where it has been observed that GIRK2 
subunit-containing GIRK channels regulate the tonic activity of LC neurons in 
vivo (Torrecilla et al., 2013). In vitro studies have reported that dopamine 
neurons in GIRK2-/- mice exhibit a reduced firing rate (Arora et al., 2010), and 
in GIRK2/3-/- mice LC neurons show an increased firing rate (Cruz et al., 2008). 
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In addition, the contribution of GIRK2 subunits to the resting membrane 
potential has been reported in different type of neurons, including LC and HPP 
neurons (Luscher et al., 1997; Torrecilla et al., 2002; Chen and Johnston, 2005). 
Nevertheless, in layer 5/6 pyramidal neurons of the prelimbic cortex of GIRK2-/-
mice, intrinsic electrophysiological properties remained unaltered compared to 
WT mice (Hearing et al., 2013). Taken all together, the contribution of GIRK2 
subunits to neuronal excitability seems to vary across cell types and brain 
regions. On the other hand, the complete blockade of GIRK channels with 
tertiapin-Q results in a similar increase in the firing rate of DR neurons to that 
observed in GIRK2-/- mice. This suggests that GIRK2 subunits, though their 
expression is low in the DR (Saenz del Burgo et al., 2008), are forming 
important populations of GIRK channels, which are involved in the control of 
neuronal tonic activity. Given that GIRK1 subunits are almost absent when 
deleting GIRK2 subunits (Signorini et al., 1997), both GIRK1 and GIRK2
subunits might be forming functional GIRK channels that control the tonic 5-
HT activity of the DR. Alternatively, alterations in neurotransmitter levels could 
also affect the firing pattern of DR neurons in GIRK2 mutant mice, since there 
are decreased and increased levels of 5-HT and 5-HIAA, respectively 
(Torrecilla et al., 2013). Secondly, our study also reveals that DR 5-HT1A
receptors, both endogenously and exogenously activated, are affected by the 
deletion of GIRK2 subunits, which is shown by reduced receptor functionality. 
Similar results were observed in an in vivo electrophysiological study in LC 
#(# "# *?J7 (# "
 "#'  L #   
desensitized (Torrecilla et al., 2013). Our results agree with this study, 
indicating that in the DR, ablation of the Girk2 gene produces loss of function 
of the 5-HT1A-GIRK signaling pathway. It is important to remark that the 
reduced function of 5-HT1A # 2 autoreceptors has been proposed as a key 
consequence of chronic antidepressant treatments, which would explain the 
delayed onset effect of antidepressants (McMillen et al., 1980; Lacroix et al., 
1991; Artigas et al., 1996; Szabo et al., 2000; Invernizzi et al., 2001). In fact, 
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new pharmacological or genetic strategies to faster desensitize 5-HT1A #2
autoreceptors have been of great interest in the study of depression treatment 
(Sanacora et al., 2004; Richardson-Jones et al., 2010; Portella et al., 2011). The 
observation that 8-OH-DPAT and citalopram preserved their maximal 
inhibitory efficacy is consistent with other studies. In LC neurons in GIRK2 
mutant mice, the potency of morphine and clonidine was reduced, yet the 
inhibitory efficacy remained unaltered in vivo (Torrecilla et al., 2013). In 
hippocampal neurons in GIRK2-/- mice, in vitro postsynaptic GIRK currents 
induced by stimulation of the 5-HT1A receptor were markedly reduced but not 
absent (Luscher et al., 1997). Studies conducted to determine the analgesic 
properties of morphine showed that while the potency of morphine was reduced, 
its efficacy was preserved in GIRK2-/- and GIRK2/3-/- mice (Mitrovic et al., 
2003; Cruz et al., 2008). Also the pharmacological blockade of GIRK channels 
caused a reduction in the potency but not in the inhibitory efficacy of 
citalopram, supporting the role of GIRK2 subunit-containing GIRK channels in 
the inhibitory response of 5-HT1A receptors. The dose of tertiapin-Q used was 
selected according to a previous study, where doses higher than 100 pmol 
caused dangerous effects (Marker et al., 2004). By testing the 8-OH-DPAT-
induced hypothermia, which reflects the sensitivity of 5-HT1A autoreceptors in 
mice (Goodwin et al., 1985; Richardson-Jones et al., 2011), we confirmed that 
GIRK2 subunits regulate the functionality of 5-HT1A autoreceptors, as 
previously reported (Costa et al., 2005). Overall, all the functional findings in 
our work indicate that in the DR GIRK2 subunits may be forming important 
GIRK channel populations, in charge of controlling the tonic electrical activity 
and mediating of 5-HT1A receptor-mediated signaling.
In addition, in adult hippocampal neurogenesis, the fate of neural 
progenitors is substantially conditioned by the emotional state, which is 
demonstrated by the fact that in enriched environments hippocampal stem cells 
give rise to more neurons and fewer stem cells than in impoverished 
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environments (Dranovsky et al., 2011). Specifically, it has also been confirmed 
that depressive behavior and stress responses are buffered by adult hippocampal 
neurogenesis (Snyder et al., 2011). Our findings show that in basal conditions,
Girk2 gene ablation promotes a depression-resistant phenotype without 
modifying adult neurogenesis in the DG of the HPP or in the SVZ. In line with 
this, it has also been observed that deletion of the background potassium 
channel TREK-1 results in a depression-resistant phenotype while the adult 
neurogenesis is unaltered (Heurteaux et al., 2006). It is worth mentioning that 
there is a very abundant expression of GIRK2 protein in the HPP and in the 
SVZ (Saenz del Burgo et al., 2008), and GIRK2 subunit-containing GIRK 
channels are also coupled to postsynaptic 5-HT1A receptors (Luscher et al., 
1997). Taking into consideration the presence and function of GIRK2 subunit-
containing GIRK channels in the HPP, we suggest that the absence of changes 
in basal neurogenesis observed in GIRK2 mutant mice may be ascribed to the 
probable requirement of 5-HT1A receptor stimulation to promote neurogenesis 
(Santarelli et al., 2003).
In conclusion, our results show the specific role of GIRK2 subunit-
containing GIRK channels in the promotion of a depression-resistant 
phenotype, as well as their control of the tonic neuronal activity and mediation 
of the 5-HT1A receptor inhibitory responses. New strategies targeting the 5-
HT1A-GIRK2 pathway could be of great therapeutic interest for the study of 
pathologies related to an altered 5-HT transmission, such as depression, and 
development of alternative treatments. 
 
Discussion
171 
 
5.2. Altered inhibitory pre- and postsynaptic activity of dorsal raphe
neurons in GIRK2 mutant mice
The goal of this study was, on one hand, to characterize the contribution 
of GIRK2 subunit-containing GIRK channels to the electrophysiological 
properties of DR neurons and, on the other hand, to determine the role that 
GIRK2 subunits play in the 5-HT, GABAergic and glutamatergic presynaptic 
and postsynaptic activity in vitro, when the majority of the projections to the 
DR are disrupted. The present work shows that GIRK2 subunits of GIRK 
channels contribute to some of the passive and active electrophysiological 
properties of DR neurons, and play a pivotal role in the control of 5-HT1A and 
GABAB receptor-mediated postsynaptic currents. Moreover, also the inhibitory 
GABAergic pre- and postsynaptic activity is affected when deleting the GIRK2 
subunit, whereas the excitatory glutamatergic synaptic activity remains 
unaltered. 
The deletion of GIRK2 subunit increased the membrane input resistance 
of DR neurons, without altering the resting membrane potential. Given that 
changes in input resistance could be due to presence/absence or opening/closing 
of ion channels, such as K+ and/or Cl-, it is conceivable that the lack of GIRK 
channels increases the membrane input resistance of DR cells. In fact, in dorsal 
CA1 neurons, a higher adenosine A1 receptor-mediated GIRK channel activity 
has been demonstrated to be responsible of some differences in intrinsic 
membrane properties found between dorsal and ventral hippocampus, including 
the lower input resistance that dorsal CA1 neurons show (Kim and Johnston, 
2015). Alternatively, and given that GIRK2 mutation also affects GABAergic 
transmission (see results section 4.2.3.), the observed increase in input 
resistance could be due to changes in GABAA receptors. In addition, the kinetic 
of action potentials in GIRK2-/- mice was faster, shown as a shorter half-width 
and decay time of the spikes. 
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However, no changes were observed in the in vitro stimulated 5-HT 
neuronal firing in GIRK2-/- mice compared to wild-type, although it was 
increased in vivo (see previous section). Therefore, once having detected that 
GIRK2-/- mice have a dysfunctional GABAergic activity, we suggest that the 
decreased GABAergic inhibition in DR could account for the increased 5-HT 
neuronal firing that GIRK2 mutant mice show. Some in vitro studies show that 
GIRK2 subunit-containing GIRK channels contribute to the 
electrophysiological properties of neurons from different brain regions, mainly
hyperpolarizing the membrane potential (Luscher et al., 1997; Torrecilla et al., 
2002). However, others provide opposite results in Layer 5/6 prelimbic cortex
(Hearing et al., 2013). From our results we suggest that in DR the tonic activity 
of GIRK2 subunit-containing GIRK channels contribute to some of the passive
and active electrophysiogical properties of DR neurons, without impacting on 
the excitability of the membrane in vitro.
In addition, here we showed that 5-CT-induced whole-cell postsynaptic 
currents were greatly reduced in DR neurons of GIRK2 mutant mice. Similarly, 
baclofen-induced whole-cell postsynaptic currents were also markedly 
diminished when deleting the GIRK2 subunit, suggesting that GIRK channels 
formed by GIRK2 subunits mediate the inhibitory actions of 5-HT1A and 
GABAB receptors. Collectively, these results indicate that there is a 
postsynaptic expression of GIRK2 subunits forming GIRK channels coupled to 
5-HT1A and GABAB receptors in DR neurons, and importantly, GIRK2 subunits 
are the main responsible for the control of both 5-HT1A and GABAB receptor-
mediated postsynaptic transmissions. It has been previously reported that in the 
DR both GABAB and 5-HT1A receptors are coupled to a common pool of GIRK 
channels (Mannoury la Cour et al., 2004), which mediate their inhibitory 
actions. In this study we further demonstrate that the specific ablation of GIRK2 
subunits affects to the same extent 5-HT1A and GABAB receptor-mediated 
postsynaptic currents in DR neurons. Although not studied in the DR till date, 
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the involvement of specific GIRK subunits in the whole-cell currents induced 
by stimulation of different GPCRs has been demonstrated in different brain 
areas. In CA1 pyramidal cells from the hippocampus, baclofen-, adenosine-, and 
5-HT-induced postsynaptic currents were essentially absent in GIRK2-/- mice 
(Luscher et al., 1997). In the same way, in mice lacking GIRK2 subunit-
containing GIRK channels a great reduction of the baclofen-induced currents 
was shown in VTA dopamine neurons compared to those in wild-type mice 
(Arora et al., 2010). In addition, another study in LC neurons of GIRK2 mutant 
mice showed that met-enkephalin-induced whole-cell currents were markedly 
reduced (Torrecilla et al., 2002). Similar results were obtained studying the 
morphine-induced postsynaptic currents in these mice in LC neurons (Cruz et 
al., 2008). Altogether, the contribution of GIRK2 subunits to the postsynaptic 
currents induced by agonists of inhibitory GPCR seems to be consistent in 
different regions. Interestingly, in our work it was still visible a small residual 
current, also seen in LC neurons of GIRK2/3 double knockout mice (Torrecilla 
et al., 2002). The modest presence of other GIRK subunits in the DR, such as 
GIRK1 and/or GIRK3 (Saenz del Burgo et al., 2008) could account for this 
small current. However, given that GIRK1 subunits are almost absent when 
deleting GIRK2 subunits (Signorini et al., 1997; Torrecilla et al., 2002), it 
seems unlikely that this subunit is mediating the residual current. Alternatively, 
another possible explanation is the involvement of GIRK-independent 
mechanisms. In this sense, it has been demonstrated that baclofen-induced 
currents in VTA neurons were greatly reduced in GIRK2-/- mice, and the small 
residual current was Ba2+ insensitive, which is a K+ channels blocker, 
demonstrating its GIRK-independent nature. Given that it was inhibited by a 
cAMP analog, the involvement of the two-pore K+ channel family was 
suggested (Cruz et al., 2004).
The current study indicates that GABAergic synaptic transmission is 
impaired in the DR of GIRK2 mutant mice. Regarding the GABAergic 
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presynaptic activity, the frequency of sIPSCs in DR neurons in GIRK2 mutant 
mice was reduced compared to that in wild-type mice, suggesting that 
probability of release of GABA in these mutant mice is diminished compared to 
wild-type. In addition, from the evoked synaptic activity we observed that the 
amplitude of the peak1 of the eIPSC was decreased in GIRK2-/- mice compared 
to wild-type mice and it was accompanied by a greater paired-pulse ratio. All of 
these effects are associated with a decrease in neurotransmitter release (Bonci 
and Williams, 1997; Dobrunz and Stevens, 1997; Melis et al., 2002; Kirby et 
al., 2008). Thus, these results suggest that in the DR GIRK2 subunits are 
expressed presynaptically and control the release of GABA. In the DR 
presynaptic GABAB receptors are expressed in both 5-HT and GABA cells 
(Innis and Aghajanian, 1987; Waldmeier et al., 1988; Bowery, 1993) and they 
exert an inhibitory control over GABA release (Brenowitz et al., 1998; 
Waldmeier et al., 2008; Kobayashi et al., 2012). Accordingly, when deleting the 
GIRK2 subunit there would be a loss of functionality of the GIRK channel that 
could limit the GABAB receptor-mediated GABA release. Our results indicate 
that the deletion of GIRK2 subunit diminishes the release of GABA, which is 
contrary to the expected effect given the inhibitory nature of GIRK channels.
Therefore, it is likely that other mechanisms impacted by the mutation would be 
affecting the release of GABA.
Regarding the presynaptic role of GIRK channels observed in this 
study, it has been repeatedly reported the presynaptic labeling of GIRK 
channels in the proximity of active zone with a potential role in the regulation of 
neurotransmitter release (Ponce et al., 1996; Drake et al., 1997; Grosse et al., 
2003; Koyrakh et al., 2005; Aguado et al., 2008). In addition, it has been 
reported that Ba2+ can block the GABAB receptor-mediated presynaptic 
inhibition in the hippocampus (Misgeld et al., 1989; Thompson and Gahwiler, 
1992). Characterizations of GABAB receptor-mediated presynaptic inhibition in 
Xenopus oocytes have revealed a component that is sensitive to the GIRK-
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specific channel blocker tertiapin-Q (Jin and Lu, 1998). Indeed, in VTA 
dopamine neurons it has been demonstrated that the inhibition of GABAA
receptor-mediated eIPSC occurs via activation of presynaptic GIRK channels 
(Michaeli and Yaka, 2010). In the same line, it has been described that in the rat 
cerebral cortex the presynaptic actions of GABAB receptors involve GIRK 
channel activation (Ladera et al., 2008). Altogether, our results, which are in 
line with these results, indicate that there is a presynaptic expression of GIRK2 
subunit-containing GIRK channels in DR neurons, which play a key role in the 
control of GABA release. Nevertheless, there are other studies that suggest that 
GIRK channels are not implicated in the presynaptic actions mediated by 
different receptors, and therefore, these observations are still a matter of debate. 
As an example, it has been demonstrated that in ventrolateral periaqueductal 
gray neurons, GIRK channels underlie postsynaptic but not presynaptic GABAB
receptor-mediated inhibition (Liu et al., 2012). In hippocampal cells, when 
evaluating the presynaptic inhibition induced by different GPCR agonists, no 
impairments were seen in GIRK2-/- mice compared to wild-type mice, even 
though postsynaptic actions of the different agonists were reduced (Luscher et 
al., 1997). It was then suggested that in hippocampal cells, GPCRs in response 
to agonists exert a presynaptic depression by a GIRK-independent signaling 
mechanisms, such as the inhibition of Ca2+ channels or an interaction with the 
release machinery. Overall, this suggests that the presynaptic contribution of 
GIRK channels to the neurotransmitter release could be depending on their 
subunit composition, cell type-specific expression, and cellular localization 
among brain areas.
To further study the difference in GABA release found between 
genotypes, we perfused antagonists of 5-HT1A and GABAB receptors onto DR 
slices. In wild-type animals, antagonists of both receptors induced an increase in 
the frequency, but not amplitude, of sIPSCs, but this effect was not seen in 
GIRK2-/- mice. First, this indicates that in normal conditions, as observed in 
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wild-type mice, presynaptic 5-HT1A ad GABAB receptors exert a tonic 
inhibitory control over GABA release in DR neurons, possibly through a 5-HT-
mediated indirect effect and a GABA direct effect over GABA release. It has 
been shown that GABAA/B and 5-HT1A/B agonists decrease 5-HT and GABA 
release in rat raphe nuclei (Bagdy et al., 2000), so it is conceivable that 
antagonist of these receptors would increase the release of GABA, as seen in 
this study. Secondly, since antagonists of 5-HT1A and GABAB receptors had no 
effect on GIRK2-/- mice, these results further support the idea that in DR
neurons, GIRK2 subunit-containing GIRK channels are coupled to these 
presynaptic receptors and more importantly, they regulate the roles of GABAB
receptors on GABA release. 
Two main observations in this study make us to come to the idea that 
GIRK2 subunit deletion alters the fast GABAergic postsynaptic activity. First, 
the amplitude of sIPSCs is reduced in GIRK2 mutant mice, indicating that 
postsynaptic factors could be altered. Secondly, unexpectedly, GABA-induced 
fast inward currents were markedly reduced in GIRK2-/- mice, suggesting that 
the functionality of postsynaptic GABAA receptors is under the control of 
GIRK2 channels and/or 5-HT1A and GABAB receptors in the DR. Similarly, the 
inactivation of 5-HT1A receptors in mice has revealed that expression of certain 
GABAA receptor subunits as well as the whole receptor functionality are under 
the control of 5-HT1A receptors in the hippocampus and other brain regions 
(Sibille et al., 2000). In fact, one possible explanation for this GABA regulation 
by 5-HT1A receptors in the hippocampus is that due to their coupling to GIRK 
channels, genetic inactivation of the receptor could alter the membrane 
potential, frequency and duration of electrical impulses (Aghajanian and 
Lakoski, 1984; Corradetti et al., 1996) leading to a depolarization and increase 
in depolarization-evoked Ca2+ influx. Alternatively, chronic lack of GABA in 
the DR of these GIRK2 mutant mice could also lead to compensative or 
adaptative mechanisms regarding the functionality of postsynaptic GABA
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receptors. Nevertheless, further studies will be needed to reveal how GIRK2 
subunit-containing GIRK channels are controlling the GABAA receptor-
mediated transmission in the DR. 
Taking these results beyond their physiological meaning, and linking 
the observed GABAergic dysfunction to the depression-resistant phenotype that 
GIRK2 mutant mice display, it is important to indicate that much evidence 
identifies a GABAergic dysfunction in mood disorders. It has been described a 
GABAergic deficit in prefrontal regions of unmedicated depressed patients, and 
also in the PFC in animal models of depression (induced by chronic social 
defeat stress, CSDS) (Hasler et al., 2007; Venzala et al., 2013). On the contrary, 
GABA levels in the DR are not altered in mice subjected to CSDS (Venzala et 
al., 2013). It has been shown that chronic treatment with the SSRI fluoxetine,
which is known to desensitize 5-HT1A receptors, reduces GABAergic 
transmission in the visual cortex (Maya Vetencourt et al., 2008), and reduces 
eIPSCs in the PFC of normal rats (Zhong and Yan, 2004). In addition, the 
repeated administration of imipramine, which is a tricyclic antidepressant, 
markedly reduces the GABAergic transmission in healthy rats, as frequency of 
sIPSCs in layer 2/3 pyramidal neurons was decreased (Wabno and Hess, 2013). 
In this sense, from our studies we observe that mice lacking GIRK2 
subunits show desensitized 5-HT1A receptors and also a reduced frequency of 
sIPSCs, mimicking the effects of repeated antidepressant administrations on 5-
HT and GABAergic transmissions. It is also important to mention that Challis et 
al. (2013) showed that social defeat stress, which results in long-lasting social 
avoidance and is sensitive to the effects of antidepressants (Berton et al., 2006; 
Tsankova et al., 2006), suppresses the 5-HT neuronal firing through increased 
activity of GABA interneurons in the DR.
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Furthermore, decreasing GABA activity dishinibited 5-HT cells and 
promoted a “resilient” phenotype in mice exposed to social defeat (Challis et al., 
2013). It is interesting that in our study GIRK2-/- mice show a depression-
resistant phenotype and an increased 5-HT neuronal firing combined with a 
decreased GABA transmission in the DR. Therefore, further investigations in 
GIRK2-/- mice aimed at studying other physiological changes that occur during 
depression and antidepressant treatments might elucidate if these mutant mice 
could be regarded as an “antidepressant” model or as an animal model of 
repeated antidepressant administration.
Regarding the glutamatergic neurotransmission in the DR, it is intact in 
GIRK2-/- mice, since no alterations are displayed on properties of sEPSCs and 
eEPSCs compared to those in wild-type mice. The involvement of GIRK2 
subunit-containing GIRK channels in the glutamatergic neurotransmission has 
been reported the rat cerebral cortex. In this case, GABAB receptors reduce 
glutamate release via P/Q-type Ca2+ channels, and this response is reversed by 
the GIRK channel blocker tertiapin-Q (Ladera et al., 2008). In addition, 
dopamine neurons from the VTA GIRK2-/- showed an elevated glutamatergic 
neurotransmission (Arora et al., 2010). However, given that this effect was 
paralleled by increased synaptic levels of AMPA receptors, it is likely that 
GIRK2 subunit deletion affects glutamatergic neurotransmission involving 
secondary adaptations facilitating glutamatergic signaling in the mesolimbic 
reward system. Despite lacking data regarding the synaptic levels of AMPA and 
NMDA receptors in the DR, in the present study we separately evaluated 
AMPA- and NMDA-mediated eEPSCs and we did not observe differences 
between the AMPA/NMDA ratio in DR neurons of GIRK2 mutant mice and 
wild-type mice. This suggests that GIRK2 subunit deletion does not affect the 
AMPA and NMDA receptors synaptic levels, although further studies aimed at 
quantifying AMPA and NMDA synaptic levels could directly confirm it.
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Altogether, our data indicate that the 5-HT and GABAergic systems are 
affected by the deletion of GIRK2 subunits. Thus, both intrinsic and extrinsic 
inhibitory mechanisms are diminished in DR neurons of GIRK2 mutant mice. 
In addition, the dysregulation of the GABAergic transmission could disrupt the 
balance between the glutamatergic and GABAergic systems, which is an 
important factor in the pathophysiology and treatment of mood disorders, 
including depression (Krystal, 2007).
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5.3. Ketamine promotes electrophysiological and biochemical alterations in 
the glutamatergic transmission in the dorsal raphe
In this study we used electrophysiological and biochemical approaches 
to determine whether ketamine is altering the glutamatergic transmission and 
the mTOR pathway in the DR, besides exerting rapid antidepressant actions. In 
this way, we replicated the clinical and preclinical findings of ketamine in 
humans and in mice, showing that ketamine has acute and sustained 
antidepressant-like effects in behavioral models. Electrophysiological analysis 
revealed that the acute administration of ketamine increased the frequency of 
sEPSCs in DR neurons, which was attenuated by the pre-incubation of the slices 
with the mTOR inhibitor PP242. However, when ketamine was administered 24 
hours prior to the recordings it produced no effects either in sEPSCs or eEPSCs, 
pointing out a functional difference between the acute and sustained effects of 
ketamine in the DR. The differential functional effects between the acute and 
sustained actions of ketamine extend to the intracellular mTOR signaling. In 
this sense, we found that ketamine administered 30 min before the experiments
did not induce the phosphorylation of mTOR in the DR, whereas 24 hours after 
the administration of ketamine, it increased the levels of the phosphorylated and 
active form of mTOR in the DR. Collectively, these results identify functional 
actions of ketamine on the glutamatergic transmission in the DR, and also 
reveal that the electrophysiological “rapid onset effects”, which may trigger 
other functional/cellular effects, are not maintained 24 hours after the ketamine 
administration. 
The administration of some glutamatergic antagonists in humans, and 
specifically a single intravenous infusion of ketamine, has demonstrated that 
these compounds can alleviate depressive symptoms in patients within hours of 
administration (Berman et al., 2000; Zarate et al., 2006). These effects in 
humans have been widely mimicked in animal models of depression (Maeng et 
al., 2008; Li et al., 2010; Gigliucci et al., 2013; Koike et al., 2013). In this 
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study, we replicated these reported acute and sustained antidepressant-like 
effects of ketamine (30 mg/kg, i.p.), using the TST 30 minutes and 24 hours 
after the ketamine injection. The dose used was selected based on previous 
literature where ketamine doses lower than 50 mg/kg (i.p.) had significant 
antidepressant-like effects without impacting on locomotor activity, ataxia, and 
stereotypy (Popik et al., 2008; Li et al., 2010; Koike et al., 2011; Koike et al., 
2013).
It has also been reported that ketamine exerts the antidepressant-like 
effects via activation of the mTOR and the mTOR-dependent synapse 
formation, given that local infusions of the mTOR inhibitor, ramapycin in the 
PFC blocked the acute behavioral effect of ketamine and the formation of spines 
(Li et al., 2010; Li et al., 2011). In this sense, we found that 24 hours after 
ketamine administration mTOR signaling was also activated in the DR, but only 
a slight tendency to be increased was seen 30 minutes after the injection. On 
one hand, this may suggest that the acute antidepressant effects of ketamine do 
not involve mTOR signaling activation, whereas the sustained effects do 
involve an activation of the mTOR pathway in the DR. In this sense, another 
study reports that the upstream components of the mTOR pathway, BDNF/TrK, 
are not involved in the acute behavioral effects of ketamine but they play an 
important role in the sustained antidepressant-like effects (Koike et al., 2013). 
On the other hand, Li et al. (2010) showed that in the mPFC mTOR signaling 
was highly activated 30 minutes after the injection, and this activation returned 
to baseline levels 2 hours after the injection, even though the antidepressant-like 
effect persists for at least 24 hours. Thus, another possible explanation may be 
that ketamine is first activating the mTOR pathway in PFC and then, through 
the prominent projections to the DR (Aghajanian and Wang, 1977; Takagishi 
and Chiba, 1991; Hajos et al., 1998; Peyron et al., 1998; Celada et al., 2001), 
indirectly acting on the mTOR pathway in the DR. Thus, the time required to 
obtain this latter indirect effect in the DR might explain the absence of changes 
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in mTOR phosphorylation levels 30 minutes after the ketamine injection. From 
a behavioral point of view, the fact that ketamine induced an activation of the 
mTOR pathway in both the PFC and DR may be important, given that it has 
been recently shown that selective activation of mPFC cells projecting to the 
DR induces a profound and rapid effect on selection of the active behavioral 
state in the forced swim test in freely moving rats (Warden et al., 2012).
Ketamine perfusion onto DR slices induced an increase in the frequency 
of sEPSCs in the DR neurons, but no other changes were found regarding the 
amplitude of sEPSCs, amplitude of eEPSCs, and AMPA/NMDA ratio. The 
observed increase in sEPSC frequency can be attributed to an increase in 
presynaptic glutamate release probability and/or an increase in excitatory 
synapse density. However, to observe the latter effect more time would be 
required, given that it has been shown that ketamine increases spine density in 
the PFC 24 hours after treatment (Li et al., 2010). This suggests that it is likely 
that ketamine is inducing a presynaptic glutamate release in DR neurons. 
Although several studies have shown that systemically administered NMDA 
receptor antagonists increase glutamate release in the mPFC (Adams 
Moghaddam et al., 1997; Moghaddam and Adams, 1998; and Moghaddam, 
2001), another study in the striatum provides different results (Yamamoto et al., 
1999). The mechanism that we propone here is that, as occurs in mPFC, 
ketamine may produce disinhibition of GABAergic inputs within the DR, which 
are abundant, to the glutamate-containing neurons thereby enhancing the 
glutamate release. It has been repeatedly reported that ketamine requires AMPA 
receptors to exert antidepressant actions (Li et al., 2010; Koike et al., 2011; 
Maeng et al., 2008; Tizabi et al., 2012). Thus, we asked if the observed 
ketamine-induced increase in sIPSCs was mediated by AMPA receptors. For 
this purpose, we tested D-AP5, which is an NMDA receptor antagonist, and it 
did not mimic ketamine’s effect. Moreover, DNQX, which is an AMPA 
receptor antagonist, completely blocked it, suggesting that the ketamine-induced 
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increase in sEPSCs frequency observed in our work may be mediated by DR 
AMPA receptors. In fact, Nishitani et al. (2014) also showed the involvement of 
DR AMPA receptors in ketamine-induced effects. Here, we examined the effect 
of ketamine 50 µM, which it is a concentration below the anesthetic range 
(McCardle and Gartside, 2012) and that would correspond to the brain levels 
reached after an intraperitoneal injection of 30 mg/kg, given that ketamine brain 
levels in mice after 100 mg/kg (i.p.) have been reported to be approximately 
180 µM (Irifune et al., 1992; Petrenko et al., 2004). 
It has been reported that the electrophysiological effects induced by 
ketamine in the PFC are blocked by the local infusion of the mTOR inhibitor 
rapamycin (Li et al., 2010). Similarly, in our study we show the pre-incubation 
of DR slices with the potent and selective active-site mTOR inhibitor, PP242 
attenuated the increase in sEPSC frequency shown after perfusion of ketamine, 
suggesting that in the DR mTOR pathway may play a key role in the ketamine-
induced glutamate release. In this sense, it has been previously reported that 
mTOR activation positively regulates excitatory synaptic function (Schratt et 
al., 2004; Jaworski et al., 2005; Kumar et al., 2005). 
Regarding the electrophysiological effects of ketamine 24 hours after 
the injection, we found that neither the sEPSCs nor the eEPSCs were changed. 
In contrast, the electrophysiological effects of ketamine in 5-HT-induced EPSCs 
in the PFC are maintained 24 hours after the injection (Li et al., 2010) 
suggesting that the duration of the ketamine-induced electrophysiological 
changes could be depending on the brain region, being more prolonged in the 
PFC than in the DR. 
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The DR has received much attention in the study of the 
pathophysiology of depression, and ketamine effects have been well described 
in the PFC. Given the prominent connections between these regions, and the 
evidence regarding the involvement of PFC-DR projections in behavioral 
responses related to depressive states, we believe that this study provides 
relevant data suggesting that also the DR may play a key role in the effects of 
the new-type fast-acting glutamatergic antidepressants.
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6. CONCLUSIONS
1. GIRK2 subunits control the DR tonic activity in vivo, since DR 
neurons from GIRK2-/- mice show an increased firing rate compared to wild-
type mice. Moreover, the blockade of GIRK channels with tertiapin-Q results in 
a similar increase in the firing rate of DR neurons to that observed in GIRK2-/-
mice, indicating that GIRK2 subunits are the main subunits in those GIRK 
channel populations that control DR activity in a constitutive manner. 
2. In vivo, the inhibitory effect induced by the stimulation of 5-HT1A
autoreceptors is regulated by GIRK2 subunit-containing GIRK channels. Since 
the inhibitory potency of the 5-HT1A receptor agonist 8-OH-DPAT, and the 
selective serotonin reupake inhibitor, citalopram is diminished compared to that 
in wild-type, this result suggests that 5-HT1A autoreceptors are desensitized in 
GIRK2-/- mice.
3. GIRK2 subunit-containing GIRK channels contribute to the 
occurrence of depression-related behaviors. This is supported by our results 
showing that GIRK2 mutant mice show depression-resistant behaviors in the 
tail suspension test and novelty suppressed feeding test. 
4. 5-HT1A-GIRK2 signaling pathway mediates, at least in part, the 
behavioral response to citalopram, since in GIRK2 mutant mice citalopram 
causes a lower antidepressant effect compared to that in wild-type mice. 
5. GIRK2 subunit-containing channels are not essential for adult 
neurogenesis, since basal levels of proliferating cells in the dentate gyrus and 
subventricular zone are unaltered in GIRK2 mutant mice compared to those in 
wild-type mice. 
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6. In vitro, membrane intrinsic characteristics of DR neurons are 
controlled by GIRK2 subunit-containing GIRK channels, since DR neurons of 
GIRK2-/- mice have a higher input resistance compared to wild-type mice. 
7. GIRK2 subunit-containing GIRK channels in the DR are expressed 
postsynaptically and play a pivotal role in the in vitro outward currents induced 
by activation of 5-HT1A and GABAB receptors. This is supported by the almost 
absent 5-CT- and baclofen-induced currents in DR neurons of GIRK2-/- mice 
observed in this study. 
8. GIRK channels formed by GIRK2 subunits are expressed at the 
presynaptic level where they exert a robust control over GABA release. This is 
demonstrated by our in vitro results showing that deletion of GIRK2 subunit 
causes a reduction in the frequency of sIPSCs, a decrease in the amplitude of 
eIPSCs, and an increase in the paired-pulse ratio.
9. The inhibition of GABA release by presynaptic 5-HT1A and GABAB
receptors is limited by GIRK2 subunit-containing GIRK channels. This is 
confirmed by the in vitro results showing that, contrary to wild-type mice, the 
perfusion of 5-HT1A and GABAB receptor antagonists do not increase the 
frequency or amplitude of sIPSCs in DR neurons in GIRK2-/- mice. 
10. The fast GABAergic postsynaptic activity in the DR is critically 
controlled by GIRK2 subunit containing GIRK channels, as it is demonstrated 
by our in vitro results showing a decreased amplitude of sIPSCs and diminished 
GABAA receptor-mediated inward currents in GIRK2-/- mice compared to those 
in wild-type mice. 
11. On the contrary, GIRK channels containing GIRK2 subunit do not 
control the glutamatergic input in the DR, since no alterations are observed 
either in the sEPSCs or in the eEPSCs in DR neurons of GIRK2-/- mice 
compared to wild-type mice.
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12. The electrophysiological effects of ketamine related to its 
antidepressant-like actions extend to the DR and involve AMPA receptors, 
since acute ketamine selectively increases the frequency of AMPA-sEPSCs. 
Moreover, since another NMDA antagonist, D-AP5, fails to mimic this effect 
these results indicate that ketamine is increasing the glutamatergic synaptic 
activity through a NMDA-independent mechanism.
13. mTOR activation in the DR is necessary for the acute 
electrophysiological effects of ketamine in this area, and it is involved its
sustained antidepressant-like behavioral effects. This is demonstrated by the fact 
that pre-incubation with the mTOR inhibitor, PP242 partially blocks the 
ketamine-induced increase in the frequency of AMPA-sEPSCs, and
additionally, 24 hours after ketamine injection mice show a marked 
antidepressant-like behavior together with mTOR activation in the DR.
In conclusion, approaches directed towards the pharmacological 
blockade or genetic removal of the GIRK2 subunit could limit the occurrence of 
depression-related behaviors, and specifically addressing GIRK2 subunits in the 
DR could give rise to faster acting therapies in depression. Furthermore, the DR 
constitutes a target for new strategies aimed at improving the current scenario of 
depression treatment. In this sense, in the DR ketamine promotes the “glutamate 
surge” and the accompanying AMPA activation, which are proposed 
requirements for generating the antidepressant-like response of ketamine.
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